Compounds > cyproheptadine
Page last updated: 2024-09-20

cyproheptadine

Description

Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2913
CHEMBL ID516
CHEBI ID4046
SCHEMBL ID4021
MeSH IDM0005519

Synonyms (131)

Synonym
BIDD:GT0324
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
gtpl277
cyproheptidine
1-methyl-4-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}piperidine
4-(5h-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
BIOMOL-NT_000131
eiproheptadine
piperidine, 4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-
lopac-c-6022
tocris-0996
NCGC00015252-01
NCGC00024293-02
NCGC00015252-02
cas-969-33-5
PDSP2_001213
ciprovit (tn)
cyproheptadine (inn)
D07765
BSPBIO_000086
BPBIO1_000155
BPBIO1_000096
PDSP1_001229
OPREA1_498140
LOPAC0_000246
PRESTWICK3_000103
dronactin
hsdb 3048
4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
cyproheptadine [inn:ban]
cyproheptadinum [inn-latin]
mk 141
ccris 5232
einecs 204-928-9
ciproheptadina [inn-spanish]
piperidine, 4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-
brn 1685976
4-(dibenzo[[?],[?]][7]annulen-11-ylidene)-1-methyl-piperidine
periactin
4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
129-03-3
cyproheptadine
C06935
4-dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
1-methyl-4-(5h-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene
DB00434
4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5-dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
periactinol
NCGC00024293-05
SPBIO_002025
PRESTWICK1_000103
PRESTWICK0_000103
PRESTWICK2_000103
NCGC00024293-04
NCGC00015252-03
HMS2090P20
NCGC00015252-09
L001016
ciprovit
CHEMBL516 ,
cyproheptadinum
ciproheptadina
CHEBI:4046 ,
STK802098
bdbm50017721
4-(5h-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
NCGC00015252-08
AKOS004119847
BBL010977
dtxcid702872
cas-129-03-3
dtxsid8022872 ,
tox21_110112
cyproheptadiene
cypoheptadine
CCG-204341
NCGC00015252-06
NCGC00015252-04
NCGC00015252-07
NCGC00015252-05
NCGC00015252-10
5-20-08-00500 (beilstein handbook reference)
unii-2yhb6175do
2yhb6175do ,
FT-0631755
NCGC00015252-13
cyproheptadine [mi]
cyproheptadine [hsdb]
cyproheptadine [who-dd]
cyproheptadine [vandf]
cyproheptadine [inn]
DL-136
SCHEMBL4021
tox21_110112_1
NCGC00015252-12
reactin
peritol (salt/mix)
1-methyl-4-(5h-dibenzo[a,d]cycloheptenylidene)piperidine
1-methyl-4-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-ylidene}piperidine
4-(dibenzo[1,2-a:2',1'-d][7]annulen-11-ylidene)-1-methyl-piperidine
SBI-0050234.P002
BRD-K28143534-001-03-0
Q417884
1-methyl-4-{tricyclo[9.4.0.0(3),?]pentadeca-1(11),3,5,7,9,12,14-heptaen-2-ylidene}piperidine
VS-02784
BRD-K28143534-003-14-3
SDCCGSBI-0050234.P003
NCGC00015252-26
1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidinehydrochloride
A915360
1-methyl-4-(2-tricyclo[9.4.0.0^{3,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
EN300-18552723
1-methyl-4-{tricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-ylidene}piperidine
HY-B1622
CS-0013555
ciproeptadina
cyproheptadin
r06ax02
4-(5h-dibenzo(a,d)(7)annulen-5-ylidene)-1-methylpiperidine
5-(1-methylpiperidylidene-4)-5h-dibenzo
4-(5h-dibenzo
1-methyl-4-(5-dibenzo
ciproheptadina (inn-spanish)
cyproheptadinum (inn-latin)
1-methyl-4-(5h-dibenzo
4-dibenzo(a,d)cyclohepten-5-ylidene-1-methyl-piperidine

Research Excerpts

Overview

ExcerptReference
"Cyproheptadine is a safe treatment option in patients with poor appetite."( Cho, B; Cho, KH; Cho, YG; Kim, SY; Lee, JW; Park, YG; Yun, JM, 2021)
"Cyproheptadine HCl (CyproH) is an appetite-stimulating drug and while it was prescribed for a patient with growth hormone insensitivity syndrome (GHIS) for increasing appetite, his height growth was surprisingly increased. "( Nourbakhsh, M; Razzaghy-Azar, M, 2018)
"Cyproheptadine is a serotonin and histamine antagonist that has been suggested as a treatment for serotonin syndrome in case reports."( Cantrell, LF; Kearney, T; Nguyen, H; Pan, A; Smollin, C, 2019)
"Cyproheptadine (Cph) is an antiserotoninergic and antihistaminergic agent with alpha-blocking activity and central sedative effect. "( Eto, B; Limas-Nzouzi, N; Mamadou, G; Meddah, B; Miantezila, J; Soudy, ID, 2014)
"Cyproheptadine is a medication with antihistaminergic, antiserotonergic and anticholinergic effects, thought to increase gastric accommodation."( Butler, DR; Kaul, A; Meinzen-Derr, J; Merhar, SL; Mukkada, VA; Pentiuk, SP, 2016)
"Cyproheptadine (Periactin) is a first-generation antihistamine available in over-the-counter cold medications and is used to treat allergic-type symptoms. "( Hargrove, V; Molina, DK, 2009)
"Cyproheptadine (CPH) is a histamine- and serotonin-receptor antagonist, and its effects are observed recently in the modulation of multiple intracellular signals. "( Gao, XF; He, YL; Hu, CL; Mei, YA; Yao, JJ; Zhang, CL, 2012)
"Cyproheptadine is a cheap and safe drug that does not have significant interactions with antiretroviral drugs. "( Dabaghzadeh, F; Dashti-Khavidaki, S; Ghaeli, P; Khalili, H, 2012)
"Cyproheptadine is a cheap, widely available anti-allergy drug with a broad receptor binding profile which resembles that of clozapine. "( Cole, JC; Cooper, GD; Goudie, AJ; Sumnall, HR, 2007)
"Cyproheptadine is a potent antagonist of serotonin and has been used successfully in some patients with Cushing's disease, although, generally, in women without radiological evidence of pituitary tumors."( Bellido, C; Jaimez, L; Jimenez-Alonso, J; Jiménez-Perepérez, JA; Munoz-Avila, J; Pérez-Jimenez, F, 1982)
"Cyproheptadine is a serotonergic antagonist that has been suggested for the treatment of schizophrenia."( Harrington, A; Kaczmarek, HJ; Steinpreis, RE, 1996)
"Cyproheptadine is a drug that shows high affinity for type 2 (5-HT2) receptors. "( Cadavid, MI; Calleja, JM; Dominguez, R; Honrubia, MA; Loza, MI; Lozoya, E; Maayani, S; Manaut, F; Rodriguez, J; Sanz, F; Seijas, JA; Villaverde, MC, 1997)
"Cyproheptadine is an antihistamine and serotonin antagonist given to children for allergies, migraine headaches, and growth problems. "( Strayhorn, JM, 1998)
"Cyproheptadine is a relatively safe compound and may be of therapeutic benefit in treating negative symptoms of schizophrenia in combination with typical neuroleptics. "( Akhondzadeh, S; Amini-Nooshabadi, H; Davari-Ashtiani, R; Mohammadi, MR, 1999)
"Cyproheptadine is an agent with considerable side effects, and it should be prescribed to children only after very careful deliberation."( Krienke, EG; von Mühlendahl, KE, 1978)
"Cyproheptadine would appear to be a useful therapeutic tool for the management of diarrhea associated with the malignant carcinoid syndrome."( Kvols, LK; Moertel, CG; Rubin, J, 1991)
"Cyproheptadine (CH) is a serotonin antagonist that increases food intake and body weight. "( Brondel, L; Fantino, M; Lebec, O; Swiergiel, AH, 1990)
"Cyproheptadine is an antihistamine with antiserotoninergic and anticholinergic properties. "( Ashton, AK; Samie, MR, 1989)

Effects

ExcerptReference
"Cyproheptadine has a unique pharmacologic portfolio that speaks to the idea of a pluripotent molecule beyond an antiallergic agent which can expand its therapeutic potential to address a multitude of psychiatric indications. "( Badr, B; Naguy, A, 2022)
"Cyproheptadine has a unique pharmacologic portfolio that speaks to the idea of a pluripotent molecule beyond an antiallergic agent which can expand its therapeutic potential to address a multitude of psychiatric indications. "( Badr, B; Naguy, A, 2022)
"Cyproheptadine has been shown to produce dose-dependent inhibition of haem polymerization activity both in vitro and in vivo."( Agrawal, R; Dutta, GP; Jain, SK; Shukla, OP; Tekwani, BL; Tripathi, R, 2002)
"Cyproheptadine has been shown in medical samples to stimulate weight gain."( Daviss, WB; Scott, J, 2004)
"Cyproheptadine has recently been reported to blunt the furosemide-induced rise in PRA in normal subjects and to acutely lower plasma aldosterone levels in patients with hyperaldosteronism due to bilateral adrenal hyperplasia; both actions have tentatively been ascribed to the antiserotoninergic action of the drug. "( Adam, WR; Armanini, D; Funder, JW; Goland, GJ, 1983)
"Cyproheptadine (CY) has been used therapeutically as an appetite stimulant at a dose which appears to have antiserotoninergic activity. "( Dellia-Sfikaki, A; Konstandi, M; Varonos, D, 1996)
"Cyproheptadine has especially high affinity for the H2-receptor."( Green, JP; Maayani, S; Weinstein, H, 1978)
"Cyproheptadine has been used to counteract these side effects."( Goldbloom, DS; Kennedy, SH, 1991)
"Cyproheptadine has been reported to effect remissions in up to 50% of patients with Cushing's disease presumably at a hypothalamic level. "( Jackson, IM; Nowakowski, KJ; Tucci, JR, 1989)

Actions

ExcerptReference
"Cyproheptadine was found to inhibit the Ca2+ uptake of sarcoplasmic reticulum with an IC50 of 1.94 x 10(-4) mol/L."( Xin, HB; Zhang, BH, 1993)
"Cyproheptadine tended to increase (P < .10) LH pulsatility on d 5 and 14, but MEL had no effect (P > .20)."( Hallford, DM; Kridli, RT, 1997)
"for cyproheptadine. Using an increase in food consumption of 20% or more as the criterion of a positive response, the dose effective in 50% of the animals was 0.35 mg/kg p.o."( Clineschmidt, BV; Hanson, HM; Lotti, VJ; McGuffin, JC; Scriabine, A; Stone, CA, 1976)
"The cyproheptadine-induced increase in energy intake was statistically significant in one of the subjects, who was at his desirable weight level at the outset."( Hashim, SA; Saleh, JW; van Itallie, TB; Yang, MU, 1979)

Treatment

ExcerptReference
"Cyproheptadine is a safe treatment option in patients with poor appetite."( Cho, B; Cho, KH; Cho, YG; Kim, SY; Lee, JW; Park, YG; Yun, JM, 2021)
"Cyproheptadine pretreatment inhibited ether-induced ACTH hypersecretion in adrenalectomized animals."( Fekete, MI; Kanyicska, B; Karteszi, M; Kiss, JZ; Palkovits, M; Stark, E, 1981)
"Cyproheptadine pretreatment did not alter plasma levels of fenfluramine."( Lewis, DA; Sherman, BM, 1984)
"Cyproheptadine pretreatment blocked or largely inhibited the cutaneous vasoconstriction produced by serotonin only in doses which also inhibited norepinephrine and vasopressin cutaneous vasoconstriction."( Adamski, SW; Dobbins, DE; Grega, GJ; Lokhandwala, MF, 1983)
"Cyproheptadine pretreatment resulted in a substantial suppression of the GH response to glucagon."( Hainer, V; Krejcik, L; Malec, B; Urbánek, J, 1981)
"In cyproheptadine-treated animals the incidence and severity of clinical manifestations and pathologic alterations were reduced, and mortality was marked decreased."( Chryssanthou, C; Graber, B; Rubin, L, 1980)
"Cyproheptadine treatment was beneficial in more than two thirds of treated horses."( Bell, SA; Madigan, JE, 2001)
"Cyproheptadine treatment resulted in a marked lowering of plasma ACTH concentrations (221-320 pg/ml)."( Bardin, CW; Krieger, DT; Samojlik, E, 1978)
"Cyproheptadine pretreatment also prevented the hyperinsulinemia and hypoglucagonemia resulting from glucose loading."( Bryce, GF; Jacoby, JH, 1979)
"Cyproheptadine pretreatment was associated with erratic increases or decreases in the hGH response to apomorphine, but did not alter PRL levels or apomorphine-induced PRL suppression."( Angrist, B; Branchey, L; Gershon, S; Halpern, F; Oleshansky, M; Paquin, J; Rotrosen, J; Sachar, EJ, 1979)
"Cyproheptadine pretreatment failed to depress the quipazine (serotonin agonist)-induced PRL rise."( el Halawani, ME; Fehrer, SC; Silsby, JL, 1985)
"Cyproheptadine pre-treatment did not alter plasma levels of fenfluramine."( Lewis, DA; Sherman, BM, 1985)
"Pre-treatment with cyproheptadine also resulted in a decrease of other toxic symptoms associated with Boophone disticha."( Gadaga, LL; Mutseura, M; Tagwireyi, D, 2013)
"Treatment with cyproheptadine, a 5HT antagonist, did not delay parturition."( ROBSON, JM; SENIOR, JB, 1964)
"Treatment with cyproheptadine was attempted."( Bell, AJ, 2004)
"Treatment with cyproheptadine again induced hypocorticism necessitating corticosteroid substitution therapy."( Croughs, RJ; Koppeschaar, HP; Schwarz, F; Thijssen, JH, 1983)
"Dogs treated with cyproheptadine both prior to and after induction of endotoxin shock were compared with the standard endotoxin shock model."( Almqvist, P; Kuenzig, M; Schwartz, SI; Skudder, P, 1984)
"Treatment with cyproheptadine was continued till six weeks after delivery by which time all the features of Cushing's syndrome had disappeared."( Hartwig, W; Kasperlik-Załuska, A; Lozińska, D; Marianowski, L; Migdalska, B; Stopińska-Głuszak, U; Wilczyńska, J, 1980)
"pretreatment with cyproheptadine attenuated the inhibition of the tail-flick response induced by i.t."( Choi, YS; Kim, YH; Song, DK; Suh, HW, 1996)
"Treatment with cyproheptadine produced improvement of symptoms in 76% of cases."( Bell, SA; Madigan, JE, 1998)
"pretreatment with cyproheptadine or thioperamide dose-dependently attenuated the inhibition of the tail-flick response induced by i.c.v."( Chung, KM; Huh, SO; Kim, YH; Song, DK; Suh, HW, 1999)
"Treatment with cyproheptadine, indomethacin, or theophylline had no effect, but treatment with dexamethasone significantly reduced PS to near normal levels."( Evans, ML; Graham, MM; Peterson, LM; Thomas, KL, 1992)
"Pretreatment with cyproheptadine significantly inhibited the fall in FEV1.0 120 minutes after ethanol challenge (p less than 0.05)."( Asai, S; Hara, K; Inuyama, M; Kiya, T; Miura, N; Sakamoto, Y; Shimoda, T; Tomonaga, H; Watanabe, T, 1992)
"Pretreatment with cyproheptadine (2.5 mg/kg, iv), a dual serotonin/histamine antagonist, or ketanserin (3 mg/kg, iv), a selective serotonin antagonist, prevented the GH-RP-6-induced hypotension and lethality."( Gabel, RA; Macia, RA; Matthews, WD; Reginato, MJ, 1990)
"Pretreatment with cyproheptadine (5 mg/kg), an inhibitor of both histamine and serotonin, significantly suppressed pleural fluid accumulation and the exudation rate at 0.5 hr."( Hayashi, M; Imai, Y; Oh-ishi, S, 1991)
"Pretreatment with cyproheptadine, a 5-HT2 receptor antagonist, prevented the BBB increase and the regional blood flow was near normal values."( Dey, PK; Olsson, Y; Sharma, HS, 1990)
"Pretreatment with cyproheptadine (1.5 and 3 mg/kg), methysergide (5 and 10 mg/kg) and (-)-propranolol (2.5 and 5 mg/kg) significantly decreased the number of head twitches induced by ergometrine."( Balsara, JJ; Bapat, TR; Chandorkar, AG; Gada, VP; Nandal, NV, 1986)
"Pretreatment with cyproheptadine and vinblastine, however, prevented only the increased permeability of the blood-brain barrier; the plasma and level of 5-HT in brain continued to remain high."( Dey, PK; Sharma, HS, 1986)
"Treatment with cyproheptadine caused a documented response in the patient's debilitating diarrhoea and also produced symptomatic improvement in her muscular power."( Berry, EM; Maunder, C; Wilson, M, 1974)

Roles (5)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
antipruritic drugA drug, usually applied topically, that relieves pruritus (itching).
anti-allergic agentA drug used to treat allergic reactions.
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
piperidines
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

cyproheptadine is involved in 1 pathway(s), involving a total of 8 unique proteins and 7 unique compounds

PathwayProteinsCompounds
Cyproheptadine H1-Antihistamine Action87

Protein Targets (101)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID886
phosphopantetheinyl transferaseBacillus subtilisPotency64.07490.141337.9142100.0000AID1490; AID2701
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID493106
Fumarate hydrataseHomo sapiens (human)Potency24.90520.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency14.74030.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency28.23200.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.50160.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency25.47390.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency37.65050.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.00000.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency17.26530.001022.650876.6163AID1224838; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency3.70490.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency17.02890.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency13.06380.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.33320.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency13.33220.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.75230.000229.305416,493.5996AID1259244; AID743069; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency2.18760.00108.379861.1304AID1645840
polyproteinZika virusPotency24.90520.00308.794948.0869AID1347053
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency37.68580.035520.977089.1251AID504332
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency6.02460.057821.109761.2679AID1159526; AID1159528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency6.36080.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID902
cytochrome P450 2C19 precursorHomo sapiens (human)Potency12.58930.00255.840031.6228AID899
D(1A) dopamine receptorHomo sapiens (human)Potency1.20310.02245.944922.3872AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency11.22020.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency15.87280.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency11.66810.00669.809418.4927AID1347050
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency26.12160.00378.618923.2809AID2668
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.81780.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.02700.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency8.17120.020010.786931.6228AID912
chaperonin GroELMethanococcus maripaludis S2Potency100.000031.622831.622831.6228AID488978
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency11.94200.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency18.83360.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency14.74030.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency5.30800.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency18.83360.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency11.94200.00638.235039.8107AID881
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency29.35920.009610.525035.4813AID1479145; AID1479148
Ataxin-2Homo sapiens (human)Potency19.95260.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium-dependent noradrenaline transporterMus musculus (house mouse)Ki0.29000.01200.09050.2900AID145696
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.00240.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.00130.00000.887110.0000AID625218
Prostaglandin G/H synthase 1Ovis aries (sheep)Ki0.00160.00162.12129.0000AID5444
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.56400.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.55900.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.03500.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.00800.00000.690210.0000AID141115; AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)0.01600.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.00310.00000.79519.1201AID141115; AID625154
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki0.00400.00010.579710.0000AID141115
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.00400.00011.48339.1400AID141115
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki0.00400.00010.68688.2600AID141115
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00040.629810.0000AID4791
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki0.00400.00010.66618.2600AID141115
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.00380.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.00340.00000.72926.9183AID141115; AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.28300.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.10600.00010.807410.0000AID625201
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki0.00400.00010.58908.2600AID141115
Glycogen phosphorylase, brain formHomo sapiens (human)Ki0.00400.00404.06807.0000AID141115
Glycogen phosphorylase, muscle formHomo sapiens (human)Ki0.00400.00403.43475.2000AID141115
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)0.01600.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.00400.00000.59729.1201AID141115; AID625151
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)17.04910.00001.612910.0000AID625171
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki13.96790.00042.03378.6606AID625171
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.16400.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.08350.00000.651810.0000AID625253; AID63979
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.00310.00040.908610.0000AID4791
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00160.00010.601710.0000AID5514
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.03800.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.01700.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)1.27500.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.18500.00030.483410.0000AID625203
DRattus norvegicus (Norway rat)Ki0.06300.00010.610010.0000AID63015
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00010.25675.8000AID63015
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.12200.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.07000.00010.739610.0000AID625190
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)0.04600.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.00680.00000.54057.7600AID141115; AID625153
Endothelin receptor type BRattus norvegicus (Norway rat)Ki0.05010.00630.05750.3710AID6685
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)0.15800.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki0.07900.00010.836310.0000AID625252
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.56400.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.42450.00031.465610.0000AID145895; AID625207
Endothelin receptor type BHomo sapiens (human)Ki0.05010.00010.05430.3710AID6670; AID6685
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)0.19800.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki0.19500.00062.197310.0000AID625270
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.10700.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.05300.00000.360910.0000AID625200
D(1B) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00020.24622.0000AID63015
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.00100.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.00130.00000.385510.0000AID5355; AID5444; AID625192; AID697464
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.00240.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.00610.00010.954910.0000AID5945; AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.12200.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.07000.00031.29679.2440AID625190
D(4) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00020.18872.0000AID63015
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00040.615610.0000AID4791
Sodium-dependent serotonin transporterHomo sapiens (human)Ki4.10000.00000.70488.1930AID204880
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Ki0.05010.00000.14803.1800AID6670
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)Ki0.01100.00080.50322.8420AID5677
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.08800.00030.380610.0000AID1546005; AID6685
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.00370.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.00040.00000.511010.0000AID625269
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)0.04800.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.01600.00000.602010.0000AID625254
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.00940.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.00600.00030.769310.0000AID625217
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)0.28100.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.13000.00020.522910.0000AID625221
D(2) dopamine receptorMus musculus (house mouse)Ki0.11200.11201.60643.9811AID61054
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.14000.00010.54948.4000AID61545
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00000.437510.0000AID63015
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)17.04910.00091.901410.0000AID625171
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki13.96790.00211.840710.0000AID625171
Sodium-dependent serotonin transporterMus musculus (house mouse)Ki4.10000.00040.59574.1000AID204217
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)IC50 (µMol)17.04910.10482.83988.3173AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)Ki13.96790.08582.95428.6606AID625171
Histone-lysine N-methyltransferase SETD7Homo sapiens (human)IC50 (µMol)8.13330.00202.52666.0800AID1251558; AID1302504; AID1311948
Histone-lysine N-methyltransferase SETD7Homo sapiens (human)Ki15.00000.00030.00030.0003AID1302523
TransporterRattus norvegicus (Norway rat)Ki0.29000.00010.866710.0000AID145696
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorHomo sapiens (human)Kd5.40000.00010.40215.4000AID254254
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km106.00007.00007.00007.0000AID214939; AID624633
UDP-glucuronosyltransferase 1A3Homo sapiens (human)Km240.00007.34007.34007.3400AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (533)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, brain formHomo sapiens (human)
glycogen metabolic processGlycogen phosphorylase, muscle formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, muscle formHomo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEndothelin receptor type BHomo sapiens (human)
neural crest cell migrationEndothelin receptor type BHomo sapiens (human)
positive regulation of protein phosphorylationEndothelin receptor type BHomo sapiens (human)
renin secretion into blood streamEndothelin receptor type BHomo sapiens (human)
regulation of heart rateEndothelin receptor type BHomo sapiens (human)
regulation of pHEndothelin receptor type BHomo sapiens (human)
cell surface receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
negative regulation of adenylate cyclase activityEndothelin receptor type BHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEndothelin receptor type BHomo sapiens (human)
nervous system developmentEndothelin receptor type BHomo sapiens (human)
peripheral nervous system developmentEndothelin receptor type BHomo sapiens (human)
posterior midgut developmentEndothelin receptor type BHomo sapiens (human)
positive regulation of cell population proliferationEndothelin receptor type BHomo sapiens (human)
gene expressionEndothelin receptor type BHomo sapiens (human)
negative regulation of neuron maturationEndothelin receptor type BHomo sapiens (human)
response to organic cyclic compoundEndothelin receptor type BHomo sapiens (human)
vein smooth muscle contractionEndothelin receptor type BHomo sapiens (human)
calcium-mediated signalingEndothelin receptor type BHomo sapiens (human)
cGMP-mediated signalingEndothelin receptor type BHomo sapiens (human)
heparin metabolic processEndothelin receptor type BHomo sapiens (human)
melanocyte differentiationEndothelin receptor type BHomo sapiens (human)
regulation of fever generationEndothelin receptor type BHomo sapiens (human)
aldosterone metabolic processEndothelin receptor type BHomo sapiens (human)
enteric smooth muscle cell differentiationEndothelin receptor type BHomo sapiens (human)
positive regulation of urine volumeEndothelin receptor type BHomo sapiens (human)
renal sodium excretionEndothelin receptor type BHomo sapiens (human)
epithelial fluid transportEndothelin receptor type BHomo sapiens (human)
vasoconstrictionEndothelin receptor type BHomo sapiens (human)
vasodilationEndothelin receptor type BHomo sapiens (human)
negative regulation of apoptotic processEndothelin receptor type BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionEndothelin receptor type BHomo sapiens (human)
macrophage chemotaxisEndothelin receptor type BHomo sapiens (human)
response to painEndothelin receptor type BHomo sapiens (human)
enteric nervous system developmentEndothelin receptor type BHomo sapiens (human)
regulation of epithelial cell proliferationEndothelin receptor type BHomo sapiens (human)
negative regulation of protein metabolic processEndothelin receptor type BHomo sapiens (human)
canonical Wnt signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of penile erectionEndothelin receptor type BHomo sapiens (human)
establishment of endothelial barrierEndothelin receptor type BHomo sapiens (human)
renal sodium ion absorptionEndothelin receptor type BHomo sapiens (human)
calcium ion transmembrane transportEndothelin receptor type BHomo sapiens (human)
cellular response to lipopolysaccharideEndothelin receptor type BHomo sapiens (human)
protein transmembrane transportEndothelin receptor type BHomo sapiens (human)
podocyte differentiationEndothelin receptor type BHomo sapiens (human)
endothelin receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
renal albumin absorptionEndothelin receptor type BHomo sapiens (human)
neuroblast migrationEndothelin receptor type BHomo sapiens (human)
chordate pharynx developmentEndothelin receptor type BHomo sapiens (human)
response to sodium phosphateEndothelin receptor type BHomo sapiens (human)
response to endothelinEndothelin receptor type BHomo sapiens (human)
developmental pigmentationEndothelin receptor type BHomo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
bile acid secretionUDP-glucuronosyltransferase 1A3Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
DNA damage responseHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin remodelingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (122)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingGlycogen phosphorylase, brain formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, brain formHomo sapiens (human)
nucleotide bindingGlycogen phosphorylase, muscle formHomo sapiens (human)
protein bindingGlycogen phosphorylase, muscle formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, muscle formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, muscle formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, muscle formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, muscle formHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
endothelin receptor activityEndothelin receptor type BHomo sapiens (human)
protein bindingEndothelin receptor type BHomo sapiens (human)
peptide hormone bindingEndothelin receptor type BHomo sapiens (human)
type 1 angiotensin receptor bindingEndothelin receptor type BHomo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3K4 monomethyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (87)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
extracellular regionGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
membraneGlycogen phosphorylase, brain formHomo sapiens (human)
azurophil granule lumenGlycogen phosphorylase, brain formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
cytosolGlycogen phosphorylase, muscle formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, muscle formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, muscle formHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneEndothelin receptor type BHomo sapiens (human)
nuclear membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleolusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (238)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
AID1345908Human alpha1A-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID1345170Human 5-HT6 receptor (5-Hydroxytryptamine receptors)1996Journal of neurochemistry, Jan, Volume: 66, Issue:1
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
AID1346037Human H1 receptor (Histamine receptors)1994European journal of biochemistry, Sep-01, Volume: 224, Issue:2
Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene.
AID1345971Human alpha1D-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Sep-15, Volume: 90, Issue:18
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
AID1346000Human alpha1B-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Nov-05, Volume: 268, Issue:31
Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Aug-25, Volume: 268, Issue:24
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1302514Inhibition of Set7/9 in human MCF7 cells assessed as reduction of ERalpha expression after 48 hrs by immunoblotting analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID49413Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 50/2561982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID1302509Inhibition of Set7/9 in human MCF7 cells assessed as suppression of beta-estradiol-induced cell viability incubated for 4 days by haemocytometer2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID49570Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 50/2211982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID1148116Orexigenic activity in cat assessed as food consumption at 0. 0312 mg/kg, po (Rvb = 133 +/- 31 g)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID254947Inhibitory concentration against LTD4-induced contraction of guinea pig ileum at 10 uM concentration2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID1132687Toxicity in adrenalectomized Sprague-Dawley rat at 10 mg/kg, iv1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID23962logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1302521Non competitive inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ac-KRSK-MCA peptide as substrate and varying SAM preincubated for 1 hr followed by substrate addition measured after 15 mins by Lineweaver-Bur2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1311949Displacement of [3H]ketanserin from Sprague-Dawley rat cerebral cortex 5-HT2A receptor after 30 mins by liquid scintillation counting analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.
AID49421Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 47/1901982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID49401Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 35/2001982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID58619Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing for conversion to sinus rhythm.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID86244Inhibition of [3H]mepyramine binding with histamine H1 receptor in guinea pig cerebellum membranes after 30 min1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor.
AID203926Serotonin antagonism in guinea pig 3 h after oral administration.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties.
AID1132677Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID5355Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1148109Anticholinergic activity in po dosed CF-1 mouse assessed as dose required to increase pupil diameter to 1.5 micrometer after 1 hr1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID330659Effect on life span of Caenorhabditis elegans at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID330705Effect on life span of Caenorhabditis elegans ser7(tm1325) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID203927Serotonin antagonism in guinea pig 3 hr after subcutaneous administration.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1302526Inhibition of G9a (unknown origin) by fluorogenic assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26311logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID330703Effect on life span of Caenorhabditis elegans ser3(ok2007) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID356052Antiinflammatory activity against Naja mossambica PLA2-induced Swiss mouse paw edema assessed as inhibition of paw volume at 5 mg/kg, ip administered before 30 mins of PLA2 challenge measured after 30 mins relative to control2003Journal of natural products, Jun, Volume: 66, Issue:6
Warangalone, the isoflavonoid anti-inflammatory principle of Erythrina addisoniae stem bark.
AID1132678Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1251558Inhibition of SET7 (unknown origin)2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening.
AID1302504Inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using biotinylated histone H3-derived peptide/SAM as substrate by alphaLISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148107Antiserotonin activity against po dosed Sprague-Dawley rat assessed as inhibition of serotonin-induced edema of right hind paw compound administered 1 hr prior to serotonin challenge1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID1302507Inhibition of Set7/9 in human MCF7 cells assessed as suppression of beta-estradiol-induced ERE promoter activation at 14 to 43 uM preincubated for 18 hrs followed by beta-estradiol addition measured after 24 hrs by luciferase reporter gene assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID63015Displacement of [3H]- spiperone radioligand binding at the dopamine binding site of rat caudate1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and receptor binding studies relevant to the neuroleptic activities of some 1-methyl-4-piperidylidene-9-substituted-pyrrolo[2,1-b][3]benzazepine derivatives.
AID1302518Inhibition of Set7/9 in human MCF7 cells assessed as ERalpha destabilization at 43 uM for 36 hrs by immunoblotting analysis in presence of proteasome inhibitor MG1322016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID63979Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID254254Dissociation constant against histamine H1 receptor2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID61054Binding affinity to Dopamine receptor D2 using [3H]spiperone as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID23966logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID178522Inhibition of histamine skin reaction in rat after 2 hr of oral administration.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID1311948Inhibition of recombinant SET7/9 (unknown origin) using biotinylated histone H3-derived peptide/SAM as substrate after 60 mins by AlphaLISA assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.
AID178529Inhibition of mydriatic activity in rat after 2 hr of oral administration.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID330724Effect on life span of Caenorhabditis elegans N2 treated on day 5 at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1332271Antiinflammatory activity in Wistar rat assessed as inhibition of dextran-induced paw edema administered orally 30 mins prior to dextran treatment measured after 3 hrs2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
In vivo and in silico anti-inflammatory mechanism of action of the semisynthetic (-)-cubebin derivatives (-)-hinokinin and (-)-O-benzylcubebin.
AID6685Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
AID1302527Inhibition of Suv39h1 (unknown origin) by ELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID145895Binding affinity towards Norepinephrine transporter using [3H]nisoxitine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID5444Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID23968logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID49221Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 41/1601982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID49240Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 14/1121982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID330704Effect on life span of Caenorhabditis elegans ser4(ok512) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1302513Effect on body weight in Balb/c-nu/nu mouse xenografted with Fucci introduced human MCF7 cells at 20 mg/kg, ip qd administered as continuous dose for 8 days measured every 3 to 4 days until day 152016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID6670Binding affinity towards 5-hydroxytryptamine 7 receptor2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
First pharmacophoric hypothesis for 5-HT7 antagonism.
AID1132681Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis at 25 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID624633Drug glucuronidation reaction catalyzed by human recombinant UGT1A42005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1546005Displacement of [3H]5-HT from recombinant human 5-HT7 receptor expressed in African green monkey COS7 cells2019European journal of medicinal chemistry, Dec-01, Volume: 183Structure-activity relationships of serotonin 5-HT
AID76788In vivo histamine induced lethality after 24 hours of iv administration in guinea pig1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID1302523Inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ac-KRSK-MCA peptide/SAM as substrate preincubated for 1 hr followed by substrate addition measured after 15 mins by Dixon plot analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1132683Antiallergic activity in in guinea pig lung tissue assessed as inhibition of SRS-A production at 1 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1302511Antitumor activity against Fucci introduced human MCF7 cells xenografted in Balb/c-nu/nu mouse at 20 mg/kg, ip qd administered as continuous dose for 8 days measured every 3 to 4 days until day 152016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID5945Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID86241Potency against histamine H1 receptor on guinea pig ileum1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor.
AID1132680Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2-induced anaphylaxis at 25 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID624632Drug glucuronidation reaction catalyzed by human recombinant UGT1A32005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID337405Antiinflammatory activity against PLA2-induced Swiss mouse paw edema at 5 mg/kg, ip administered 30 mins before PLA2 challenge2003Journal of natural products, Sep, Volume: 66, Issue:9
Griffonianone D, an isoflavone with anti-inflammatory activity from the root bark of Millettia griffoniana.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302528Inhibition of Set8 (unknown origin) by AlphaELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1279905 HTP (5-hydroxytryptophan) antagonism in mouse 0.5 hr after subcutaneous administration (0.003-0.1 dose range).1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties.
AID23960logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1302529Inhibition of Dot1L (unknown origin) by AlphaELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1148117Orexigenic activity in cat assessed as food consumption at 0. 25 mg/kg, po (Rvb = 179 +/- 31 g)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID76791In vivo histamine induced lethality after 8 hours of iv administration in guinea pig1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1302508Inhibition of Set7/9 in human MCF7 cells assessed as suppression of beta-estradiol-induced pS2 mRNA expression at 14 to 43 uM preincubated for 18 hrs followed by beta-estradiol addition measured after 24 hrs by RT-PCR analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302510Antitumor activity against Fucci introduced human MCF7 cells xenografted in Balb/c-nu/nu mouse at 20 mg/kg, ip qd administered as single dose2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID58617Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing 50% reduction in ectopic rate.. 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1302517Inhibition of Set7/9 in human MCF7 cells assessed as half life of ERalpha at 43 uM by immunoblotting analysis in presence of cycloheximide (Rvb = 15.6 +/- 1.2 hrs)2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID356053Antiinflammatory activity against Naja mossambica PLA2-induced Swiss mouse paw edema assessed as inhibition of paw volume at 5 mg/kg, ip administered before 30 mins of PLA2 challenge measured after 60 mins relative to control2003Journal of natural products, Jun, Volume: 66, Issue:6
Warangalone, the isoflavonoid anti-inflammatory principle of Erythrina addisoniae stem bark.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1132682Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis at 100 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID49237Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 59/1951982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID76789In vivo histamine induced lethality after 3 hours of iv administration in guinea pig1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID26310Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1302516Effect on ERalpha mRNA expression in human MCF7 cells at 4.3 to 43 uM after 48 hrs by RT-PCR analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1148108Antihistaminic activity against ip dosed Duncan-Harley guinea pig assessed as inhibition of histamine aerosol-induced bronchoconstriction compound administered 30 mins prior to histamine challenge1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID61545Binding affinity at dopamine D2 receptor by [3H]spiperone displacement.1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors.
AID176160In vivo antihistaminic activity using compound 48/80 induced lethality test in rat after 2 hr( oral administration)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID23976logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID49217Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 35/1181982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID330698Effect on life span of Caenorhabditis elegans eat2(ad1116) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1135534Peripheral anticholinergic activity in po dosed Carworth CF1 mouse assessed as dose required to produce pupil dilation to 1.5 micrometer units in 50% mouse after 2 hrs1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Synthesis and stereospecific antipsychotic activity of (-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine.
AID178534Inhibition of serotonin skin reaction in rat after 2 hr of oral administration.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID141115Displacement of [3H]- QNB binding at the muscarinic-cholinergic binding site of rat brain S11983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and receptor binding studies relevant to the neuroleptic activities of some 1-methyl-4-piperidylidene-9-substituted-pyrrolo[2,1-b][3]benzazepine derivatives.
AID337406Antiinflammatory activity against PLA2-induced Swiss mouse paw edema at 5 mg/kg, ip administered 60 mins before PLA2 challenge2003Journal of natural products, Sep, Volume: 66, Issue:9
Griffonianone D, an isoflavone with anti-inflammatory activity from the root bark of Millettia griffoniana.
AID49213Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 46/1931982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID330692Effect on life span of diet restricted Caenorhabditis elegans N2 at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID671883Inhibition of hypersensitive immune responses in rat passive cutaneous anaphylaxis model at 30 mg/kg2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302512Effect on body weight in Balb/c-nu/nu mouse xenografted with Fucci introduced human MCF7 cells at 20 mg/kg, ip qd administered as single dose2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID49394Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 34/1651982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID4791Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors.
AID145696Binding affinity to Norepinephrine transporter using [3H]-nisoxatine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID204217Binding affinity to Serotonin transporter using [3H]-paroxetine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1135536Central anticholinergic activity against physostigmine-induced lethality in Carworth CF1 mouse assessed as animal death at 10 mg/kg, po treated 5 hrs before 1.6 mg/kg, sc physostigmine treatment and 2 mg/kg, ip atropine methyl nitrate treated 0.5 hrs befo1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Synthesis and stereospecific antipsychotic activity of (-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine.
AID204880Binding affinity towards Serotonin transporter using [3H]paroxetine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID23972logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID49386Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 45/2311982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID1302524Inhibition of G9a (unknown origin) by AlphaELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302522Competitive inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using varying Ac-KRSK-MCA peptide as substrate in presence of SAM preincubated for 1 hr followed by substrate addition measured after 15 mins by Linewea2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID23975logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1132676Antiallergic activity in in guinea pig ileum strips assessed as inhibition of bradykinin-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1132686Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction at 3 mg/kg, iv after 30 mins by Evans blue staining1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID49246Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 28/1301982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1302505Inhibition of recombinant his-tagged Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using GST-fused histone H3 (1 to 57 residues) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by Western blot analy2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302515Inhibition of Set7/9 in human MCF7 cells assessed as reduction of ERalpha expression at 43 uM by immunoblotting analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302525Inhibition of G9a (unknown origin) by ELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID697464Antagonist activity at 5HT2A receptor2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
AID330691Effect on life span of Caenorhabditis elegans N2 treated on day 1 at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1576317Antiinflammatory activity in Swiss mouse assessed as reduction in dextran-induced paw edema at 10 mg/kg, po treated 1 hr prior to dextran challenge and measured every 60 mins for 4 hrs by plethysmometer analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Evaluation of anti-inflammatory activity and molecular docking study of new aza-bicyclic isoxazoline acylhydrazone derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID330660Effect on life span of Caenorhabditis elegans at 100 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132679Antiallergic activity in in guinea pig lung tissue assessed as inhibition of SRS-A production1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID23964logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1132688Antiallergic activity in in guinea pig ileum strips assessed as inhibition of histamine-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID23970logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1132675Antiallergic activity in in guinea pig ileum strips assessed as inhibition of serotonin-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID5677Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID5514Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor.
AID23973Partition coefficient (logD, measured by HPLC, log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID330696Effect on life span of Caenorhabditis elegans daf16(mu86) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132684Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction at 10 mg/kg, iv after 30 mins by Evans blue staining1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,098)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901301 (62.01)18.7374
1990's376 (17.92)18.2507
2000's200 (9.53)29.6817
2010's167 (7.96)24.3611
2020's54 (2.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials262 (11.41%)5.53%
Reviews119 (5.18%)6.00%
Case Studies218 (9.49%)4.05%
Observational3 (0.13%)0.25%
Other1,695 (73.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (23)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe A[NCT04108104]Phase 2154 participants (Actual)Interventional2019-11-30Completed
Effect of Cyproheptadine on Weight Gain and Feeding Behavior in 2 to 4 Years Old Children With Failure to Thrive[NCT01314989]Phase 420 participants (Anticipated)Interventional2010-12-31Recruiting
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients[NCT04488081]Phase 21,500 participants (Anticipated)Interventional2020-07-31Recruiting
Altering Activation Patterns in the Distal Upper Extremity After Stroke[NCT02418949]96 participants (Actual)Interventional2015-11-30Active, not recruiting
Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk[NCT01132547]Phase 322 participants (Actual)Interventional2010-06-30Terminated(stopped due to The study was terminated due to slow accrual.)
A Double-Blind Placebo-Controlled Study of Combination Therapy in Children With ADHD[NCT01940978]Phase 499 participants (Actual)Interventional2014-03-31Completed
An Open Label Randomized Phase II Study of an Appetite Stimulant, Cyproheptadine Hydrochloride, With and Without a Nutritional Supplement, in Children With Cancer/Treatment-Related Weight Loss[NCT00949117]Phase 29 participants (Actual)Interventional2009-09-30Terminated(stopped due to study not feasible with low accrual. DSMB recommended closure)
Mechanisms of Neuromuscular Fatigue Post Stroke[NCT01688570]Early Phase 127 participants (Actual)Interventional2011-08-31Completed
Molecular Markers of Neuroplasticity During High-Intensity Exercise in Subjects With Incomplete Spinal Cord Injury[NCT01538693]30 participants (Anticipated)Interventional2011-12-31Completed
A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking[NCT01076283]Phase 214 participants (Actual)Interventional2009-12-31Completed
Double-blind, Three-way Cross-over, Placebo-controlled Study to Assess the Efficacy, Safety and Mechanisms of Treatment With Rupatadine 20 mg and 40 mg in Cold Contact Urticaria (CCU)[NCT01605487]Phase 224 participants (Actual)Interventional2012-06-30Completed
The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia[NCT00066248]Phase 270 participants (Actual)Interventional2003-06-30Completed
Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders[NCT02568007]Phase 44 participants (Actual)Interventional2015-12-31Terminated(stopped due to Unable to enroll adequate participants)
The Pediatric Oncology Interventional Nutrition Therapy (POINT) Trial: A Pilot Study[NCT06175273]Phase 2/Phase 345 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial[NCT04820751]Phase 3200 participants (Anticipated)Interventional2021-04-10Not yet recruiting
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community With Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide in Decreasing Recovery Time[NCT05087381]Phase 41,200 participants (Actual)Interventional2021-10-01Completed
Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19[NCT04979221]Phase 3274 participants (Anticipated)Interventional2021-07-26Recruiting
Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19: a Single-center, Observational Retrospective-prospective Comparative Study.[NCT04876573]Phase 260 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Noninvasive Markers of Functional Nausea in Children[NCT03593811]130 participants (Anticipated)Interventional2018-08-03Enrolling by invitation
A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine.[NCT02358265]Phase 3192 participants (Actual)Interventional2014-12-31Terminated(stopped due to poor recruitment)
Blocking the Effects of Serotonin to Prevent Ischemic Mitral Regurgitation: a Randomized Trial (CYPRO-MR)[NCT05469165]Phase 2214 participants (Anticipated)Interventional2023-06-20Recruiting
A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain[NCT01675050]Phase 24 participants (Actual)Interventional2012-08-31Terminated(stopped due to Due to the wide availability of the drug in clinical practice, it was impossible to recruit adequate numbers for scientific power.)
A Phase 1, Open-label, Cross-over Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine Following Single Dose Oral Administration of KT110 Tablet and Following Administration of Alpress and Periactin Marketed Tab[NCT06147622]Phase 18 participants (Anticipated)Interventional2024-02-29Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC)

Following a maximum voluntary contraction (MVC) -- Time (s) required for muscle electromyographic (EMG) signals to reduce to within 3 SD of pre-MVC EMG activity. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)

InterventionSeconds (Mean)
Cyproheptadine + AMP-1.66
Placebo for Cyproheptadine + Stretching-0.96
Cyproheptadine + Stretching-1.06
Placebo for Cyproheptadine + AMP-2.65

Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT)

GWMFT is a clinical outcome measure comprised of 15 timed tasks focusing on upper extremity function. Maximum allowable time per task is 120 seconds. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)

InterventionSeconds (Mean)
Cyproheptadine + AMP-3.66
Placebo for Cyproheptadine + Stretching-0.51
Cyproheptadine + Stretching-4.00
Placebo for Cyproheptadine + AMP-3.89

Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline

(NCT01132547)
Timeframe: 8 weeks

Interventionparticipants (Number)
Arm I Cyproheptadine Hydrochloride0
Arm II Placebo2

Pattern of Weight in the Study Population

Change from Baseline in Weight (NCT01132547)
Timeframe: Baseline and 8 weeks

InterventionKilograms (Mean)
Arm I Cyproheptadine Hydrochloride0.18
Arm II Placebo-0.32

Severity of Weight Loss

Change from Baseline in Weight Z score (NCT01132547)
Timeframe: Baseline and 8 weeks

InterventionZ score (Mean)
Arm I Cyproheptadine Hydrochloride0.12
Arm II Placebo-0.02

Body Mass Index as Assessed at Baseline and 24 Weeks

Change in Body Mass Index (BMI) in subjects from Baseline visit to 24 week visit. (NCT00949117)
Timeframe: 24 weeks

Interventionkg/m^2 (Mean)
Arm I- Cyproheptadine Hydrochloride1.9

Change in Weight for Age Z-score From Baseline Through 24 Weeks

Change in weight for age Z-score from Baseline through 24 weeks while on study treatment. Weight for age Z-score calculated using the Center for Disease Control and Prevention (CDC) weight-for-age Z score data tables. (NCT00949117)
Timeframe: Baseline and 24 weeks

Interventionz score (Mean)
Arm I- Cyproheptadine Hydrochloride1.47

Difference Between Measures of Weight at Baseline and at Week 24

Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period. (NCT00949117)
Timeframe: 24 weeks

Interventionkilograms (Mean)
Arm I- Cyproheptadine Hydrochloride4.3

Alcohol Drinking

"Whether baclofen, as compared to active placebo, results in lower quantity of alcohol consumed during the Alcohol Self-Administration (ASA).~Consistent with O'Malley et al. 2002, the ASA paradigm allows to use a fixed-dose (the priming drink), followed by a 2-hour free-choice phase when subjects may choose to drink or not up to 8 mini-drinks. Participants receive a monetary compensation of $3 dollars per each mini-drink not consumed; therefore the amount of minidrinks consumed during the 2-hour sessions ranges 0-8, and the monetary compensation ranges $0-24. The quantity of alcohol consumed during the free-choice session is expressed as standard drinking unit, where a standard drink unit contains about 14 grams of pure alcohol (about 0.6 fluid ounces or 1.2 tablespoons)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionstandard drinking units (Mean)
Baclofen0.17
Cyproheptadine1.43

Alcohol Urge

"Whether baclofen, as compared to active placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Urge Questionnaire (AUQ)] during the Cue Reactivity.~The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from strongly disagree to strongly agree. Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by summing the item scores and ranges from 8 (lowest craving value) to 56 (highest craving value). Higher scores reflect greater craving (i.e. worse outcome)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionunits on a scale (Mean)
Baclofen22.5
Cyproheptadine19.4

Abdominal Pain

"Participants rated the highest intensity of abdominal pain they experienced during the past two weeks on a scale of 0 (No Pain) to 10 (The Most Pain Possible), as derived from the Abdominal Pain Index - Child Version (Laird et al. 2015. Journal of Pediatric Psychology, 40(5), 517-525)." (NCT01675050)
Timeframe: 10 weeks

Interventionunits on a scale (Mean)
All Participants Post Cyproheptadine5.25
All Participants Post Placebo8

Pressure Pain Threshold

Increasing pressures were applied with a pressure plunger to the participants' thumbnail. The pressure at which the participant said that s/he felt pain is noted. The pressure is measured in kilograms by centimeters squared. (NCT01675050)
Timeframe: at 4 weeks of cyproheptadine or placebo treatment

Interventionkg/cm^2 (Mean)
All Participants Post Cyproheptadine1.15
All Participants Post Placebo1.23

SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
haloperidol[no description available]high825aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
haloperidol[no description available]high820aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
thioridazine hydrochloride[no description available]medium10hydrochloridefirst generation antipsychotic;
geroprotector
cromolyn sodium[no description available]medium190organic sodium saltanti-asthmatic drug;
drug allergen
cromolyn sodium[no description available]medium191organic sodium saltanti-asthmatic drug;
drug allergen
quinacrine[no description available]medium50acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
gallopamil[no description available]medium10benzenes;
organic amino compound
4-aminopyridine[no description available]medium30aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
phenytoin[no description available]medium130imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
phenytoin[no description available]medium131imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
8-(4-sulfophenyl)theophylline[no description available]medium10
8-phenyltheophylline[no description available]medium30
theophylline[no description available]medium260dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
amitriptyline[no description available]high507carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amitriptyline[no description available]high500carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
anisindione[no description available]medium10aromatic ketone;
beta-diketone		anticoagulant;
vitamin K antagonist
baclofen[no description available]medium90amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
baclofen[no description available]medium92amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
benzocaine[no description available]medium10benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
bepridil[no description available]high30pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
biperiden[no description available]medium20piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
bupivacaine[no description available]medium30aromatic amide;
piperidinecarboxamide;
tertiary amino compound
buspirone[no description available]medium100azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
butacaine[no description available]medium10benzoate ester
butamben[no description available]medium10amino acid ester;
benzoate ester;
primary amino compound;
substituted aniline		local anaesthetic
caffeine[no description available]medium100purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
caffeine[no description available]medium101purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil[no description available]medium160aromatic ether;
nitrile;
polyether;
tertiary amino compound
verapamil[no description available]medium161aromatic ether;
nitrile;
polyether;
tertiary amino compound
carbamazepine[no description available]medium170dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
chlordiazepoxide[no description available]medium190benzodiazepine
chlorpheniramine[no description available]high378monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpheniramine[no description available]high370monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine[no description available]high642organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpromazine[no description available]high640organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
cimetidine[no description available]medium290aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cimetidine[no description available]medium291aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
clomipramine[no description available]high251dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clomipramine[no description available]high250dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
desipramine[no description available]high260dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
diazepam[no description available]medium2901,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazepam[no description available]medium2921,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide[no description available]medium80benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
dibucaine[no description available]medium50aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
dicyclomine[no description available]high40carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
diphenidol[no description available]medium10benzenes;
piperidines;
tertiary alcohol		antiemetic
dilazep[no description available]medium20benzoate ester;
diazepane;
diester;
methoxybenzenes		cardioprotective agent;
platelet aggregation inhibitor;
vasodilator agent
diphenhydramine[no description available]high635ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
diphenhydramine[no description available]high630ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
dipyridamole[no description available]high90piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
doxepin[no description available]medium140dibenzooxepine;
tertiary amino compound		antidepressant
doxepin[no description available]medium141dibenzooxepine;
tertiary amino compound		antidepressant
droperidol[no description available]medium40aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
etazolate[no description available]medium10ethyl ester;
hydrazone;
pyrazolopyridine		alpha-secretase activator;
antidepressant;
antipsychotic agent;
anxiolytic drug;
GABA agent;
neuroprotective agent;
phosphodiesterase IV inhibitor
felodipine[no description available]medium40dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
flufenamic acid[no description available]medium90aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluphenazine[no description available]medium70N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil[no description available]medium70ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
hydroxyzine[no description available]high5119hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
hydroxyzine[no description available]high510hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
lidocaine[no description available]medium100benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
ici 118551[no description available]medium10indanes
imipramine[no description available]medium420dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin[no description available]medium720aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
indomethacin[no description available]medium722aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
1-methyl-3-isobutylxanthine[no description available]medium203-isobutyl-1-methylxanthine
loperamide[no description available]medium30monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
mepivacaine[no description available]medium50piperidinecarboxamidedrug allergen;
local anaesthetic
benzoic acid [2-methyl-2-(propylamino)propyl] ester[no description available]medium10benzoate ester
metoprolol[no description available]medium30aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
mianserin[no description available]high380dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
nifedipine[no description available]medium90C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nifedipine[no description available]medium91C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nisoldipine[no description available]medium30C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrendipine[no description available]medium20C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nortriptyline[no description available]medium110organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
oxethazaine[no description available]medium20amino acid amide
benoxinate[no description available]medium10amino acid ester;
benzoate ester;
substituted aniline;
tertiary amino compound		drug allergen;
local anaesthetic;
topical anaesthetic
papaverine[no description available]medium60benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pentobarbital[no description available]medium150barbituratesGABAA receptor agonist
pheniramine[no description available]medium20pyridines;
tertiary amino compound
phenobarbital[no description available]medium120barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenoxybenzamine[no description available]medium550aromatic amine
phenoxybenzamine[no description available]medium551aromatic amine
practolol[no description available]medium30acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
pramoxine[no description available]medium10aromatic ether;
morpholines		local anaesthetic
prazosin[no description available]medium120aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine[no description available]medium10amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
proadifen[no description available]medium20diarylmethane
procainamide[no description available]medium40benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
procaine[no description available]medium20benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
promazine[no description available]high70phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine[no description available]high370phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
proxymetacaine[no description available]medium10benzoate ester
protriptyline[no description available]medium60carbotricyclic compoundantidepressant
pyrilamine[no description available]high320aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone[no description available]medium20methoxybenzenes
rolipram[no description available]medium20pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
secobarbital[no description available]medium30barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
sotalol[no description available]medium40ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
spiperone[no description available]high270aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
tetracaine[no description available]medium50benzoate ester;
tertiary amino compound		local anaesthetic
thioridazine[no description available]high90phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
trazodone[no description available]high70monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
trequinsin[no description available]medium10pyridopyrimidine
trifluoperazine[no description available]medium60N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
reserpine[no description available]medium680alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
reserpine[no description available]medium681alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
phentolamine[no description available]medium540imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
hexobendine[no description available]medium10trihydroxybenzoic acid
dichloroisoproterenol[no description available]medium20
tetraethylammonium chloride[no description available]medium10organic chloride salt;
quaternary ammonium salt		potassium channel blocker
tetrabenazine[no description available]medium80benzoquinolizine;
cyclic ketone;
tertiary amino compound
piperoxan[no description available]medium20
nifenalol[no description available]medium10C-nitro compound
brompheniramine[no description available]high60organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
propoxycaine[no description available]medium10benzoate ester
dimethisoquin[no description available]medium10isoquinolines
parethoxycaine[no description available]medium10benzoate ester
yohimbine[no description available]high240methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
2-chloroadenosine[no description available]medium10purine nucleoside
prenylamine[no description available]medium30diarylmethane
bicuculline[no description available]medium100benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
hexylcaine[no description available]medium10benzoate ester
piperocaine[no description available]medium10benzoate ester
diperodon[no description available]medium10carbamate ester
cyclomethycaine[no description available]medium10benzoate ester
carcainium chloride[no description available]medium10
azacyclonol[no description available]medium20diarylmethane
butoxamine[no description available]medium10
dexpropranolol[no description available]medium20propranolol
iprindole[no description available]medium10indoles
carticaine[no description available]medium10thiophenecarboxylic acid
timolol[no description available]medium40timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
butaclamol[no description available]medium30organic heteropentacyclic compound
etidocaine[no description available]medium10amino acid amidelocal anaesthetic
diltiazem[no description available]medium1105-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
diltiazem[no description available]medium1115-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
Arbaclofen[no description available]medium10organonitrogen compound;
organooxygen compound
colforsin[no description available]medium20acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
opromazine[no description available]medium10phenothiazines
corynanthine[no description available]medium10yohimban alkaloid
phenylisopropyladenosine[no description available]medium10aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound		adenosine A1 receptor agonist;
neuroprotective agent
w 7[no description available]medium10
2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene[no description available]medium10
rac 109[no description available]medium10
atropine[no description available]medium830
atropine[no description available]medium832
strychnine[no description available]medium50monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
quinidine[no description available]medium50cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
cocaine[no description available]medium110benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylstilbestrol[no description available]medium50olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
rauwolscine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylate
chlorprothixene[no description available]medium30chlorprothixene
flunarizine[no description available]medium40diarylmethane
thiothixene[no description available]medium30N-methylpiperazineanticoronaviral agent
cinnarizine[no description available]high83diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
cinnarizine[no description available]high80diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
quinine[no description available]medium30cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
codeine[no description available]medium90morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
codeine[no description available]medium91morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
morphine[no description available]medium490morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
morphine[no description available]medium492morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
levorphanol[no description available]medium40morphinane alkaloid
levorphanol[no description available]medium41morphinane alkaloid
dextrorphan[no description available]medium10morphinane alkaloid
zimeldine[no description available]medium80styrenes
1-methyl-d-lysergic acid butanolamide[no description available]medium60ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
scopolamine hydrobromide[no description available]medium150
astemizole[no description available]high195benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
astemizole[no description available]high190benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
oxatomide[no description available]medium70benzimidazoles;
diarylmethane;
N-alkylpiperazine		anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
azatadine[no description available]high480benzocycloheptapyridine;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
azatadine[no description available]high4820benzocycloheptapyridine;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
desmethylastemizole[no description available]medium10benzimidazoles
3-phenylpropionic acid[no description available]medium10benzenes;
monocarboxylic acid		antifungal agent;
human metabolite;
plant metabolite
gamma-aminobutyric acid[no description available]medium190amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
acetic acid[no description available]medium50monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
citric acid, anhydrous[no description available]medium30tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
2-aminoacetaldehyde[no description available]medium10amino aldehyde;
omega-aminoaldehyde		Escherichia coli metabolite
phosphoglycolate[no description available]medium10carboxyalkyl phosphateEscherichia coli metabolite;
mouse metabolite
hexachlorocyclohexane[no description available]medium10chlorocyclohexane
oxalic acid[no description available]medium10alpha,omega-dicarboxylic acidalgal metabolite;
human metabolite;
plant metabolite
phenol[no description available]medium30phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
phenethylamine[no description available]medium30alkaloid;
aralkylamine;
phenylethylamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
phosphoric acid[no description available]medium10phosphoric acidsalgal metabolite;
fertilizer;
human metabolite;
NMR chemical shift reference compound;
solvent
tryptamine[no description available]medium90aminoalkylindole;
aralkylamino compound;
indole alkaloid;
tryptamines		human metabolite;
mouse metabolite;
plant metabolite
alprenolol[no description available]medium10secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
apraclonidine[no description available]medium10dichlorobenzene;
guanidines;
imidazolines		alpha-adrenergic agonist;
antiglaucoma drug;
beta-adrenergic agonist;
diagnostic agent;
ophthalmology drug
arecoline[no description available]medium30enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
bromazepam[no description available]medium10organic molecular entity
carbinoxamine[no description available]medium30monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
carbofuran[no description available]medium101-benzofurans;
carbamate ester		acaricide;
agrochemical;
avicide;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nematicide
clonidine[no description available]medium380clonidine;
imidazoline
clonidine[no description available]medium385clonidine;
imidazoline
cycloleucine[no description available]medium10non-proteinogenic alpha-amino acidEC 2.5.1.6 (methionine adenosyltransferase) inhibitor
amphetamine[no description available]medium350primary amine
diclofenac[no description available]medium60amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
ddt[no description available]medium30benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant
valproic acid[no description available]medium230branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
valproic acid[no description available]medium232branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
domperidone[no description available]medium30benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
flurbiprofen[no description available]medium40fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluspirilene[no description available]medium20diarylmethane
guanfacine[no description available]medium20acetamides
ibuprofen[no description available]medium80monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
ketanserin[no description available]high620aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
lorazepam[no description available]medium80benzodiazepine
lorazepam[no description available]medium81benzodiazepine
mescaline[no description available]medium90methoxybenzenes;
phenethylamine alkaloid;
primary amino compound		hallucinogen
methadone[no description available]medium80benzenes;
diarylmethane;
ketone;
tertiary amino compound
metharbital[no description available]medium10organic molecular entity
muscimol[no description available]medium30alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
naphazoline[no description available]medium10naphthalenes
nisoxetine[no description available]medium10aromatic ether;
secondary amino compound		adrenergic uptake inhibitor;
antidepressant
nomifensine[no description available]medium30isoquinolinesdopamine uptake inhibitor
oxotremorine[no description available]medium50N-alkylpyrrolidine
oxymetazoline[no description available]medium20carboxamidine;
imidazolines;
phenols		alpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
phenylbutazone[no description available]medium180pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
pipamperone[no description available]medium50aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
propranolol[no description available]medium750naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
propranolol[no description available]medium755naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
pyrimethamine[no description available]medium50aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
trimethoprim[no description available]medium30aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
wb 4101[no description available]medium20aromatic ether;
benzodioxine;
secondary amino compound		alpha-adrenergic antagonist
xylazine[no description available]medium101,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
corticosterone[no description available]medium14011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
lysergic acid diethylamide[no description available]medium780ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound		dopamine agonist;
hallucinogen;
serotonergic agonist
3,3',5-triiodothyroacetic acid[no description available]medium20
thyroxine[no description available]medium1302-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
carbachol[no description available]medium60ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
aldosterone[no description available]medium11011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
pilocarpine[no description available]medium110pilocarpineantiglaucoma drug
apomorphine[no description available]medium360aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
apomorphine[no description available]medium361aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
carbaryl[no description available]medium20carbamate ester;
naphthalenes		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant
cytidine monophosphate[no description available]medium10cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
medroxyprogesterone acetate[no description available]medium2020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
cordycepin[no description available]medium203'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
ethylamine[no description available]medium10primary aliphatic aminehuman metabolite
tetramethylammonium[no description available]medium10quaternary ammonium ion
mephobarbital[no description available]medium20barbituratesanticonvulsant
ketobemidone[no description available]medium10piperidines
cytisine[no description available]medium10alkaloid;
bridged compound;
lactam;
organic heterotricyclic compound;
secondary amino compound		nicotinic acetylcholine receptor agonist;
phytotoxin;
plant metabolite
bufotenin[no description available]medium10tertiary amine;
tryptamine alkaloid		coral metabolite;
hallucinogen
fructose-1,6-diphosphate[no description available]medium10D-fructofuranose 1,6-bisphosphatemouse metabolite
dihydrotestosterone[no description available]medium6017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
trimellitic acid[no description available]medium10tricarboxylic acid
pimozide[no description available]high310benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
benperidol[no description available]medium20aromatic ketone
benzetimide[no description available]medium10piperidines
acetylpyruvic acid[no description available]medium10beta-diketone;
dioxo monocarboxylic acid		bacterial metabolite
metoprine[no description available]medium10
coformycin[no description available]medium10coformycinsEC 3.5.4.4 (adenosine deaminase) inhibitor
pizotyline[no description available]high383benzocycloheptathiophenehistamine antagonist;
muscarinic antagonist;
serotonergic antagonist
pizotyline[no description available]high380benzocycloheptathiophenehistamine antagonist;
muscarinic antagonist;
serotonergic antagonist
metergoline[no description available]high552carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
metergoline[no description available]high550carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
lofexidine[no description available]medium10aromatic ether;
carboxamidine;
dichlorobenzene;
imidazoles		alpha-adrenergic agonist;
antihypertensive agent
5-(2-cyclohexylidene-ethyl)-5-ethylbarbiturate[no description available]medium10
indoramin[no description available]medium20tryptamines
penfluridol[no description available]medium30diarylmethane
tiamenidine[no description available]medium10organochlorine compound
sufentanil[no description available]high30anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
carfentanil[no description available]medium10methyl ester;
piperidines;
tertiary amino compound;
tertiary carboxamide		mu-opioid receptor agonist;
opioid analgesic;
tranquilizing drug
fenclofenac[no description available]medium10aromatic ether
flutonidine[no description available]medium20
tutin[no description available]medium10gamma-lactone
nicotine[no description available]medium703-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
5,6-dihydrouridine[no description available]medium10uridinesbiomarker
methotrexate[no description available]medium50dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
methotrexate[no description available]medium51dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
naproxen[no description available]medium60methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
camphora[no description available]medium10camphor
biotin[no description available]medium20biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
ouabain[no description available]medium5011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
xylose 1-phosphate[no description available]medium10xylose phosphate
picrotoxinin[no description available]medium10epoxide;
gamma-lactone;
organic heteropentacyclic compound;
picrotoxane sesquiterpenoid;
tertiary alcohol		GABA antagonist;
plant metabolite;
serotonergic antagonist
1-(5'-phospho-beta-d-ribofuranosyl)barbituric acid[no description available]medium10pyrimidine ribonucleoside 5'-monophosphate
etorphine[no description available]medium10alcohol;
morphinane alkaloid		opioid analgesic;
opioid receptor agonist;
sedative
dieldrin[no description available]medium10epoxide;
organochlorine compound;
organochlorine insecticide		carcinogenic agent;
xenobiotic
benztropine[no description available]medium90diarylmethane
tamoxifen[no description available]medium80stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
tamoxifen[no description available]medium81stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
ketazocine[no description available]medium10
dinoprostone[no description available]medium80prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost[no description available]medium40monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
alprostadil[no description available]medium40prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
flupenthixol[no description available]medium10flupenthixoldopaminergic antagonist
triprolidine[no description available]high131N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
triprolidine[no description available]high130N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
guanabenz[no description available]medium10dichlorobenzene
2-amino-4-methoxy-3-butenoic acid[no description available]medium10
24,25-dihydroxyvitamin d 3[no description available]medium10
dicumarol[no description available]medium20hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
warfarin[no description available]medium60benzenes;
hydroxycoumarin;
methyl ketone
clozapine[no description available]high261benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
clozapine[no description available]high260benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
oxypurinol[no description available]medium20pyrazolopyrimidinedrug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor
allopurinol[no description available]medium60nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
allopurinol[no description available]medium61nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
butaclamol[no description available]medium20amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound		dopaminergic antagonist
benzene[no description available]medium10aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
benzophenone[no description available]medium10benzophenonesphotosensitizing agent;
plant metabolite
mesoridazine[no description available]medium20phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
perphenazine[no description available]medium80N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
perphenazine[no description available]medium81N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
prochlorperazine[no description available]medium70N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
prochlorperazine[no description available]medium71N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
tilorone[no description available]medium10aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
nitrobenzene[no description available]medium10nitroarene;
nitrobenzenes
anisole[no description available]medium10monomethoxybenzeneplant metabolite
chlorobenzene[no description available]medium10monochlorobenzenessolvent
acridines[no description available]medium10acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
dextropropoxyphene[no description available]medium501-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
fluanisone[no description available]medium10aromatic ketone
acetophenazine[no description available]medium10N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
phenothiazines		phenothiazine antipsychotic drug
naloxone[no description available]medium420morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
cyclobenzaprine[no description available]medium40carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
lidocaine hydrochloride[no description available]medium10hydrochlorideanti-arrhythmia drug;
local anaesthetic
epinastine[no description available]medium30benzazepine;
guanidines		anti-allergic agent;
H1-receptor antagonist;
histamine antagonist;
ophthalmology drug
phenindamine[no description available]medium20indene
1-(1-naphthyl)piperazine[no description available]medium40N-arylpiperazine
1-(3-chlorophenyl)piperazine[no description available]medium130monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
5-carboxamidotryptamine[no description available]medium80tryptamines
5-methoxytryptamine[no description available]medium150aromatic ether;
primary amino compound;
tryptamines		5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist
amoxapine[no description available]medium30dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
cgs 12066[no description available]medium10N-arylpiperazine;
organofluorine compound;
pyrroloquinoxaline		serotonergic agonist
fluoxetine[no description available]medium400(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
loxapine[no description available]medium70dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
methiothepin[no description available]high230aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound		antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist
1-(3-trifluoromethylphenyl)piperazine[no description available]medium70(trifluoromethyl)benzenes;
N-arylpiperazine		environmental contaminant;
psychotropic drug;
serotonergic agonist;
xenobiotic
ritanserin[no description available]high250organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
methysergide[no description available]medium2470ergoline alkaloid
methysergide[no description available]medium2479ergoline alkaloid
2-bromolysergic acid diethylamide[no description available]medium50
dihydroergotamine[no description available]medium140ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
lisuride[no description available]medium80monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
lisuride[no description available]medium81monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
pergolide[no description available]medium70diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
mesulergine[no description available]medium80ergot alkaloid;
sulfamides		antiparkinson drug;
dopamine agonist;
serotonergic antagonist
5-benzyloxytryptamine[no description available]medium10
1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine[no description available]medium10(trifluoromethyl)benzenes;
N-alkylpiperazine;
N-arylpiperazine;
primary arylamine;
substituted aniline		geroprotector;
serotonergic agonist
lergotrile[no description available]medium20organic heterotetracyclic compound;
organonitrogen heterocyclic compound
histamine[no description available]medium1120aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
histamine[no description available]medium11219aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
cetirizine[no description available]high3616ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
cetirizine[no description available]high360ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
dexchlorpheniramine[no description available]medium50chlorphenamine
dexchlorpheniramine[no description available]medium52chlorphenamine
w-a 335[no description available]medium10
sertindole[no description available]medium10heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
irindalone[no description available]medium10
tefludazine[no description available]medium10
octoclothepine, (s)-isomer[no description available]medium10
8-hydroxy-2-(di-n-propylamino)tetralin[no description available]high130phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
sumatriptan[no description available]medium90sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
1-(2-methoxyphenyl)piperazine[no description available]medium20piperazines
methylbufotenin[no description available]medium10aromatic ether;
tertiary amino compound;
tryptamine alkaloid		hallucinogen;
plant metabolite
bromocriptine[no description available]medium520indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
bromocriptine[no description available]medium524indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
risperidone[no description available]high701,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
n,n-dimethyltryptamine[no description available]medium70tryptamine alkaloid;
tryptamines
fluperlapine[no description available]medium10benzazepine
tiospirone[no description available]medium10
5-methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1h indole[no description available]medium30indoles
ici 169369[no description available]medium20
olanzapine[no description available]high81benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
olanzapine[no description available]high80benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
4-hydroxybenzoic acid[no description available]medium10monohydroxybenzoic acidalgal metabolite;
plant metabolite
benzoic acid[no description available]medium10benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
benzyl alcohol[no description available]medium10benzyl alcoholsantioxidant;
fragrance;
metabolite;
solvent
butyric acid[no description available]medium10fatty acid 4:0;
straight-chain saturated fatty acid		human urinary metabolite;
Mycoplasma genitalium metabolite
salicylic acid[no description available]medium20monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
gallic acid[no description available]medium10trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
octanoic acid[no description available]medium10medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite
4-aminophenol[no description available]medium10aminophenolallergen;
metabolite
hydroquinone[no description available]medium20benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
methanol[no description available]medium50alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
n,n-dimethylaniline[no description available]medium10dimethylaniline;
tertiary amine
4-nitrophenol[no description available]medium204-nitrophenolshuman xenobiotic metabolite;
mouse metabolite
pyrogallol[no description available]medium20benzenetriol;
phenolic donor		plant metabolite
tryptophan[no description available]medium10alpha-amino acid;
amino acid zwitterion;
aminoalkylindole;
aromatic amino acid;
polar amino acid		Daphnia magna metabolite
vanillin[no description available]medium10benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
catechin[no description available]medium20hydroxyflavan
menthol[no description available]medium20p-menthane monoterpenoid;
secondary alcohol		volatile oil component
2-aminofluorene[no description available]medium10
homovanillic acid[no description available]medium50guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
6-hydroxymelatonin[no description available]medium10acetamides;
tryptamines		metabolite;
mouse metabolite
oxyquinoline[no description available]medium10monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
acetaminophen[no description available]medium100acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
aspirin[no description available]medium310benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
aspirin[no description available]medium311benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
beta-naphthoflavone[no description available]medium10extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist
bumetanide[no description available]medium30amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
ciprofibrate[no description available]medium20cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clofibrate[no description available]medium40aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clofibric acid[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide[no description available]medium10sulfonamide
4-cresol[no description available]medium10cresolEscherichia coli metabolite;
human metabolite;
uremic toxin
danthron[no description available]medium20dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
dapsone[no description available]medium70substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
decanoic acid[no description available]medium10medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
anti-inflammatory agent;
antibacterial agent;
human metabolite;
plant metabolite;
volatile oil component
diflunisal[no description available]medium40monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
doxylamine[no description available]high30pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
emodin[no description available]medium10trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
ethacrynic acid[no description available]medium40aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
fenoprofen[no description available]medium30monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
berotek[no description available]medium10resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
fluorescite[no description available]medium20benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
furosemide[no description available]medium70chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
ketoprofen[no description available]medium60benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketotifen[no description available]high242cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
ketotifen[no description available]high240cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
labetalol[no description available]medium40benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lamotrigine[no description available]medium401,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lauric acid[no description available]medium10medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
antibacterial agent;
plant metabolite
losartan[no description available]medium30biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
meperidine[no description available]medium60ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mesalamine[no description available]medium30amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
mexiletine[no description available]medium20aromatic ether;
primary amino compound		anti-arrhythmia drug
mitoxantrone[no description available]medium30dihydroxyanthraquinoneanalgesic;
antineoplastic agent
oxazepam[no description available]medium501,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxyphenbutazone[no description available]medium20phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
aminosalicylic acid[no description available]medium30aminobenzoic acid;
phenols		antitubercular agent
phenolphthalein[no description available]medium20phenols
phenolsulfonphthalein[no description available]medium102,1-benzoxathiole;
arenesulfonate ester;
phenols;
sultone		acid-base indicator;
diagnostic agent;
two-colour indicator
probenecid[no description available]medium60benzoic acids;
sulfonamide		uricosuric drug
propofol[no description available]medium40phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
propyl gallate[no description available]medium10trihydroxybenzoic acid
1,2,5,8-tetrahydroxy anthraquinone[no description available]medium10tetrahydroxyanthraquinoneEC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
salicylamide[no description available]medium20phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
sulfadimethoxine[no description available]medium30aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfathiazole[no description available]medium301,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfinpyrazone[no description available]medium50pyrazolidines;
sulfoxide		uricosuric drug
suprofen[no description available]medium20aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
temazepam[no description available]medium40benzodiazepine
terfenadine[no description available]medium460diarylmethane
terfenadine[no description available]medium4619diarylmethane
thonzylamine[no description available]medium10methoxybenzenes
tiaprofenic acid[no description available]medium20aromatic ketone;
monocarboxylic acid;
thiophenes		drug allergen;
non-steroidal anti-inflammatory drug
triflupromazine[no description available]medium30organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
tripelennamine[no description available]medium170aromatic amine
zomepirac[no description available]medium20aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
estriol[no description available]medium2016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
2-aminophenol[no description available]medium10aminophenolbacterial metabolite
tetrahydrocortisol[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3alpha-hydroxy steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
prednisone[no description available]medium14011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
prednisone[no description available]medium14211-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
tetrahydrocortisone[no description available]medium1021-hydroxy steroid
estrone[no description available]medium3017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
androsterone[no description available]medium1017-oxo steroid;
3alpha-hydroxy steroid;
androstanoid;
C19-steroid		androgen;
anticonvulsant;
human blood serum metabolite;
human metabolite;
human urinary metabolite;
mouse metabolite;
pheromone
etiocholanolone[no description available]medium1017-oxo steroid;
3alpha-hydroxy steroid;
androstanoid		human metabolite;
mouse metabolite
dehydroepiandrosterone[no description available]medium2017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
hydroxyacetylaminofluorene[no description available]medium102-acetamidofluorenes
triiodothyronine[no description available]medium902-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
benz(a)anthracene[no description available]medium10ortho-fused polycyclic arene;
tetraphenes
chloramphenicol[no description available]medium60C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
ethinyl estradiol[no description available]medium3017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
aniline[no description available]medium10anilines;
primary arylamine
desoxycorticosterone[no description available]medium5020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
norethindrone[no description available]medium2017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
norethynodrel[no description available]medium20oxo steroid
17-alpha-hydroxyprogesterone[no description available]medium1017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
tertiary alpha-hydroxy ketone		human metabolite;
metabolite;
mouse metabolite;
progestin
ampicillin[no description available]medium40beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
alizarin[no description available]medium10dihydroxyanthraquinonechromophore;
dye;
plant metabolite
linalool[no description available]medium10monoterpenoid;
tertiary alcohol		antimicrobial agent;
fragrance;
plant metabolite;
volatile oil component
1,4-dihydroxyanthraquinone[no description available]medium10dihydroxyanthraquinonedye
cyclizine[no description available]high30N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
2,6-dihydroxyanthraquinone[no description available]medium10dihydroxyanthraquinoneantimutagen;
plant metabolite
9,10-anthraquinone[no description available]medium10anthraquinone
thymol[no description available]medium10monoterpenoid;
phenols		volatile oil component
1-naphthol[no description available]medium10naphtholgenotoxin;
human xenobiotic metabolite
2-aminodiphenyl[no description available]medium20
2-phenylphenol[no description available]medium10hydroxybiphenylsantifungal agrochemical;
environmental food contaminant
quinoline[no description available]medium10azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinolines
2-naphthylamine[no description available]medium10naphthylaminecarcinogenic agent
4-biphenylamine[no description available]medium20aminobiphenylcarcinogenic agent
4-phenylphenol[no description available]medium10hydroxybiphenyls
benzidine[no description available]medium20biphenyls;
substituted aniline		carcinogenic agent
4,4'-dihydroxybiphenyl[no description available]medium10hydroxybiphenyls
propylparaben[no description available]medium10benzoate ester;
paraben;
phenols		antifungal agent;
antimicrobial agent
butylphen[no description available]medium10phenolsallergen
methylparaben[no description available]medium10parabenantifungal agent;
antimicrobial food preservative;
neuroprotective agent;
plant metabolite
4-isopropylphenol[no description available]medium10phenolsflavouring agent
4-hydroxyacetophenone[no description available]medium10monohydroxyacetophenonefungal metabolite;
mouse metabolite;
plant metabolite
4-benzylphenol[no description available]medium10
2-ethylhexanol[no description available]medium10primary alcoholplant metabolite;
volatile oil component
2,2,2-trichloroethanol[no description available]medium10chloroethanolmouse metabolite
anthrarufin[no description available]medium10dihydroxyanthraquinone
2-toluic acid[no description available]medium10methylbenzoic acidxenobiotic metabolite
ethyl-p-hydroxybenzoate[no description available]medium10ethyl ester;
paraben		antifungal agent;
antimicrobial food preservative;
phytoestrogen;
plant metabolite
3-tert-butyl-4-hydroxyanisole[no description available]medium10aromatic ether;
phenols		antioxidant;
human xenobiotic metabolite
1-naphthylamine[no description available]medium20naphthylaminehuman xenobiotic metabolite
2-naphthol[no description available]medium10naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
shikimic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid;
hydroxy monocarboxylic acid		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
citronellol[no description available]medium10monoterpenoidplant metabolite
hexanoic acid[no description available]medium10medium-chain fatty acid;
straight-chain saturated fatty acid		human metabolite;
plant metabolite
pregnenolone[no description available]medium1020-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid		human metabolite;
mouse metabolite
ditiocarb[no description available]medium40dithiocarbamic acidschelator;
copper chelator
mequinol[no description available]medium20methoxybenzenes;
phenols		metabolite
catechin[no description available]medium10catechinantioxidant;
plant metabolite
phenetidine[no description available]medium10aromatic ether;
primary amino compound;
substituted aniline		drug metabolite
4-hydroxyphenobarbital[no description available]medium10barbiturates
lithocholic acid[no description available]medium10bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
chenodeoxycholic acid[no description available]medium30bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
epitestosterone[no description available]medium1017alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen antagonist;
human metabolite
chrysophanic acid[no description available]medium10dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite
carvacrol[no description available]medium20botanical anti-fungal agent;
p-menthane monoterpenoid;
phenols		agrochemical;
antimicrobial agent;
flavouring agent;
TRPA1 channel agonist;
volatile oil component
androstenediol[no description available]medium1017beta-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid		androgen;
human metabolite;
mouse metabolite;
radiation protective agent
1,2,3,4-tetrahydro-1-naphthalenol[no description available]medium10
4-iodophenol[no description available]medium10iodophenol
myristic acid[no description available]medium10long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite
4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol[no description available]medium10terpineol;
tertiary alcohol		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiparasitic agent;
apoptosis inducer;
plant metabolite;
volatile oil component
3-hydroxyflavone[no description available]medium10flavonols;
monohydroxyflavone
6-hydroxyquinoline[no description available]medium10monohydroxyquinoline
3-hydroxybiphenyl[no description available]medium10hydroxybiphenyls
diphenylamine[no description available]medium20aromatic amine;
bridged diphenyl fungicide;
secondary amino compound		antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger
alpha-naphthoflavone[no description available]medium10extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
4-propylphenol[no description available]medium10alkylbenzene
hexafluoroisopropanol[no description available]medium10organofluorine compound;
secondary alcohol		drug metabolite
d-alpha tocopherol[no description available]medium40alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
fenchol[no description available]medium10
4-n-Butylphenol[no description available]medium10phenols
4-hydroxyazobenzene[no description available]medium10
4-nitrothiophenolate[no description available]medium10
5 alpha-androstane-3 alpha,17 beta-diol[no description available]medium10androstane-3alpha,17beta-diolDaphnia magna metabolite;
human metabolite
menthol[no description available]medium10p-menthan-3-olantipruritic drug;
antispasmodic drug;
antitussive
hydroxyphenytoin[no description available]medium10imidazolidine-2,4-dione;
phenols		metabolite
mono-(2-ethylhexyl)phthalate[no description available]medium10phthalic acid monoester
1-naphthalenemethanol[no description available]medium10naphthylmethanolmouse metabolite
butylated hydroxyanisole[no description available]medium10
3-hydroxybenzo(a)pyrene[no description available]medium10ortho- and peri-fused polycyclic arene
4-n-Pentylphenol[no description available]medium10phenols
9-hydroxybenzo(a)pyrene[no description available]medium10ortho- and peri-fused polycyclic arene
daunorubicin[no description available]medium30aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
n-phenylethanolamine[no description available]medium10aralkylamine
4-ethylphenol[no description available]medium10phenolsfungal xenobiotic metabolite
ursodeoxycholic acid[no description available]medium30bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
pregnanolone[no description available]medium103-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
butylated hydroxytoluene[no description available]medium10phenolsantioxidant;
ferroptosis inhibitor;
food additive;
geroprotector
zidovudine[no description available]medium50azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
6-hydroxybenzo(a)pyrene[no description available]medium10ortho- and peri-fused polycyclic arene
dexibuprofen[no description available]medium10ibuprofennon-narcotic analgesic;
non-steroidal anti-inflammatory drug
benoxaprofen[no description available]medium401,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
2-hydroxybenzo(a)pyrene[no description available]medium10ortho- and peri-fused polycyclic arene
octyl gallate[no description available]medium10gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol[no description available]medium20stilbenoid
2',7'-dichlorofluorescein[no description available]medium102-benzofuransfluorochrome
16-hydroxytestosterone[no description available]medium1016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid;
C19-steroid;
diol;
secondary alcohol		androgen
2-methoxyestradiol[no description available]medium2017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
5,6,7,8-tetrahydro-1-naphthol[no description available]medium10tetralins
alfatradiol[no description available]medium1017alpha-hydroxy steroid;
3-hydroxy steroid;
estradiol		estrogen;
geroprotector
4-hydroxyquinoline[no description available]medium10monohydroxyquinoline;
quinolone
17-alpha-hydroxypregnenolone[no description available]medium1017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid;
hydroxypregnenolone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
5-(3-hydroxyphenyl)-5-phenylhydantoin[no description available]medium10
7-amino-4-methylcoumarin[no description available]medium107-aminocoumarinsfluorochrome
11-hydroxyprogesterone, (11alpha)-isomer[no description available]medium1011alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid
brexanolone[no description available]medium103-hydroxy-5alpha-pregnan-20-oneantidepressant;
GABA modulator;
human metabolite;
intravenous anaesthetic;
sedative
3,5-diiodothyronine, (l)-isomer[no description available]medium10phenylalanine derivative
harmol hydrochloride[no description available]medium10
diosgenin[no description available]medium203beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal		antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite
sarsasapogenin, (3beta,5alpha,25r)-isomer[no description available]medium20sapogeningout suppressant;
plant metabolite
3 alpha,17 alpha-dihydroxy-5 beta-pregnan-20-one[no description available]medium1017alpha-hydroxy steroid;
20-oxo steroid;
3alpha-hydroxy steroid;
C21-steroid;
corticosteroid hormone		human urinary metabolite
2-methoxyestriol[no description available]medium10
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine[no description available]medium10hydroxylamine;
imidazopyridine		carcinogenic agent;
genotoxin;
human xenobiotic metabolite;
mouse metabolite;
mutagen;
neurotoxin;
rat metabolite
ecopipam[no description available]medium10benzazepine
ibuprofen, (r)-isomer[no description available]medium10ibuprofen
11-hydroxytestosterone[no description available]medium1011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid;
C19-steroid		bacterial xenobiotic metabolite;
human xenobiotic metabolite;
marine metabolite
norbuprenorphine[no description available]medium20phenanthrenes
benzo(a)pyrene-3,6-quinol[no description available]medium10
cortolone[no description available]medium1021-hydroxy steroid
carbocysteine[no description available]medium10L-cysteine thioether;
non-proteinogenic L-alpha-amino acid		mucolytic
cholic acid[no description available]medium1012alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
5 alpha-androstane-3 beta,17 beta-diol[no description available]medium2017beta-hydroxy steroid;
3beta-hydroxy steroid;
androstane-3,17-diol		Daphnia magna metabolite;
human metabolite
cortol[no description available]medium1021-hydroxy steroid
21-hydroxypregnenolone[no description available]medium1021-hydroxy steroid;
hydroxypregnenolone;
primary alpha-hydroxy ketone		mouse metabolite
2-hydroxyestradiol[no description available]medium1017beta-hydroxy steroid;
2-hydroxy steroid		carcinogenic agent;
human metabolite;
metabolite;
mouse metabolite;
prodrug
epietiocholanolone[no description available]medium1017-oxo steroid;
3beta-hydroxy steroid;
androstanoid		androgen;
animal metabolite;
human blood serum metabolite;
mouse metabolite;
rat metabolite
naringenin[no description available]medium10(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
2-hydroxyestrone[no description available]medium102-hydroxy steroid;
catechols		human metabolite
epiandrosterone[no description available]medium1017-oxo steroid;
3beta-hydroxy steroid;
androstanoid		androgen;
human metabolite
naringin[no description available]medium10(2S)-flavan-4-one;
4'-hydroxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
neohesperidoside		anti-inflammatory agent;
antineoplastic agent;
metabolite
1-alpha-terpineol[no description available]medium10alpha-terpineolplant metabolite
diprenorphine[no description available]medium10morphinane alkaloid
ergosterol[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite
tretinoin[no description available]medium30retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
retinol[no description available]medium50retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
retinol[no description available]medium52retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
ferulic acid[no description available]medium10ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
mycophenolic acid[no description available]medium402-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
geraniol[no description available]medium103,7-dimethylocta-2,6-dien-1-ol;
monoterpenoid;
primary alcohol		allergen;
fragrance;
plant metabolite;
volatile oil component
dienestrol[no description available]medium10
captax[no description available]medium10aryl thiol;
benzothiazoles		carcinogenic agent;
metabolite
chlorogenic acid[no description available]medium10cinnamate ester;
tannin		food component;
plant metabolite
sch 23390[no description available]medium20benzazepine
digitoxigenin[no description available]medium1014beta-hydroxy steroid;
3beta-hydroxy steroid
quercetin[no description available]medium207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
bilirubin[no description available]medium10biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
apigenin[no description available]medium10trihydroxyflavoneantineoplastic agent;
metabolite
scopoletin[no description available]medium10hydroxycoumarinplant growth regulator;
plant metabolite
hymecromone[no description available]medium10hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
vitamin d 2[no description available]medium20hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
cholecalciferol[no description available]medium40D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
esculetin[no description available]medium10hydroxycoumarinantioxidant;
plant metabolite;
ultraviolet filter
7-hydroxycoumarin[no description available]medium10hydroxycoumarinfluorescent probe;
food component;
plant metabolite
baicalein[no description available]medium10trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chrysin[no description available]medium107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
fisetin[no description available]medium103'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
galangin[no description available]medium107-hydroxyflavonol;
trihydroxyflavone		antimicrobial agent;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
plant metabolite
4-hydroxyestradiol[no description available]medium104-hydroxy steroidmetabolite
isotretinoin[no description available]medium30retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
hyodeoxycholic acid[no description available]medium105beta-cholanic acids;
6alpha,20xi-murideoxycholic acid;
bile acid;
C24-steroid		human metabolite;
mouse metabolite
hydromorphone[no description available]medium20morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
nalmefene[no description available]medium10morphinane alkaloid
nalorphine[no description available]medium60morphinane alkaloid
oxycodone[no description available]medium20organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
oxymorphone[no description available]medium30morphinane alkaloid
6alpha-hydroxy-17beta-estradiol[no description available]medium106alpha-hydroxy steroid
nalbuphine[no description available]medium20organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
cinnamyl alcohol[no description available]medium10cinnamyl alcoholplant metabolite
naltrexone[no description available]medium50cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
normorphine[no description available]medium10morphinane alkaloid
naltrindole benzofuran[no description available]medium10morphinane alkaloid
naltrindole[no description available]medium10isoquinolines
19-hydroxycholesterol[no description available]medium10cholestanoid
borneol[no description available]medium10borneol
norcodeine[no description available]medium10morphinane alkaloid
4-hydroxyestrone[no description available]medium1017-oxo steroid;
3-hydroxy steroid;
4-hydroxy steroid;
catechols;
phenolic steroid		carcinogenic agent;
estrogen;
human urinary metabolite
11 beta-hydroxyandrosterone[no description available]medium103-hydroxy steroidandrogen
2-hydroxyestriol[no description available]medium10
novobiocin[no description available]medium20carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline[no description available]medium40
4-hydroxycoumarin[no description available]medium10hydroxycoumarin
rifampin[no description available]medium40cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
norclozapine[no description available]medium20dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist
sb 258719[no description available]medium30
sb258741[no description available]medium30
pimethixene[no description available]medium30thioxanthenes
9-(aminomethyl)-9,10-dihydroanthracene[no description available]medium30
didesipramine[no description available]medium10dibenzoazepine
bmy 7378[no description available]medium10piperazines
nan 190[no description available]medium30N-alkylpiperazine;
N-arylpiperazine;
phthalimides		serotonergic antagonist
spiroxatrine[no description available]medium10imidazolidines
5-methylurapidil[no description available]medium10
ezogabine[no description available]medium20carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline		anticonvulsant;
potassium channel modulator
daidzein[no description available]medium107-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
warangalone[no description available]medium10
sb 269970[no description available]medium20sulfonamide
fluconazole[no description available]medium50conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flunitrazepam[no description available]medium201,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
mefenamic acid[no description available]medium40aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
niflumic acid[no description available]medium20aromatic carboxylic acid;
pyridines
sulfisoxazole[no description available]medium10isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
troglitazone[no description available]medium30chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
clonixin[no description available]medium10aminopyridine;
organochlorine compound;
pyridinemonocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
vasodilator agent
etoposide[no description available]medium50beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
epirubicin[no description available]medium30aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
atovaquone[no description available]medium20hydroxy-1,2-naphthoquinone
sn 38[no description available]medium10delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol		antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
ezetimibe[no description available]medium30azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
bms204352[no description available]medium10
tacrolimus[no description available]medium60macrolide lactambacterial metabolite;
immunosuppressive agent
almokalant[no description available]medium10
alpha-hydroxytamoxifen[no description available]medium10stilbenoid
tolcapone[no description available]medium302-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
entacapone[no description available]medium302-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
cyclosporine[no description available]medium30homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
alvocidib[no description available]medium20dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
morphine-6-glucuronide[no description available]medium10morphinane alkaloid
morphine-3-glucuronide[no description available]medium10morphinane alkaloid
5-hydroxyrofecoxib[no description available]medium10
celecoxib[no description available]medium40organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fentanyl[no description available]high50anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
avapro[no description available]medium30azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
loratadine[no description available]high10550benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
loratadine[no description available]high1050benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
pindolol[no description available]high40indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
roxatidine acetate[no description available]medium10piperidines
imatinib[no description available]medium20aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
captopril[no description available]medium60alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
sulotroban[no description available]medium20
sch 37370[no description available]medium10
duloxetine[no description available]medium30duloxetine
ziprasidone[no description available]medium201,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
prifelone[no description available]medium10aromatic ketone
sq 28603[no description available]medium10
rupatadine[no description available]medium1080benzocycloheptapyridine
rupatadine[no description available]medium10839benzocycloheptapyridine
ml-3000[no description available]medium10
mk 767[no description available]medium10
bms 207940[no description available]medium10
e 3040[no description available]medium10benzothiazoles;
organic hydroxy compound;
pyridines;
secondary amino compound		anti-inflammatory drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
uricosuric drug
tropisetron[no description available]medium60indolyl carboxylic acid
l 365260[no description available]medium10benzodiazepine
bosutinib[no description available]medium10aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
6-(4-(2-(((4-chlorophenyl)sulfonyl)amino)ethyl)phenyl)-6-(3-pyridyl)hex-5-enoic acid[no description available]medium10
bms 248360[no description available]medium10
sb-649915[no description available]medium10
milnacipran[no description available]medium20acetamides
bupropion[no description available]medium70aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
amantadine[no description available]medium90adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
amantadine[no description available]medium91adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
amiodarone[no description available]medium301-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amlodipine[no description available]medium30dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
antazoline[no description available]high20aromatic amine;
imidazolines;
tertiary amino compound		cholinergic antagonist;
H1-receptor antagonist;
xenobiotic
benfluorex[no description available]medium10benzoate ester
bromhexine[no description available]medium10organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
bromopride[no description available]medium10benzamides
bromperidol[no description available]medium10aromatic ketone
carbetapentane[no description available]medium10benzenes
chloroquine[no description available]medium240aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chloroquine[no description available]medium242aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
cisapride[no description available]medium20benzamides
citalopram[no description available]medium1502-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
citalopram[no description available]medium1532-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clebopride[no description available]medium10piperidines
clomiphene[no description available]medium30tertiary amineestrogen antagonist;
estrogen receptor modulator
cloperastine[no description available]medium10diarylmethane
diphenylpyraline[no description available]high10piperidines;
tertiary amine		cholinergic antagonist;
H1-receptor antagonist
donepezil[no description available]medium20aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
cycloadiphenine[no description available]medium10benzenes
fendiline[no description available]medium10diarylmethane
fipexide[no description available]medium20benzodioxoles
flavoxate[no description available]medium20carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
hydroxyurea[no description available]medium40one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
alverine[no description available]medium20tertiary amineantispasmodic drug
lofepramine[no description available]medium20aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
maprotiline[no description available]medium20anthracenes
mebeverine[no description available]medium10methoxybenzoic acid
mecamylamine[no description available]medium60primary aliphatic amine
memantine[no description available]medium30adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
mirtazapine[no description available]high60benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
norfluoxetine[no description available]medium10(trifluoromethyl)benzenes
orphenadrine[no description available]medium30ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxidopamine[no description available]medium50benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
oxybutynin[no description available]medium30acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
oxyphencyclimine[no description available]medium10monocarboxylic acid
perhexiline[no description available]medium20piperidinescardiovascular drug
periciazine[no description available]medium10hydroxypiperidine;
nitrile;
phenothiazines		adrenergic antagonist;
first generation antipsychotic;
sedative
pridinol[no description available]medium10piperidines;
tertiary alcohol		antiparkinson drug;
muscle relaxant
procyclidine[no description available]medium20pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
sibutramine[no description available]medium40organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol[no description available]medium30alkylbenzene
sulpiride[no description available]medium60benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
tofisopam[no description available]medium10organic molecular entity
ultram[no description available]medium30aromatic ether;
tertiary alcohol;
tertiary amino compound
trihexyphenidyl[no description available]medium20amine
trimeprazine[no description available]medium70phenothiazines
trimeprazine[no description available]medium71phenothiazines
trimipramine[no description available]medium20dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
xylometazoline[no description available]medium10alkylbenzene
camylofine[no description available]medium10alpha-amino acid ester
cycloheximide[no description available]medium20antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
azacitidine[no description available]medium30N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
selegiline[no description available]medium50selegiline;
terminal acetylenic compound		geroprotector
paroxetine[no description available]high91aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
paroxetine[no description available]high90aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
flupirtine[no description available]medium20aminopyridine
mifepristone[no description available]medium403-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
mibefradil[no description available]medium10tetralinsT-type calcium channel blocker
esreboxetine[no description available]medium10aromatic ether
lercanidipine[no description available]medium10diarylmethane
sertraline[no description available]medium100dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
cloricromen[no description available]medium10coumarins
demecolcine[no description available]medium10alkaloid;
secondary amino compound		antineoplastic agent;
microtubule-destabilising agent
noscapine[no description available]medium20aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
vinpocetine[no description available]medium10alkaloidgeroprotector
etomidate[no description available]medium40ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
harmine[no description available]medium40harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
dextromethorphan[no description available]medium406-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
dextromethorphan[no description available]medium416-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
octopamine[no description available]medium120phenylethanolamines;
tyramines		neurotransmitter
tyramine[no description available]medium80monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
phenylalanine[no description available]medium60amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
gramine[no description available]medium10aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
ipsapirone[no description available]medium10N-arylpiperazine
eltoprazine[no description available]medium10
mm 77[no description available]medium10piperazines
acetamide[no description available]medium10acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia
adenine[no description available]medium206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
allantoin[no description available]medium10imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
betaine[no description available]medium20amino-acid betaine;
glycine derivative		fundamental metabolite
carnitine[no description available]medium30amino-acid betainehuman metabolite;
mouse metabolite
carnitine[no description available]medium31amino-acid betainehuman metabolite;
mouse metabolite
aminocaproic acid[no description available]medium30amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
creatine[no description available]medium20glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
lactic acid[no description available]medium102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
dimethyl sulfoxide[no description available]medium30sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
formaldehyde[no description available]medium50aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glycine[no description available]medium30alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycerol[no description available]medium10alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
inositol[no description available]medium10cyclitol;
hexol
niacinamide[no description available]medium30pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin[no description available]medium40pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
orotic acid[no description available]medium20pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
4-aminobenzoic acid[no description available]medium20aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
phenylacetic acid[no description available]medium10benzenes;
monocarboxylic acid;
phenylacetic acids		allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin
pyrazinamide[no description available]medium20monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
pyridoxal phosphate[no description available]medium10methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine[no description available]medium40hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thiamine[no description available]medium20primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
uracil[no description available]medium10pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
urea[no description available]medium60isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
urea[no description available]medium62isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
acebutolol[no description available]medium20aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetazolamide[no description available]medium20monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide[no description available]medium10acetophenones;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
acetohydroxamic acid[no description available]medium20acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
albendazole[no description available]medium20aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
albuterol[no description available]medium40phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alfuzosin[no description available]medium20monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
ambroxol[no description available]medium10aromatic amine
aminoglutethimide[no description available]medium80dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
pimagedine[no description available]medium20guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
amobarbital[no description available]medium10barbiturates
amsacrine[no description available]medium10acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole[no description available]medium20nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
anethole trithione[no description available]medium10methoxybenzenes
anthralin[no description available]medium10anthracenesantipsoriatic
atenolol[no description available]medium20ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azathioprine[no description available]medium70aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
barbital[no description available]medium20barbituratesdrug allergen
bendazac[no description available]medium20indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
benzbromarone[no description available]medium201-benzofurans;
aromatic ketone		uricosuric drug
bicalutamide[no description available]medium20(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bay h 4502[no description available]medium10biphenyls;
imidazoles
bisoprolol[no description available]medium20secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bromisovalum[no description available]medium10N-acylurea;
organobromine compound
brotizolam[no description available]medium10organic molecular entity
busulfan[no description available]medium20methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
butalbital[no description available]medium10barbituratesanalgesic;
sedative
candesartan cilexetil[no description available]medium10biphenyls
carisoprodol[no description available]medium30carbamate estermuscle relaxant
carmustine[no description available]medium10N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carprofen[no description available]medium10carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
carvedilol[no description available]medium20carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
chloral hydrate[no description available]medium10aldehyde hydrate;
ethanediol;
organochlorine compound		general anaesthetic;
mouse metabolite;
sedative;
xenobiotic
chlorambucil[no description available]medium20aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlormezanone[no description available]medium201,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
chloroxylenol[no description available]medium10monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorpropamide[no description available]medium20monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorzoxazone[no description available]medium201,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cinoxacin[no description available]medium10cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
ciprofloxacin[no description available]medium30aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
clioquinol[no description available]medium10monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clobazam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clofazimine[no description available]medium10monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
clotiazepam[no description available]medium10organic molecular entity
clotrimazole[no description available]medium20conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cyclandelate[no description available]medium10carboxylic ester;
secondary alcohol		vasodilator agent
deferoxamine[no description available]medium20acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
eflornithine[no description available]medium10alpha-amino acid;
fluoroamino acid		trypanocidal drug
disopyramide[no description available]medium20monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram[no description available]medium60organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
econazole[no description available]medium30dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
enflurane[no description available]medium10ether;
organochlorine compound;
organofluorine compound		anaesthetic
enoxacin[no description available]medium101,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
estazolam[no description available]medium30triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
estazolam[no description available]medium31triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
ethoxzolamide[no description available]medium10aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
etodolac[no description available]medium20monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
brl 42810[no description available]medium202-aminopurines;
acetate ester		antiviral drug;
prodrug
felbamate[no description available]medium20carbamate esteranticonvulsant;
neuroprotective agent
fenofibrate[no description available]medium20aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
flecainide[no description available]medium20aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
flucytosine[no description available]medium20aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
fluorouracil[no description available]medium70nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluorouracil[no description available]medium71nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
flutamide[no description available]medium20(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
fomepizole[no description available]medium20pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
gemfibrozil[no description available]medium20aromatic etherantilipemic drug
glafenine[no description available]medium20aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gliclazide[no description available]medium10N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
glutethimide[no description available]high20piperidines
glyburide[no description available]medium20monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
gossypol[no description available]medium10
guaiazulene[no description available]medium10sesquiterpene
fasudil[no description available]medium10isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
halothane[no description available]medium40haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
hexachlorophene[no description available]medium10bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
miltefosine[no description available]medium10phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexestrol[no description available]medium10stilbenoid
hexetidine[no description available]medium10organic heteromonocyclic compound;
organonitrogen heterocyclic compound
hexobarbital[no description available]medium20barbiturates
hydralazine[no description available]medium30azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydrochlorothiazide[no description available]medium20benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
phenelzine[no description available]medium70primary amine
idebenone[no description available]medium101,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
ifosfamide[no description available]medium20ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
amrinone[no description available]medium20bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide[no description available]medium20indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
iohexol[no description available]medium10benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iodipamide[no description available]medium10benzoic acids;
organoiodine compound;
secondary carboxamide		radioopaque medium
iproniazid[no description available]medium60carbohydrazide;
pyridines
isoflurane[no description available]medium10organofluorine compoundinhalation anaesthetic
isoniazid[no description available]medium40carbohydrazideantitubercular agent;
drug allergen
2-propanol[no description available]medium10secondary alcohol;
secondary fatty alcohol		protic solvent
isoproterenol[no description available]medium170catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isoxsuprine[no description available]medium20alkylbenzene
isradipine[no description available]medium20benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
itraconazole[no description available]medium20piperazines
ketamine[no description available]medium30cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketoconazole[no description available]medium50dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
khellin[no description available]medium10furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
lansoprazole[no description available]medium20benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
beta-lapachone[no description available]medium10benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
leflunomide[no description available]medium20(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
lomustine[no description available]medium20N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
malathion[no description available]medium10diester;
ethyl ester;
organic thiophosphate
diisopropyl 1,3-dithiol-2-ylidenemalonate[no description available]medium10isopropyl ester
mazindol[no description available]medium20organic molecular entity
mebendazole[no description available]medium20aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
meclizine[no description available]medium40diarylmethane
meclofenoxate[no description available]medium10monocarboxylic acid
vitamin k 3[no description available]medium101,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
mephenytoin[no description available]medium20imidazolidine-2,4-dioneanticonvulsant
meprobamate[no description available]medium40organic molecular entity
metformin[no description available]medium20guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methoxsalen[no description available]medium20aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methoxyflurane[no description available]medium10ether;
organochlorine compound;
organofluorine compound		hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
methyl salicylate[no description available]medium10benzoate ester;
methyl ester;
salicylates		flavouring agent;
insect attractant;
metabolite
methylphenidate[no description available]high111beta-amino acid ester;
methyl ester;
piperidines
methylphenidate[no description available]high110beta-amino acid ester;
methyl ester;
piperidines
methyprylon[no description available]medium10organic molecular entity
metoclopramide[no description available]high90benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metronidazole[no description available]medium20C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
metyrapone[no description available]medium160aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
miconazole[no description available]medium10dichlorobenzene;
ether;
imidazoles
midazolam[no description available]medium50imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
minoxidil[no description available]medium20dialkylarylamine;
tertiary amino compound
mitotane[no description available]medium200diarylmethane
modafinil[no description available]medium20monocarboxylic acid amide;
sulfoxide
moxisylyte[no description available]medium20monoterpenoid
deet[no description available]medium10benzamides;
monocarboxylic acid amide		environmental contaminant;
insect repellent;
xenobiotic
nabumetone[no description available]medium20methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nalidixic acid[no description available]medium201,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
nefazodone[no description available]medium20aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nevirapine[no description available]medium20cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nialamide[no description available]medium70organonitrogen compound;
organooxygen compound
niceritrol[no description available]medium10organic molecular entity
nilutamide[no description available]medium20(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nimesulide[no description available]medium20aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine[no description available]medium402-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nimodipine[no description available]medium412-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nitrazepam[no description available]medium501,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitroglycerin[no description available]medium30nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
nizatidine[no description available]medium201,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
masoprocol[no description available]medium10catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
norfloxacin[no description available]medium20fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
omeprazole[no description available]medium20aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron[no description available]medium90carbazoles
oxamniquine[no description available]medium10aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound
oxaprozin[no description available]medium201,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxprenolol[no description available]medium20aromatic ether
oxybenzone[no description available]medium10hydroxybenzophenone;
monomethoxybenzene		dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic
pantoprazole[no description available]medium20aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
pemoline[no description available]medium201,3-oxazolescentral nervous system stimulant
pentoxifylline[no description available]medium30oxopurine
perazine[no description available]medium10N-alkylpiperazine;
N-methylpiperazine;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug
phenacetin[no description available]medium10acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
moxonidine[no description available]medium10organohalogen compound;
pyrimidines
pinacidil[no description available]medium20pyridines
pipemidic acid[no description available]medium10amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
piperazine[no description available]medium10azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
praziquantel[no description available]medium20isoquinolines
primaquine[no description available]medium20aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
primidone[no description available]medium20pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
probucol[no description available]medium10dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procarbazine[no description available]medium20benzamides;
hydrazines		antineoplastic agent
pyridinolcarbamate[no description available]medium10pyridines
ranitidine[no description available]medium10aralkylamine
opc 12759[no description available]medium10secondary carboxamide
riluzole[no description available]medium20benzothiazoles
rofecoxib[no description available]medium20butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
sevoflurane[no description available]medium10ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
sulfadiazine[no description available]medium20pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
4-phenylbutyric acid, sodium salt[no description available]medium10organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug
vorinostat[no description available]medium20dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sulfamerazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfameter[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
leprostatic drug;
renal agent
sulfamethazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole[no description available]medium20sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole[no description available]medium10isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfanilamide[no description available]medium10substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfaphenazole[no description available]medium10primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
sulfapyridine[no description available]medium20pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
sulfapyridine[no description available]medium21pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
sulfasalazine[no description available]medium20
suramin[no description available]medium20naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
gatifloxacin[no description available]medium10N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tegafur[no description available]medium10organohalogen compound;
pyrimidines
temozolomide[no description available]medium20imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
terbutaline[no description available]medium50phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
terbutaline[no description available]medium51phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
thalidomide[no description available]medium50phthalimides;
piperidones
thiabendazole[no description available]medium201,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
ticlopidine[no description available]medium50monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tiopronin[no description available]medium20N-acyl-amino acid
tizanidine[no description available]medium30benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
tolazamide[no description available]medium20N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolbutamide[no description available]medium70N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolperisone[no description available]medium10aromatic ketone
tranexamic acid[no description available]medium20amino acid
triclosan[no description available]medium10aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
trimethadione[no description available]medium20oxazolidinoneanticonvulsant;
geroprotector
venlafaxine[no description available]medium20cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
vesnarinone[no description available]medium10organic molecular entity
vigabatrin[no description available]medium20gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
ici 204,219[no description available]medium30carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
ici 204,219[no description available]medium31carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zolpidem[no description available]medium20imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
guanidine hydrochloride[no description available]medium10one-carbon compound;
organic chloride salt		protein denaturant
hydrocortisone acetate[no description available]medium10cortisol ester;
tertiary alpha-hydroxy ketone
cortisone acetate[no description available]medium20corticosteroid hormone
mitomycin[no description available]medium20mitomycinalkylating agent;
antineoplastic agent
prednisolone[no description available]medium13011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
cephaloridine[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
sorbitol[no description available]medium30glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
floxuridine[no description available]medium10nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
piperonyl butoxide[no description available]medium10benzodioxolespesticide synergist
bromouracil[no description available]medium10nucleobase analogue;
pyrimidines		mutagen
histamine dihydrochloride[no description available]medium10
dextroamphetamine[no description available]medium2501-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
norethindrone acetate[no description available]medium103-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive
spironolactone[no description available]medium403-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
cyclobarbital[no description available]medium10barbiturates
allobarbital[no description available]medium10barbiturates
penicillamine[no description available]medium40non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
trichlorfon[no description available]medium10organic phosphonate;
organochlorine compound;
phosphonic ester		agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide
oxandrolone[no description available]medium2017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
nad[no description available]medium10NADgeroprotector
penicillin g[no description available]medium40penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
glutamine[no description available]medium40amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
cetrimonium bromide[no description available]medium10organic bromide salt;
quaternary ammonium salt		detergent;
surfactant
vincristine[no description available]medium20acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
physostigmine[no description available]medium150carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
sucrose[no description available]medium40glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
testosterone propionate[no description available]medium10steroid ester
aminopyrine[no description available]medium60pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
methyltestosterone[no description available]medium2017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
cephalothin[no description available]medium10azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
uridine[no description available]medium10uridinesdrug metabolite;
fundamental metabolite;
human metabolite
kanamycin a[no description available]medium20kanamycinsbacterial metabolite
phenylephrine[no description available]medium50phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
levodopa[no description available]medium210amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
levodopa[no description available]medium213amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
niridazole[no description available]medium101,3-thiazoles;
C-nitro compound
lactose[no description available]medium50lactose
lactose[no description available]medium52lactose
methionine[no description available]medium20aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
Mebutamate[no description available]medium10organic molecular entity
colchicine[no description available]medium60alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
benziodarone[no description available]medium20aromatic ketone
mannitol[no description available]medium30mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
cytarabine[no description available]medium30beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
mestranol[no description available]medium1017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
methaqualone[no description available]medium10quinazolinesGABA agonist;
sedative
trypan blue[no description available]medium10
tryptophan[no description available]medium310erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine[no description available]medium100arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
arginine[no description available]medium101arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
trichloroacetic acid[no description available]medium20monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
triamcinolone acetonide[no description available]high4011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
allylpropymal[no description available]medium10barbiturates
butobarbital[no description available]medium10barbiturates
trichloroethylene[no description available]medium10chloroethenesinhalation anaesthetic;
mouse metabolite
dehydrocholic acid[no description available]medium1012-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug
methylprednisolone[no description available]medium1006-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
methylprednisolone[no description available]medium1016-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
isosorbide dinitrate[no description available]medium30glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
synephrine[no description available]medium10ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
benzoyl peroxide[no description available]medium10carbonyl compound
furan[no description available]medium10furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product
ergotamine[no description available]medium260peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
ergotamine[no description available]medium261peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
neostigmine bromide[no description available]medium10bromide salt
phenformin[no description available]medium20biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
hexachlorobenzene[no description available]medium10aromatic fungicide;
chlorobenzenes		antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant
trinitrotoluene[no description available]medium10trinitrotolueneexplosive
framycetin[no description available]medium10aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
pyrazolanthrone[no description available]medium10anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
meglumine[no description available]medium10hexosamine;
secondary amino compound
cinchophen[no description available]medium20quinolines
quinestrol[no description available]medium1017-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
dydrogesterone[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid		progestin
ephedrine[no description available]medium180phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
ephedrine[no description available]medium1811phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
chlormadinone acetate[no description available]medium10corticosteroid hormone
2,3-dimercaptosuccinic acid[no description available]medium10
evans blue[no description available]medium30organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
testosterone enanthate[no description available]medium10heptanoate ester;
sterol ester		androgen
aminophylline[no description available]medium80mixturebronchodilator agent;
cardiotonic drug
phenyramidol[no description available]medium10aminopyridine
carbutamide[no description available]medium10benzenes;
sulfonamide
nandrolone decanoate[no description available]medium20steroid ester
bucladesine[no description available]medium103',5'-cyclic purine nucleotide;
butanamides;
butyrate ester		agonist;
cardiotonic drug;
vasodilator agent
betamethasone[no description available]medium5011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
betamethasone[no description available]medium5111beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
perflubron[no description available]medium10haloalkane;
organobromine compound;
perfluorinated compound		blood substitute;
radioopaque medium
cyproterone acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
glycyrrhetinic acid[no description available]medium10cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
dihydralazine[no description available]medium10phthalazines
phenylpropanolamine[no description available]medium20amphetamines;
phenethylamine alkaloid		plant metabolite
podophyllotoxin[no description available]medium20furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
hesperidin[no description available]medium103'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen
chlormethiazole[no description available]medium10thiazoles
methamphetamine[no description available]medium80amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
gentian violet[no description available]medium10organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
hematoporphyrin[no description available]medium20
lactulose[no description available]medium20glycosylfructosegastrointestinal drug;
laxative
megestrol acetate[no description available]medium10020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
megestrol acetate[no description available]medium10220-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
acetylcysteine[no description available]medium20acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
erythromycin stearate[no description available]medium10aminoglycoside
erythromycin[no description available]medium20cyclic ketone;
erythromycin
vinblastine[no description available]medium10
estradiol valerate[no description available]medium10steroid ester
vancomycin[no description available]medium20glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
dronabinol[no description available]medium90benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
amiloride[no description available]medium30aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
sulfadoxine[no description available]medium10pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
acadesine[no description available]medium101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
stavudine[no description available]medium20dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine[no description available]medium10organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
iproclozide[no description available]medium10aromatic ether
streptomycin[no description available]medium20antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
cladribine[no description available]medium20organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
carbenicillin disodium[no description available]medium10organic sodium salt
dehydroemetine[no description available]medium10aromatic ether;
isoquinolines;
pyridoisoquinoline		antileishmanial agent;
antimalarial;
antiprotozoal drug
benorilate[no description available]medium10carbonyl compound
trimetazidine[no description available]medium10aromatic amine
floxacillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
vidarabine[no description available]medium10beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
tiadenol[no description available]medium10aliphatic sulfide
zalcitabine[no description available]medium10pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
camptothecin[no description available]medium10delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
stanozolol[no description available]medium1017beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol		anabolic agent;
androgen
clodronic acid[no description available]medium101,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
xipamide[no description available]medium10benzamides
levamisole[no description available]medium206-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
thiamphenicol[no description available]medium10monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
isosorbide-5-mononitrate[no description available]medium10glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
danazol[no description available]medium2017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
carbimazole[no description available]medium101,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
triamcinolone[no description available]high2011beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
oxyphenisatin[no description available]medium20indoles
tetrachloroethylene[no description available]medium10chlorocarbon;
chloroethenes		nephrotoxic agent
butachlor[no description available]medium10aromatic amide;
organochlorine compound;
tertiary carboxamide		environmental contaminant;
herbicide;
xenobiotic
rose bengal b disodium salt[no description available]medium10
glutamic acid[no description available]medium20glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
cefazolin[no description available]medium20beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin[no description available]medium20penicillin allergen;
penicillin		antibacterial drug
nicergoline[no description available]medium10organic heterotetracyclic compound;
organonitrogen heterocyclic compound
oxcarbazepine[no description available]medium20cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
amineptin[no description available]medium20amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
pirprofen[no description available]medium20pyrroline
tobramycin[no description available]medium10amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel[no description available]medium20taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
dobutamine[no description available]medium20catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
ribavirin[no description available]medium201-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
amikacin[no description available]medium20alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
ticrynafen[no description available]medium20aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
methyldopa[no description available]medium130L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
bezafibrate[no description available]medium10aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
sq-11725[no description available]medium10
permethrin[no description available]medium10cyclopropanecarboxylate ester;
cyclopropanes		agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide
pirfenidone[no description available]medium10pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
desogestrel[no description available]medium1017beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
muzolimine[no description available]medium10dichlorobenzene
desflurane[no description available]medium10organofluorine compoundinhalation anaesthetic
piperacillin[no description available]medium20penicillin allergen;
penicillin		antibacterial drug
cefoperazone[no description available]medium20cephalosporinantibacterial drug
foscarnet sodium[no description available]medium10one-carbon compound;
organic sodium salt		antiviral drug
moxalactam[no description available]medium10cephalosporin;
oxacephem		antibacterial drug
nicorandil[no description available]medium10nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
cefadroxil anhydrous[no description available]medium20cephalosporinantibacterial drug
encainide[no description available]medium10benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
cefaclor anhydrous[no description available]medium20cephalosporinantibacterial drug;
drug allergen
miglustat[no description available]medium20piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
cefotetan[no description available]medium20
lovastatin[no description available]medium20delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
enoximone[no description available]medium10aromatic ketone
piritrexim[no description available]medium10
simvastatin[no description available]medium20delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
pravastatin[no description available]medium203-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
atomoxetine hydrochloride[no description available]medium10hydrochlorideadrenergic uptake inhibitor;
antidepressant
quinapril[no description available]medium20dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
gepirone[no description available]medium20N-arylpiperazine
sparfloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton[no description available]medium301-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
clopidogrel[no description available]medium30methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
cidofovir anhydrous[no description available]medium20phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
bromfenac[no description available]medium20aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
atorvastatin[no description available]medium20aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine[no description available]medium20monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
irinotecan[no description available]medium20carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan[no description available]medium20biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
adefovir dipivoxil[no description available]medium106-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
capecitabine[no description available]medium20carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
adenosine[no description available]medium60adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
halofuginone[no description available]medium10quinazolines
ortho-cept[no description available]medium10
cefprozil[no description available]medium20cephalosporin;
semisynthetic derivative		antibacterial drug
efavirenz[no description available]medium40acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz[no description available]medium41acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir[no description available]medium20aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
doxapram hydrochloride[no description available]medium10hydrochloridecentral nervous system stimulant
1,5-anhydroglucitol[no description available]medium10anhydro sugarhuman metabolite
betulinic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
amprenavir[no description available]medium20carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
glutathione disulfide[no description available]medium10glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
bendamustine[no description available]medium20benzimidazoles
erdosteine[no description available]medium10N-acyl-amino acid
mizolastine[no description available]medium10benzimidazoles
intoplicine[no description available]medium10pyridoindole
telmisartan[no description available]medium20benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
dexfenfluramine[no description available]medium10fenfluramineappetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
medetomidine[no description available]medium10imidazoles
picosulfate sodium[no description available]medium10aryl sulfate;
pyridines
dienogest[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone		progesterone receptor agonist;
progestin;
synthetic oral contraceptive
morphazinamide[no description available]medium10morpholines;
pyrazines;
secondary carboxamide
dexrazoxane[no description available]medium20razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
voriconazole[no description available]medium20conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
cyclobutyrol[no description available]medium10hydroxy monocarboxylic acidbile therapy drug
terlipressin[no description available]medium10polypeptide
isoflavone[no description available]medium10isoflavones
clevudine[no description available]medium10
tetrandrine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
rosiglitazone[no description available]medium20aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
clarithromycin[no description available]medium20macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
lopinavir[no description available]medium10amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
sr141716[no description available]medium10amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
bosentan anhydrous[no description available]medium20primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
selenomethionine[no description available]medium10amino acid zwitterion;
selenomethionine		plant metabolite
perindopril[no description available]medium20alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
fingolimod[no description available]medium10aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
ecteinascidin 743[no description available]medium10acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
nitisinone[no description available]medium20(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
marimastat[no description available]medium10hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
clofarabine[no description available]medium20adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
mitiglinide[no description available]medium10benzenes;
monocarboxylic acid
imatinib mesylate[no description available]medium10methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
gefitinib[no description available]medium20aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine[no description available]medium20adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
antiprimod[no description available]medium10
sulbactam[no description available]medium10penicillanic acids
olmesartan medoxomil[no description available]medium20biphenyls
ilomastat[no description available]medium10hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
docetaxel[no description available]medium10hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
atazanavir[no description available]medium20carbohydrazideantiviral drug;
HIV protease inhibitor
levofloxacin[no description available]medium209-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
cariporide[no description available]medium10
tezosentan[no description available]medium10
moxifloxacin[no description available]medium20aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
jtt 501[no description available]medium10
cyc 202[no description available]medium102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
paromomycin[no description available]medium20amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
avasimibe[no description available]medium10monoterpenoid
troleandomycin[no description available]medium10acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
deferasirox[no description available]medium20benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
tbc-11251[no description available]medium20benzodioxoles
sitosterol, (3beta)-isomer[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol		anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor
benzarone[no description available]medium201-benzofurans
estramustine[no description available]medium2017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
homoharringtonine[no description available]medium10alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
o-(chloroacetylcarbamoyl)fumagillol[no description available]medium10carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide		angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist
bortezomib[no description available]medium30amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir[no description available]medium201,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
nexavar[no description available]medium10organosulfonate salt
glucosamine[no description available]medium10D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
meropenem[no description available]medium20alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
griseofulvin[no description available]medium201-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
digitoxin[no description available]medium10cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir[no description available]medium20L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
netilmicin[no description available]medium10
trimethaphan camsylate[no description available]medium10
erythromycin estolate[no description available]medium10aminoglycoside sulfate salt;
erythromycin derivative		enzyme inhibitor
cyclopamine[no description available]medium10piperidinesglioma-associated oncogene inhibitor
devazepide[no description available]medium101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
tolterodine[no description available]medium20tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
doxorubicin hydrochloride[no description available]medium10anthracycline
erythromycin ethylsuccinate[no description available]medium10cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester
ao 128[no description available]medium10organic molecular entity
acarbose[no description available]medium10amino cyclitol;
glycoside
alpha-D-fructofuranose 1,6-bisphosphate[no description available]medium10D-fructofuranose 1,6-bisphosphate
docosahexaenoate[no description available]medium10docosahexaenoic acid;
omega-3 fatty acid		algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical
oleic acid[no description available]medium20octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
cerivastatin[no description available]medium10dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin[no description available]medium20dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
eicosapentaenoic acid[no description available]medium10icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
clindamycin[no description available]medium20
fosfomycin[no description available]medium20epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax[no description available]medium40macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
zithromax[no description available]medium41macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
drf 2725[no description available]medium10
alitretinoin[no description available]medium10retinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist
decitabine[no description available]medium202'-deoxyribonucleoside
teniposide[no description available]medium20aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
dactinomycin[no description available]medium20actinomycinmutagen
tiazofurin[no description available]medium101,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
melphalan[no description available]medium20L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
tenofovir[no description available]medium20nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
rubitecan[no description available]medium10C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
micafungin[no description available]medium20antibiotic antifungal drug;
echinocandin		antiinfective agent
riboflavin[no description available]medium20flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
sodium bicarbonate[no description available]medium20one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
sodium acetate, anhydrous[no description available]medium10organic sodium saltNMR chemical shift reference compound
sodium benzoate[no description available]medium10organic sodium saltalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
dipyrone[no description available]medium20organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
ditiocarb sodium[no description available]medium10organic molecular entity
carbenoxolone[no description available]medium10
discodermolide[no description available]medium10diterpenoid
cannabidiol[no description available]medium10olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
propylthiouracil[no description available]medium20pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
prothionamide[no description available]medium10pyridines
mercaptopurine[no description available]medium40aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
methimazole[no description available]medium201,3-dihydroimidazole-2-thionesantithyroid drug
sulindac[no description available]medium20monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
capsaicin[no description available]medium40capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
terbinafine[no description available]medium20acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
thioguanine anhydrous[no description available]medium302-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
tacrine hydrochloride[no description available]medium10
sodium propionate[no description available]medium10organic sodium saltantifungal drug;
food preservative
digoxin[no description available]medium20cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
streptozocin[no description available]medium20
ethionamide[no description available]medium20pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
fusidic acid[no description available]medium2011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
estrone sulfate[no description available]medium1017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
hmr 3647[no description available]medium20
toremifene[no description available]medium20aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
telaprevir[no description available]medium10cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
droloxifene[no description available]medium10stilbenoid
or 1259[no description available]medium10hydrazone;
nitrile;
pyridazinone		anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent
gestodene[no description available]medium10steroidestrogen
orlistat[no description available]medium20beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
idoxifene[no description available]medium10stilbenoid
zd 6474[no description available]medium10aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
silybin[no description available]medium10
chloramine-t[no description available]medium10organic sodium saltallergen;
antifouling biocide;
disinfectant
flosequinan[no description available]medium10quinolines
calcitriol[no description available]medium20D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
beta carotene[no description available]medium10carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
amphotericin b[no description available]medium20antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
clavulanic acid[no description available]medium10oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort[no description available]medium3011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
oxymetholone[no description available]medium20
montelukast[no description available]medium40aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
montelukast[no description available]medium41aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mycophenolate mofetil[no description available]medium20carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
astaxanthine[no description available]medium10carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
diosmin[no description available]medium10dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
cynarine[no description available]medium10alkyl caffeate ester;
quinic acid		plant metabolite
sdz psc 833[no description available]medium10homodetic cyclic peptide
coenzyme q10[no description available]medium10ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite
tranilast[no description available]medium10amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
etretinate[no description available]medium10enoate ester;
ethyl ester;
retinoid		keratolytic drug
misoprostol[no description available]medium10
ozagrel[no description available]medium10cinnamic acids
pitavastatin[no description available]medium20cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
alatrofloxacin mesylate[no description available]medium20
natamycin[no description available]medium10antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
acitretin[no description available]medium20acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
dothiepin[no description available]medium10dothiepin
levetiracetam[no description available]medium20pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
sirolimus[no description available]medium20antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
topiramate[no description available]medium30cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
seocalcitol[no description available]medium10
fenretinide[no description available]medium10monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
geldanamycin[no description available]medium101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
demycarosylturimycin h[no description available]medium10
iloprost[no description available]medium10carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
vinorelbine[no description available]medium20acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
furazolidone[no description available]medium10
fluvoxamine[no description available]medium70(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
semaxinib[no description available]medium10olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
orantinib[no description available]medium10
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium20dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
molsidomine[no description available]medium10ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
cefixime[no description available]medium20cephalosporinantibacterial drug;
drug allergen
lisinopril[no description available]medium20dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ramipril[no description available]medium20azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
indinavir sulfate[no description available]medium20dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
enalapril[no description available]medium20dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
nitrofurazone[no description available]medium10
bleomycin[no description available]medium20bleomycinantineoplastic agent;
metabolite
enalaprilat anhydrous[no description available]medium20dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
imidapril[no description available]medium10dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
sulindac sulfone[no description available]medium10monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ximelagatran[no description available]medium20amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
ceftriaxone[no description available]medium201,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
trandolapril[no description available]medium20dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
guanabenz acetate[no description available]medium10dichlorobenzenegeroprotector
famotidine[no description available]medium201,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cefotaxime[no description available]medium201,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam[no description available]medium20beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
proguanil[no description available]medium10biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rifamycin sv[no description available]medium10acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins		antimicrobial agent;
antitubercular agent;
bacterial metabolite
epoprostenol sodium[no description available]medium10prostanoid
ixabepilone[no description available]medium201,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
azlocillin[no description available]medium10penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial drug
dantrolene sodium[no description available]medium10
nitrofurantoin[no description available]medium20imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
nifurtimox[no description available]medium10nitrofuran antibiotic
roxithromycin[no description available]medium10roxithromycinenvironmental contaminant;
xenobiotic
beraprost[no description available]medium10enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol		anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent
lanreotide[no description available]medium10
lu 208075[no description available]medium20diarylmethane
acetylcarnitine[no description available]medium10O-acetylcarnitine;
saturated fatty acyl-L-carnitine		human metabolite;
Saccharomyces cerevisiae metabolite
nifurtoinol[no description available]medium10hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
fosinopril[no description available]medium20
eflucimibe[no description available]medium10
etomoxir[no description available]medium10aromatic ether
pentagastrin[no description available]medium60organic molecular entity
gentamicin sulfate[no description available]medium10
azd 6244[no description available]medium10benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
vinflunine[no description available]medium10acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid		antineoplastic agent
baci-im[no description available]medium20homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
pf 03491390[no description available]medium10
amodiaquine hydrochloride[no description available]medium10
tannins[no description available]medium10tannin
mesna[no description available]medium20organosulfonic acid
cerivastatin sodium[no description available]medium10organic sodium salt;
statin (synthetic)
monensin[no description available]medium10
oxacillin sodium[no description available]medium10organic sodium salt
sodium diatrizoate[no description available]medium10organic sodium salt;
organoiodine compound		radioopaque medium
ascorbic acid[no description available]medium60ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
chlortetracycline[no description available]medium10
oxytetracycline, anhydrous[no description available]medium30
minocycline[no description available]medium20
piroxicam[no description available]medium20benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
acenocoumarol[no description available]medium10C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
mobic[no description available]medium201,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex[no description available]medium10heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
phenprocoumon[no description available]medium10hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
rolitetracycline[no description available]medium10
lornoxicam[no description available]medium10heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ajmaline[no description available]medium10
entecavir[no description available]medium202-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir[no description available]medium202-aminopurines;
oxopurine		antimetabolite;
antiviral drug
inosine[no description available]medium10inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
folic acid[no description available]medium20folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
dacarbazine[no description available]medium20dacarbazine
didanosine[no description available]medium20purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir[no description available]medium202-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
sildenafil[no description available]medium20piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
penciclovir[no description available]medium102-aminopurines;
propane-1,3-diols		antiviral drug
raltitrexed[no description available]medium10N-acyl-amino acid
leucovorin[no description available]medium20formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
alanosine[no description available]medium10
tirapazamine[no description available]medium10aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
rifabutin[no description available]medium20
dasatinib[no description available]medium201,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
pci 32765[no description available]medium10acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
cgi 1746[no description available]medium10
rn486[no description available]medium10
lfm a13[no description available]medium10aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
sorafenib[no description available]medium30(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
N-(3-nitrophenyl)-1,3-benzodioxole-5-carboxamide[no description available]medium10aromatic amide
alaproclate[no description available]medium20alpha-amino acid ester
alendronate[no description available]medium101,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alosetron[no description available]medium10imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
alprazolam[no description available]medium20organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprazolam[no description available]medium21organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
altretamine[no description available]medium10triamino-1,3,5-triazine
ambenonium[no description available]medium10quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
diatrizoic acid[no description available]medium10acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
amifostine anhydrous[no description available]medium10diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
p-aminohippuric acid[no description available]medium10N-acylglycineDaphnia magna metabolite
bendroflumethiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
betaxolol[no description available]medium10propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bethanechol[no description available]medium10carbamate ester;
quaternary ammonium ion		muscarinic agonist
bisacodyl[no description available]medium10diarylmethane
secbutabarbital[no description available]medium10barbiturates
candesartan[no description available]medium10benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
chlorcyclizine[no description available]medium10diarylmethane
chlorothiazide[no description available]medium10benzothiadiazineantihypertensive agent;
diuretic
chlorthalidone[no description available]medium20isoindoles;
monochlorobenzenes;
sulfonamide
cilostazol[no description available]medium10lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
clonazepam[no description available]medium301,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
chlorazepate[no description available]medium101,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
cyclofenil[no description available]medium10organic molecular entity
dichlorphenamide[no description available]medium10dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
pentetic acid[no description available]medium10pentacarboxylic acidcopper chelator
dimercaprol[no description available]medium10dithiol;
primary alcohol		chelator
doxapram[no description available]medium10morpholines;
pyrrolidin-2-ones		central nervous system stimulant
doxazosin[no description available]medium10aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
dyphylline[no description available]medium10oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
edrophonium[no description available]medium10phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
ethosuximide[no description available]medium10dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethotoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
etidronate[no description available]medium101,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
fenoldopam[no description available]medium10benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fexofenadine[no description available]high60piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
flurazepam[no description available]medium201,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
foscarnet[no description available]medium10carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
gabapentin[no description available]medium30gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
glimepiride[no description available]medium10sulfonamide
glipizide[no description available]medium10aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester[no description available]medium10benzenes
granisetron[no description available]medium10aromatic amide;
indazoles
guaifenesin[no description available]medium30methoxybenzenes
guaifenesin[no description available]medium31methoxybenzenes
guanethidine[no description available]medium50azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanethidine[no description available]medium51azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanidine[no description available]medium10carboxamidine;
guanidines;
one-carbon compound
hydroflumethiazide[no description available]medium10benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxychloroquine[no description available]medium20aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
ioversol[no description available]medium10amidobenzoic acid
isocarboxazid[no description available]medium10benzenes
ketorolac[no description available]medium10amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
letrozole[no description available]medium10nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lomefloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
mechlorethamine[no description available]medium10nitrogen mustard;
organochlorine compound		alkylating agent
meclofenamic acid[no description available]medium20aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
mepenzolate[no description available]medium10diarylmethane
metaproterenol[no description available]medium10aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
methazolamide[no description available]medium10sulfonamide;
thiadiazoles
methocarbamol[no description available]medium10aromatic ether;
carbamate ester;
secondary alcohol
methyclothiazide[no description available]medium10benzothiadiazine
metolazone[no description available]medium10organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
midodrine[no description available]medium10amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
milrinone[no description available]medium10bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
nadolol[no description available]medium10tetralins
naratriptan[no description available]medium10heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nicardipine[no description available]medium10benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
ofloxacin[no description available]medium103-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
pamidronate[no description available]medium10phosphonoacetic acid
pentamidine[no description available]medium10aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
phentermine[no description available]medium20primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
4-phenylbutyric acid[no description available]medium10monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
pioglitazone[no description available]medium10aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
polythiazide[no description available]medium10benzothiadiazine
duodote[no description available]medium10pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
propafenone[no description available]medium10aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propantheline[no description available]medium20xanthenes
pyridostigmine[no description available]medium10pyridinium ion
sch 16134[no description available]medium10benzodiazepine
quetiapine[no description available]medium10dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
rabeprazole[no description available]medium10benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
raloxifene[no description available]medium101-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
rimantadine[no description available]medium10alkylamine
rizatriptan[no description available]medium20tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
ropinirole[no description available]medium10indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
salicylsalicylic acid[no description available]medium10benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
risedronic acid[no description available]medium10pyridines
succinylcholine[no description available]medium20quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
terazosin[no description available]medium10furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
thiotepa[no description available]medium10aziridines
tinidazole[no description available]medium10imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tolmetin[no description available]medium10aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
triamterene[no description available]medium10pteridinesdiuretic;
sodium channel blocker
triazolam[no description available]medium10triazolobenzodiazepinesedative
trimethobenzamide[no description available]medium10benzamides;
tertiary amino compound		antiemetic
trimetrexate[no description available]medium10
delavirdine[no description available]medium10aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zaleplon[no description available]medium10nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zonisamide[no description available]medium101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
cysteine[no description available]medium10cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
edetic acid[no description available]medium50ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
cysteamine[no description available]medium10amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride[no description available]medium10quaternary ammonium salt
mepazine[no description available]medium10phenothiazines
cloxacillin[no description available]medium10penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
calcium acetate[no description available]medium10calcium saltchelator
mebanazine[no description available]medium10benzenes
oxacillin[no description available]medium10penicillinantibacterial agent;
antibacterial drug
cycloserine[no description available]medium104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
perflutren[no description available]medium10fluoroalkane;
fluorocarbon
fluoxymesterone[no description available]medium1011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
methsuximide[no description available]medium10organic molecular entity
tromethamine[no description available]medium30primary amino compound;
triol		buffer
penicillin v[no description available]medium10penicillin allergen;
penicillin
pseudoephedrine[no description available]medium50phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
pseudoephedrine[no description available]medium52phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylpropion[no description available]high40aromatic ketone;
tertiary amine		appetite depressant
benzonatate[no description available]medium10benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
methylergonovine[no description available]medium20ergoline alkaloid
nafcillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
methohexital[no description available]medium10acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
galantamine[no description available]medium10benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
4-hydroxybutyric acid[no description available]medium104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
medroxyprogesterone[no description available]medium1017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
dimenhydrinate[no description available]medium20diarylmethane
levocarnitine[no description available]medium10carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
sulfanilylurea[no description available]medium10benzenes;
sulfonamide
pamabrom[no description available]medium10
levonorgestrel[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
diphenoxylate[no description available]high20ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
ethambutol[no description available]medium10ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
ibufenac[no description available]medium10monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
metaxalone[no description available]medium10aromatic ether
spectinomycin[no description available]medium10cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
dexbrompheniramine[no description available]medium10brompheniramineanti-allergic agent;
H1-receptor antagonist
dicloxacillin[no description available]medium10dichlorobenzene;
penicillin		antibacterial drug
megestrol[no description available]medium4017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
megestrol[no description available]medium4117alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
carbenicillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
clomacran[no description available]medium10acridines
methenamine hippurate[no description available]medium10N-acylglycine
olsalazine[no description available]medium10azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
sodium thiosulfate[no description available]medium10inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
clemastine[no description available]high148monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
clemastine[no description available]high140monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
cephalexin[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
fenclozic acid[no description available]medium10
laxagetten 4,4'-diacetoxydiphenylpyridylemethane[no description available]medium10
fludarabine phosphate[no description available]medium10nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
alclofenac[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fludrocortisone[no description available]medium2011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
clometacin[no description available]medium10N-acylindole
carbidopa[no description available]medium10catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
moricizine[no description available]medium10carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
penbutolol[no description available]medium20ethanolamines
cephradine[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
vecuronium[no description available]medium10acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
exifone[no description available]medium10benzophenones
mefloquine[no description available]medium10[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
nitazoxanide[no description available]medium10benzamides;
carboxylic ester
acarbose[no description available]medium10tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
torsemide[no description available]medium10aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
idarubicin[no description available]medium10anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
atracurium[no description available]medium10diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
fialuridine[no description available]medium10
alfentanil[no description available]medium10monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
haloperidol decanoate[no description available]medium10organic molecular entity
tolrestat[no description available]medium10naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
balsalazide[no description available]medium10
cabergoline[no description available]medium20N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
atomoxetine[no description available]medium10aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
alpidem[no description available]medium10imidazoles
fosphenytoin[no description available]medium10imidazolidine-2,4-dione
ranolazine[no description available]medium10aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
finasteride[no description available]medium103-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
esmolol[no description available]medium10aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
adefovir[no description available]medium106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
aromasil[no description available]medium1017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
tiagabine[no description available]medium10beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
topotecan[no description available]medium10pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine[no description available]medium10organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide[no description available]medium10benzenes;
organic amino compound
aripiprazole[no description available]high20aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
remifentanil[no description available]medium10alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
ibandronic acid[no description available]medium10
zolmitriptan[no description available]medium20oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
emtricitabine[no description available]medium10monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
tasosartan[no description available]medium10biphenyls
tiludronic acid[no description available]medium10organochlorine compound
tirofiban[no description available]medium10L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
trovafloxacin[no description available]medium10
fenofibric acid[no description available]medium10aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
plerixafor[no description available]medium10azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
oseltamivir[no description available]medium10acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
histamine phosphate[no description available]medium20phosphate salthistamine agonist
histamine phosphate[no description available]medium21phosphate salthistamine agonist
tilbroquinol[no description available]medium10organohalogen compound;
quinolines
droxicam[no description available]medium10organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
ebrotidine[no description available]medium10sulfonamide
repaglinide[no description available]medium10piperidines
zoledronic acid[no description available]medium101,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
acamprosate[no description available]medium10acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
isaxonine[no description available]medium10aminopyrimidine
nebivolol[no description available]medium10chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
uk 68798[no description available]medium10aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
hp 873[no description available]high101,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
fenoxypropazine[no description available]medium10aromatic ether
aceclofenac[no description available]medium10amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
nitrefazole[no description available]medium10imidazoles
doripenem[no description available]medium10carbapenems
rivastigmine[no description available]medium10carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan[no description available]medium10carbazoles
eletriptan[no description available]medium10indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
bexarotene[no description available]medium10benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
moexipril[no description available]medium10peptide
mci 9038[no description available]medium10peptide
fulvestrant[no description available]medium1017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
tadalafil[no description available]medium10benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
paliperidone[no description available]medium101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
pramipexole[no description available]medium10benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
valdecoxib[no description available]medium10isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
almotriptan[no description available]medium10indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
desloratadine[no description available]medium150benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
desloratadine[no description available]medium154benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
desvenlafaxine[no description available]medium10cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
tamsulosin[no description available]medium105-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
rufinamide[no description available]medium10aromatic amide;
heteroarene
dexpanthenol[no description available]medium10amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
fosamprenavir[no description available]medium10sulfonamideprodrug
febuxostat[no description available]medium101,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
escitalopram[no description available]medium101-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
10-propargyl-10-deazaaminopterin[no description available]medium10N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel anhydrous[no description available]medium10secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
ertapenem[no description available]medium10carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
cox 189[no description available]medium10amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
conivaptan[no description available]medium10benzazepineaquaretic;
vasopressin receptor antagonist
pralnacasan[no description available]medium10
clevidipine[no description available]medium10dihydropyridine
solifenacin[no description available]medium10isoquinolines
dexmethylphenidate[no description available]medium10methyl phenyl(piperidin-2-yl)acetateadrenergic agent
cinacalcet[no description available]medium10(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
lubiprostone[no description available]medium10
telbivudine[no description available]medium10pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
anidulafungin[no description available]medium10antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
17 alpha-hydroxyprogesterone caproate[no description available]medium10corticosteroid hormone
varenicline[no description available]medium10
fiduxosin[no description available]medium10
erlotinib[no description available]medium10aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
etravirine[no description available]medium10aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
dronedarone[no description available]medium101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
ramelteon[no description available]medium10indanes
lapatinib[no description available]medium10furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
darunavir[no description available]medium10carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
tolvaptan[no description available]medium10benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
lenalidomide[no description available]medium10aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
regadenoson[no description available]medium10purine nucleoside
lacosamide[no description available]medium10N-acyl-amino acid
vincaleukoblastine[no description available]medium10acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
oxytocin[no description available]medium30heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
pentostatin[no description available]medium10coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
cefoxitin[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
pancuronium[no description available]medium10acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
abacavir[no description available]medium102,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
miglitol[no description available]medium10piperidines
metyrosine[no description available]medium10L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
linezolid[no description available]medium20acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
clindamycin phosphate[no description available]medium10
eplerenone[no description available]medium103-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
darifenacin[no description available]medium101-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
octreotide[no description available]medium10
eptifibatide[no description available]medium10homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
posaconazole[no description available]medium10aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
arsenic trioxide[no description available]medium10arsenic oxideantineoplastic agent;
insecticide
sr 90107[no description available]medium10
meglumine iodipamide[no description available]medium10organoammonium saltradioopaque medium
thyrotropin-releasing hormone[no description available]medium10peptide hormone;
tripeptide		human metabolite
arginine vasopressin[no description available]medium30vasopressincardiovascular drug;
hematologic agent;
mitogen
s 1033[no description available]medium20(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
pyrantel[no description available]medium101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
eszopiclone[no description available]medium10zopiclonecentral nervous system depressant;
sedative
succimer[no description available]medium10dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
cancidas[no description available]medium10
lincomycin[no description available]medium10carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
ranitidine[no description available]medium50C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
aplaviroc[no description available]medium10
maraviroc[no description available]medium10tropane alkaloid
nelarabine[no description available]medium10beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
dermatan sulfate[no description available]medium10amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
dolasetron[no description available]medium10indolyl carboxylic acid
fospropofol[no description available]medium10alkylbenzene
rasagiline[no description available]medium10indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
sitagliptin[no description available]medium10triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
eprosartan[no description available]medium10dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
mivacurium[no description available]medium10isoquinolines
hemabate[no description available]medium10
paricalcitol[no description available]medium10hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
7432 s[no description available]medium10cephalosporin;
dicarboxylic acid		antibacterial drug
epoprostenol[no description available]medium10prostaglandins Imouse metabolite
indocyanine green[no description available]medium101,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
ethamolin[no description available]medium10long-chain fatty acid
estropipate[no description available]medium10piperazinium salt;
steroid sulfate
ly 163892[no description available]medium10carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nabilone[no description available]medium10
vitamin k 1[no description available]medium10phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
trospium chloride[no description available]medium10
benzphetamine[no description available]medium10amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
deamino arginine vasopressin[no description available]medium10heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
dexmedetomidine[no description available]medium20medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
goserelin[no description available]medium10organic molecular entity
nateglinide[no description available]medium10phenylalanine derivative
silodosin[no description available]medium10indolecarboxamide
su 11248[no description available]medium10monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
butorphanol[no description available]medium20morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
butorphanol[no description available]medium21morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
benazepril[no description available]medium10benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
verteporfin[no description available]medium10
trientine hydrochloride[no description available]medium10
n-methylscopolamine bromide[no description available]medium10
cefuroxime[no description available]medium103-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
cefepime[no description available]medium10cephalosporin;
oxime O-ether		antibacterial drug
pafuramidine[no description available]medium10
ceftazidime[no description available]medium10cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
pregabalin[no description available]medium20gamma-amino acidanticonvulsant;
calcium channel blocker
alvimopan anhydrous[no description available]medium10peptide
aliskiren[no description available]medium10monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
cefpodoxime[no description available]medium10carboxylic acid;
cephalosporin		antibacterial drug
palonosetron[no description available]medium10azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
rifaximin[no description available]medium10acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
everolimus[no description available]medium10cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
ceftizoxime[no description available]medium10cephalosporinantibacterial drug
dantrolene[no description available]medium10
cefdinir[no description available]medium10cephalosporin;
ketoxime		antibacterial drug
etonogestrel[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
temsirolimus[no description available]medium10macrolide lactam
dutasteride[no description available]medium10(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
bibx 1382bs[no description available]medium10substituted aniline
fesoterodine[no description available]medium10diarylmethane
gemifloxacin[no description available]medium101,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
dexlansoprazole[no description available]medium10benzimidazoles;
sulfoxide
armodafinil[no description available]medium102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
sincalide[no description available]medium20oligopeptide
tapentadol[no description available]medium10alkylbenzene
cefditoren[no description available]medium10carboxylic acid;
cephalosporin		antibacterial drug
pazopanib[no description available]medium10aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
prasugrel hydrochloride[no description available]medium10
bms 477118[no description available]medium10adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
nystatin a1[no description available]medium10nystatins
bivalirudin[no description available]medium20polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
enfuvirtide[no description available]medium10
ganirelix[no description available]medium10polypeptide
teriparatide[no description available]medium10polypeptide
salmon calcitonin[no description available]medium10heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
ly-146032[no description available]medium10heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide[no description available]medium10polypeptide
exenatide[no description available]medium10
sodium lactate[no description available]medium10lactate salt;
organic sodium salt		food acidity regulator;
food preservative
sodium iothalamate[no description available]medium10
cetrorelix[no description available]medium10oligopeptideantineoplastic agent;
GnRH antagonist
raltegravir[no description available]medium101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
demeclocycline[no description available]medium10
tipranavir[no description available]medium10sulfonamideantiviral drug;
HIV protease inhibitor
tigecycline[no description available]medium10
fertinex[no description available]medium10
valacyclovir[no description available]medium10L-valyl esterantiviral drug
vardenafil[no description available]medium10imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
citrovorum factor[no description available]medium10tetrahydrofolic acid
rifapentine[no description available]medium10N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
bl 4162a[no description available]medium10imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
tegaserod[no description available]medium10carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
pemetrexed[no description available]medium10N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
valganciclovir[no description available]medium10L-valyl ester;
purines		antiviral drug;
prodrug
aprepitant[no description available]medium20(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
fosaprepitant[no description available]medium10(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
levomefolate calcium[no description available]medium10organic calcium saltantidepressant
e-55888[no description available]medium10
1-hexadecyl-2-acetyl-glycero-3-phosphocholine[no description available]medium3972-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
mdl 100907[no description available]medium132
fumarates[no description available]medium20butenedioate;
C4-dicarboxylate		human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite
phenmetrazine[no description available]medium10morpholinesmetabolite;
sympathomimetic agent
okadaic acid[no description available]medium20ketal
chlorine[no description available]medium60halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
hydroxyindoleacetic acid[no description available]medium402indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
melatonin[no description available]medium161acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
phenyl acetate[no description available]medium61benzenes;
phenyl acetates
carbazeran[no description available]medium10
3-hydroxydesloratadine[no description available]medium42
carbamates[no description available]medium30amino-acid anion
rocuronium[no description available]medium103alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound		drug allergen;
muscle relaxant;
neuromuscular agent
methylene blue[no description available]medium20organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
luteolin[no description available]medium303'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
substance p[no description available]medium110peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
erythrosine[no description available]medium10
osimertinib[no description available]medium10acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
neuropeptide y[no description available]medium10
peptide yy[no description available]medium10
mometasone furoate[no description available]medium1011beta-hydroxy steroid;
2-furoate ester;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
organochlorine compound;
steroid ester		anti-allergic agent;
anti-inflammatory drug
trk 820[no description available]medium10phenanthrenes
morphinans[no description available]medium10isoquinoline alkaloid fundamental parent;
morphinane alkaloid
abiraterone[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
retapamulin[no description available]medium10carbotricyclic compound;
carboxylic ester;
cyclic ketone
piperidines[no description available]medium693
pyrroles[no description available]medium20pyrrole;
secondary amine
am 251[no description available]medium10amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles		antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist
4-iodo-2,5-dimethoxyphenylisopropylamine[no description available]medium30amphetamines;
dimethoxybenzene;
organoiodine compound
cp 93129[no description available]medium10pyrrolopyridine
arachidonyl-2-chloroethylamide[no description available]medium10fatty amide;
organochlorine compound;
secondary carboxamide;
synthetic cannabinoid		CB1 receptor agonist;
CB2 receptor agonist;
neuroprotective agent
2-piperidone[no description available]medium10delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
sildenafil citrate[no description available]medium10citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
tramadol[no description available]medium102-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanoladrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor
olopatadine hydrochloride[no description available]medium20dibenzooxazepine
4-amino-3-phenylbutyric acid[no description available]medium10organonitrogen compound;
organooxygen compound
hydrazine[no description available]medium172azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
anamorelin[no description available]medium10
ng-nitroarginine methyl ester[no description available]medium60alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
fenclonine[no description available]medium861phenylalanine derivative
5-hydroxytryptophan[no description available]medium691hydroxytryptophanhuman metabolite;
neurotransmitter
orabase[no description available]medium10
cellulose[no description available]medium20glycoside
hydrogen[no description available]medium20elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
stearic acid[no description available]medium10long-chain fatty acid;
saturated fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
human metabolite;
plant metabolite
ginkgolide b[no description available]medium50
interleukin-8[no description available]medium20
adenosine diphosphate[no description available]medium100adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
ciclesonide[no description available]medium10organic molecular entity
ebastine[no description available]medium31organic molecular entity
azelastine[no description available]medium40monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
azelastine[no description available]medium41monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
fluticasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
bilastine[no description available]medium21benzimidazoles
venlafaxine hydrochloride[no description available]medium20hydrochloride
cyclohexanol[no description available]medium30cyclohexanols;
secondary alcohol		solvent
levocetirizine[no description available]medium63diarylmethane
formic acid[no description available]medium20monocarboxylic acidantibacterial agent;
astringent;
metabolite;
protic solvent;
solvent
amitraz[no description available]medium10formamidines;
tertiary amino compound		acaricide;
environmental contaminant;
insecticide;
xenobiotic
u 40481[no description available]medium10benzenes;
formamidines		marine xenobiotic metabolite
vilazodone hydrochloride[no description available]medium10hydrochlorideantidepressant;
serotonergic agonist;
serotonin uptake inhibitor
bafilomycin a1[no description available]medium10cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
dantrolene[no description available]medium50hydrazone;
imidazolidine-2,4-dione		muscle relaxant;
neuroprotective agent;
ryanodine receptor antagonist
sr 140333[no description available]medium10
quinuclidines[no description available]medium10quinuclidines;
saturated organic heterobicyclic parent
enclomiphene[no description available]medium10
ifenprodil[no description available]medium10piperidines
dimethindene[no description available]medium20indene
hyoscyamine[no description available]medium10tropane alkaloid
web 2086[no description available]medium20organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
cv 6209[no description available]medium50
triazoles[no description available]medium801,2,3-triazole
4-butyrolactone[no description available]medium10butan-4-olidemetabolite;
neurotoxin
lignans[no description available]medium10
cubebin[no description available]medium10benzodioxoles;
cyclic acetal;
lactol;
lignan;
secondary alcohol		analgesic;
anti-inflammatory agent;
antimicrobial agent;
histamine antagonist;
plant metabolite;
trypanocidal drug
hinokinin[no description available]medium10benzodioxoles;
gamma-lactone;
lignan		trypanocidal drug
soman[no description available]medium10phosphonic ester
buprenorphine[no description available]medium10morphinane alkaloiddelta-opioid receptor antagonist;
kappa-opioid receptor antagonist;
mu-opioid receptor agonist;
opioid analgesic
buprenorphine, naloxone drug combination[no description available]medium10
maleic acid[no description available]medium20butenedioic acidalgal metabolite;
mouse metabolite;
plant metabolite
dizocilpine maleate[no description available]medium30maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
clorgyline[no description available]medium30aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
methacrylic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid
ethylene dimethacrylate[no description available]medium10enoate esterallergen;
cross-linking reagent;
polymerisation monomer
methylene chloride[no description available]medium20chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
pyrazines[no description available]medium70diazine;
pyrazines		Daphnia magna metabolite
cyclin d1[no description available]medium20
methandrostenolone[no description available]medium31organic molecular entity
leptin[no description available]medium20
losartan potassium[no description available]medium10
rmi 12330a[no description available]medium10
benzylaniline[no description available]medium20
1-methyl-4-phenylpyridinium[no description available]medium10pyridinium ionapoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin
capsazepine[no description available]medium10benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
hydrogen sulfide[no description available]medium10gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride		Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent
cysteine[no description available]medium10cysteiniumfundamental metabolite
sodium bisulfide[no description available]medium10
nobiletin[no description available]medium10methoxyflavoneantineoplastic agent;
plant metabolite
n-methylaspartate[no description available]medium30amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
rifamycins[no description available]medium10
carbostyril[no description available]medium10monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
sermorelin[no description available]medium10
alpha-methylserotonin[no description available]medium30tryptaminesserotonergic agonist
nitroarginine[no description available]medium10guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
ovalbumin[no description available]medium40
arachidonyltrifluoromethane[no description available]medium10fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound		EC 3.1.1.4 (phospholipase A2) inhibitor
bisindolylmaleimide i[no description available]medium10
4-(2-aminoethyl)benzenesulfonylfluoride[no description available]medium10
arginyl-glycyl-aspartyl-serine[no description available]medium20
sc 41930[no description available]medium10
sq 29548[no description available]medium30
pyrazolone[no description available]medium10
adenosine-5'-(n-ethylcarboxamide)[no description available]medium10adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
p-methoxy-n-methylphenethylamine[no description available]medium242aromatic ether;
secondary amino compound		metabolite
eucalyptol[no description available]medium10
n(6)-cyclopentyladenosine[no description available]medium10
mefloquine[no description available]medium20
indophenol[no description available]medium10quinone iminedye
bradykinin[no description available]medium241oligopeptidehuman blood serum metabolite;
vasodilator agent
icatibant[no description available]medium10
bradykinin, leu(8)-des-arg(9)-[no description available]medium10
ah 1058[no description available]medium10
thioperamide[no description available]medium30primary aliphatic amine
decursin[no description available]medium10coumarins
theobromine[no description available]medium10dimethylxanthineadenosine receptor antagonist;
bronchodilator agent;
food component;
human blood serum metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
3,7-dimethyl-1-propargylxanthine[no description available]medium10
1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine[no description available]medium10
pirenzepine[no description available]medium21pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
methdilazine[no description available]medium10N-alkylpyrrolidine;
phenothiazines		antipruritic drug;
cholinergic antagonist;
histamine antagonist
dihydroergotoxine[no description available]medium20
dihydroxyphenylalanine[no description available]medium110hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative		human metabolite
sodium salicylate[no description available]medium40organic molecular entity
phenothiazine[no description available]medium40phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
furaldehyde[no description available]medium10aldehyde;
furans		Maillard reaction product;
metabolite
oxomemazine[no description available]medium10phenothiazines
methotrimeprazine[no description available]high20phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
indoleacetic acid[no description available]medium30indole-3-acetic acids;
monocarboxylic acid		auxin;
human metabolite;
mouse metabolite;
plant hormone;
plant metabolite
paramethasone[no description available]medium10fluorinated steroid
methoxamine[no description available]medium50amphetaminesalpha-adrenergic agonist;
antihypotensive agent
aluminum[no description available]medium10boron group element atom;
elemental aluminium;
metal atom
pentylenetetrazole[no description available]medium50organic heterobicyclic compound;
organonitrogen heterocyclic compound
isopropamide iodide[no description available]medium10diarylmethane
dibenzheptropine[no description available]medium10organic tricyclic compound
chloralose[no description available]medium10
cardiovascular agents[no description available]medium10
tranylcypromine[no description available]medium502-phenylcyclopropan-1-amine
vitamin k semiquinone radical[no description available]medium30
stilbenes[no description available]medium10stilbene
arachidonic acid[no description available]medium40icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
u 73122[no description available]medium20aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
sb 242084[no description available]medium10
alpha-aminopyridine[no description available]medium30
2-diphenylmethylpiperidine[no description available]medium20
trilostane[no description available]medium3017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
sorbic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
sorbic acid
bw-755c[no description available]medium40
limaprost[no description available]medium10long-chain fatty acid
oleanolic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
beta-amyrin[no description available]medium10pentacyclic triterpenoid;
secondary alcohol		Aspergillus metabolite;
plant metabolite
fluorobenzenes[no description available]medium10monofluorobenzenesNMR chemical shift reference compound
piracetam[no description available]medium10organonitrogen compound;
organooxygen compound
ergoline[no description available]medium304diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound
1-(5-isoquinolinesulfonyl)-2-methylpiperazine[no description available]medium10isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor
oxazolidin-2-one[no description available]medium10carbamate ester;
oxazolidinone		metabolite
fluocinolone acetonide[no description available]medium2111beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
organic heteropentacyclic compound;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
flunisolide[no description available]medium1111beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
n-methyl-3,4-methylenedioxyamphetamine[no description available]medium10amphetamines;
benzodioxoles		neurotoxin
4-methoxymethamphetamine[no description available]medium10
atropine sulfate-diphenoxylate hydrochloride drug combination[no description available]medium10
nitrates[no description available]medium30monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan[no description available]medium10
D-fructopyranose[no description available]medium20cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
bw a868c[no description available]medium10imidazolidine-2,4-dione
prostaglandin d2[no description available]medium32prostaglandins Dhuman metabolite;
mouse metabolite
ramatroban[no description available]medium10organic molecular entity
hydantoins[no description available]medium10imidazolidine-2,4-dione
picryl chloride[no description available]medium10C-nitro compound;
monochlorobenzenes		allergen;
epitope;
explosive;
hapten
glycogen[no description available]medium10
bradyzide[no description available]medium10
sarpogrelate[no description available]medium10hemisuccinate;
stilbenoid
sb 206553[no description available]medium10pyrroloindole
calcimycin[no description available]medium60benzoxazole
hydrocortisone-17-butyrate[no description available]medium10butyrate ester;
cortisol ester;
primary alpha-hydroxy ketone		dermatologic drug;
drug allergen
alpha-chymotrypsin[no description available]medium30
isoflurophate[no description available]medium10dialkyl phosphate
n-vinyl-2-pyrrolidinone[no description available]medium10pyrrolidin-2-ones
kaolinite[no description available]medium10aluminosilicate mineral;
mixture		antidiarrhoeal drug;
excipient
pituitrin[no description available]medium61
methoxyhydroxyphenylglycol[no description available]medium50methoxybenzenes;
phenols
cyclic gmp[no description available]medium303',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
chlorphenamidine[no description available]medium30
beta-endorphin[no description available]medium120
lypressin[no description available]medium60cyclic peptide
quipazine[no description available]medium300piperazines;
pyridines
lithium[no description available]medium101alkali metal atom
neurotensin, trp(11)-[no description available]medium10
neurotensin[no description available]medium20peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
6-chloro-2-(1-piperazinyl)pyrazine[no description available]medium20N-arylpiperazine
metiamide[no description available]medium30imidazoles
enkephalin, methionine[no description available]medium20
d-ala(2),mephe(4),met(0)-ol-enkephalin[no description available]medium10
pirenperone[no description available]medium40aromatic ketone
4-chlorophenethylamine[no description available]medium10
quifenadine[no description available]medium10diarylmethane
diazoline[no description available]medium10polymer
2-phenylpyrazolo(4,3-c)quinolin-3(5h)-one[no description available]medium10
phencyclidine[no description available]medium51benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
picrotoxin[no description available]medium70
pholedrine[no description available]medium10amphetamines
tiaramide[no description available]medium10benzothiazoles
doxantrazole[no description available]medium20
proxicromil[no description available]medium10
barium[no description available]medium40alkaline earth metal atom;
elemental barium
barium chloride[no description available]medium20barium salt;
inorganic chloride		potassium channel blocker
diphenhydramine hydrochloride[no description available]medium11hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
lithium carbonate[no description available]medium30carbonate salt;
lithium salt		antimanic drug
cinanserin[no description available]medium300aryl sulfide;
cinnamamides;
secondary carboxamide;
tertiary amino compound		anticoronaviral agent;
antiviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
fenfluramine[no description available]medium351(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
pargyline[no description available]medium140aromatic amine
myelin basic protein[no description available]medium20
glucagon[no description available]medium180peptide hormone
5,7-dihydroxytryptamine[no description available]medium140
3-hydroxybenzylhydrazine[no description available]medium10phenols
thiophenes[no description available]medium236mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
carbidopa[no description available]medium81
benserazide[no description available]medium80carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
alanine[no description available]medium10alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
enkephalin, leucine[no description available]medium70pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite
bucladesine[no description available]medium503',5'-cyclic purine nucleotide
5,6-dihydroxytryptamine[no description available]medium50
ether[no description available]medium10ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant
dibutyryl cyclic gmp[no description available]medium10
tetrodotoxin[no description available]medium60azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
potassium chloride[no description available]medium80inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
veratridine[no description available]medium20
desmethylcyproheptadine[no description available]medium80
demethylchlordimeform[no description available]medium10
angiotensin iii[no description available]medium10
angiotensin ii[no description available]medium110amino acid zwitterion;
angiotensin II		human metabolite
saralasin[no description available]medium10oligopeptide
norfenfluramine[no description available]medium21amphetamines
beta-carboline-3-carboxylic acid ethyl ester[no description available]medium20beta-carbolines
methacholine chloride[no description available]medium21quaternary ammonium salt
menotropins[no description available]medium10
bis(4-methyl-1-homopiperazinylthiocarbonyl)disulfide[no description available]medium20
bellergal[no description available]medium10
guanosine triphosphate[no description available]medium10guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanylyl imidodiphosphate[no description available]medium10nucleoside triphosphate analogue
tyrosine[no description available]medium20amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
flupenthixol[no description available]medium40thioxanthenes
bw 501c[no description available]medium20
5-hydroxykynuramine[no description available]medium10hydroxykynurenamine;
primary amino compound		mouse metabolite
kynuramine[no description available]medium10kynurenamines;
primary amino compound		metabolite
clenbuterol[no description available]medium10amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
carbenoxolone sodium[no description available]medium11triterpenoid
methochlorpromazine[no description available]medium10
phosphorus[no description available]medium10monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
diethylcarbamazine[no description available]medium102N-carbamoylpiperazine;
N-methylpiperazine
cholecystokinin[no description available]medium20
pyrrolidonecarboxylic acid[no description available]medium105-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
vasotocin[no description available]medium10
ergonovine[no description available]medium40ergot alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		diagnostic agent;
fungal metabolite;
oxytocic;
toxin
gastrins[no description available]medium40
choline[no description available]medium30cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
cholestyramine resin[no description available]medium20
salicylates[no description available]medium40monohydroxybenzoateplant metabolite
oxalates[no description available]medium10
leucine[no description available]medium80amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
cannabinol[no description available]medium10dibenzopyran
nantradol[no description available]medium10
benzohexonium[no description available]medium20
tipindole[no description available]medium20
piribedil[no description available]medium20N-arylpiperazine
proglumide[no description available]medium20benzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate		anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite
dynorphins[no description available]medium40
hexamethonium[no description available]medium50quaternary ammonium salt
loxtidine[no description available]medium10aromatic ether;
piperidines;
primary alcohol;
triazoles		H2-receptor antagonist
n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine[no description available]medium20
enkephalin, ser(2), leu(5), thr(6)-[no description available]medium30oligopeptide
mezlocillin[no description available]medium10indolamine
rimorphin[no description available]medium20
malondialdehyde[no description available]medium40dialdehydebiomarker
thromboxane b2[no description available]medium20thromboxanes Bhuman metabolite;
mouse metabolite
6-ketoprostaglandin f1 alpha[no description available]medium20prostaglandins Falphahuman metabolite;
mouse metabolite
saccharin[no description available]medium101,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
brofaromine[no description available]medium10
kainic acid[no description available]medium40dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
beta-escin[no description available]medium10
ginsenoside rg2[no description available]medium1012beta-hydroxy steroid;
20-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		anticoagulant;
cardioprotective agent;
plant metabolite
ginsenosides[no description available]medium10
flavone acetic acid[no description available]medium10
vadimezan[no description available]medium30monocarboxylic acid;
xanthones		antineoplastic agent
xanthenes[no description available]medium30xanthene
glycosides[no description available]medium10
thiamylal[no description available]medium10barbiturates;
organosulfur compound		sedative
quisqualic acid[no description available]medium10non-proteinogenic alpha-amino acid
arginine aspartate[no description available]medium11
aspartic acid[no description available]medium11aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
ornithine[no description available]medium11non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
ro 11-2933[no description available]medium10
diminazene aceturate[no description available]medium10N-acetylglycinate saltantiparasitic agent;
trypanocidal drug
diminazene[no description available]medium10carboxamidine;
triazene derivative		antiparasitic agent;
trypanocidal drug
melarsoprol[no description available]medium10triazines
phenidone[no description available]medium30
leukotriene e4[no description available]medium10amino dicarboxylic acid;
L-cysteine thioether;
leukotriene;
non-proteinogenic L-alpha-amino acid;
secondary alcohol
idazoxan[no description available]medium10benzodioxine;
imidazolines		alpha-adrenergic antagonist
racemetirosine[no description available]medium10
u-50488[no description available]medium30dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine		analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist
leukotriene d4[no description available]medium10dipeptide;
leukotriene;
organic sulfide		bronchoconstrictor agent;
human metabolite;
mouse metabolite
fpl 55712[no description available]medium20aromatic ketone
enkephalinamide-met, ala(2)-[no description available]medium10
hirudin[no description available]medium20
silicon phthalocyanine pc4[no description available]medium10
setoperone[no description available]medium10
pyrimidinones[no description available]medium10
deoxynivalenol[no description available]medium10cyclic ketone;
enone;
primary alcohol;
secondary alpha-hydroxy ketone;
trichothecene;
triol		mycotoxin
tubocurarine[no description available]medium20bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
quinazolines[no description available]medium20azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
bw a522[no description available]medium10
cgs 15943[no description available]medium10aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant
sk&f-38393[no description available]medium30benzazepine;
catechols;
secondary amino compound
1h-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-[no description available]medium20benzazepine
pindobind[no description available]medium10
ethionine[no description available]medium10S-ethylhomocysteineantimetabolite;
carcinogenic agent
concanavalin a[no description available]medium20
moclobemide[no description available]medium10benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
enkephalin, ala(2)-mephe(4)-gly(5)-[no description available]medium10
hexarelin[no description available]medium10
hsr 609[no description available]medium10
anisodamine[no description available]medium30
phosphocreatine[no description available]medium10phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite
enkephalin, d-penicillamine (2,5)-[no description available]medium10heterodetic cyclic peptidedelta-opioid receptor agonist
renzapride[no description available]medium10
sdz 205-557[no description available]medium10methoxybenzoic acid
4-aminobenzoic acid[no description available]medium10aminobenzoate;
aromatic amino-acid anion		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
tetralin[no description available]medium10ortho-fused bicyclic hydrocarbon;
tetralins
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid[no description available]medium10polyamino carboxylic acid;
tetracarboxylic acid		chelator
egtazic acid[no description available]medium20diether;
tertiary amino compound;
tetracarboxylic acid		chelator
foropafant[no description available]medium10
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
halofantrine[no description available]medium10phenanthrenes
phenanthrenes[no description available]medium10
rhodamine 123[no description available]medium10organic cation;
xanthene dye		fluorochrome
wortmannin[no description available]medium10acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
chelerythrine[no description available]medium10benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
genistein[no description available]medium107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine[no description available]medium10
masticadienonic acid[no description available]medium10triterpenoid
morolic acid[no description available]medium10
tetradecanoylphorbol acetate[no description available]medium10acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
leukotriene b4[no description available]medium10dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
masticadienolic acid[no description available]medium10
adrenochrome[no description available]medium10indoles
p-chloroamphetamine[no description available]medium90
dimethylhydrazines[no description available]medium20
butaclamol[no description available]medium10
glutamic acid diethyl ester[no description available]medium10
xenon radioisotopes[no description available]medium10
alloxan[no description available]medium20pyrimidonehyperglycemic agent;
metabolite
furazolidone[no description available]medium10nitrofuran antibiotic;
oxazolidines		antibacterial drug;
antiinfective agent;
antitrichomonal drug;
EC 1.4.3.4 (monoamine oxidase) inhibitor
bencyclane[no description available]medium10benzenes
cortodoxone[no description available]medium10deoxycortisol;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
cortisone[no description available]medium6011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
17-ketosteroids[no description available]medium10
deoxyepinephrine[no description available]medium10catecholamine
halofenate[no description available]medium10
deoxyglucose[no description available]medium10
mannoheptulose[no description available]medium30D-manno-heptulose
oxyfedrine[no description available]medium10aromatic ketone
puromycin aminonucleoside[no description available]medium103'-deoxyribonucleoside;
adenosines
puromycin[no description available]medium10puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
adosterol[no description available]medium10
spermidine[no description available]medium10polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
deanol[no description available]medium10ethanolamines;
tertiary amine		curing agent;
radical scavenger
3,4-methylenedioxyamphetamine[no description available]medium10benzodioxoles
mmda[no description available]medium10
metanephrine[no description available]medium10catecholamine
normetanephrine[no description available]medium20catecholamine
vasoactive intestinal peptide[no description available]medium10
dibenzylchlorethamine[no description available]medium90
dita[no description available]medium10
dimethoxyphenylethylamine[no description available]medium20alkaloid;
aromatic ether;
phenylethylamine		allergen;
plant metabolite
kallidin[no description available]medium10peptide
lynestrenol[no description available]medium10steroid
tolazoline[no description available]medium40imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
iodine[no description available]medium20diatomic iodinenutrient
vasopressin, 9-des-gly-nh(2)-lys-[no description available]medium10
methyl iodide[no description available]medium10iodomethanes;
methyl halides		fumigant insecticide
3-n-methylspiperone[no description available]medium10aromatic ketone
beta-funaltrexamine[no description available]medium10morphinane alkaloid
binaltorphimine[no description available]medium10
9-(tetrahydro-2-furyl)-adenine[no description available]medium10
fonazine[no description available]medium10phenothiazines
oxetorone[no description available]medium10oxacycle
bemesetron[no description available]medium30
2-methyl-5-ht[no description available]medium10tryptaminesserotonergic agonist
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride[no description available]medium10
c-peptide[no description available]medium10
6-(5-methylimidazol-1-yl)methyl-2-naphthoic acid hydrochloride[no description available]medium10
bepafant[no description available]medium10
(9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one[no description available]medium1121-hydroxy steroid
4-chlorophenylalanine methyl ester[no description available]medium20
brimonidine tartrate[no description available]medium10
quinoxalines[no description available]medium10mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
tiotidine[no description available]medium10thiazoles
allyl cyanide[no description available]medium10aliphatic nitrile;
olefinic compound		antifeedant;
neurotoxin;
plant metabolite
2-pentenenitrile[no description available]medium10
crotononitrile[no description available]medium10nitrile
tipepidine[no description available]medium10piperidines
glucose, (beta-d)-isomer[no description available]medium10D-glucopyranoseepitope;
mouse metabolite
3-tyr-octreotide[no description available]medium10
bromerguride[no description available]medium10
acrivastine[no description available]medium20alpha,beta-unsaturated monocarboxylic acid;
N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
acrivastine[no description available]medium21alpha,beta-unsaturated monocarboxylic acid;
N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
clobetasol[no description available]medium1111beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist
dothiepin hydrochloride[no description available]medium11dothiepin
pentazocine[no description available]medium20benzazocine
thromboxane a2[no description available]medium10epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite
physostigmine salicylate[no description available]medium10azaheterocycle salicylate salt;
salicylates
urethane[no description available]medium20carbamate esterfungal metabolite;
mutagen
cv 3988[no description available]medium10
bw 540c[no description available]medium10
aa 861[no description available]medium101,4-benzoquinones;
acetylenic compound;
primary alcohol		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
arabinogalactan[no description available]medium10
2-octopamine[no description available]medium10
mequitazine[no description available]medium21phenothiazines
pipethiaden[no description available]medium20
alpha-neoendorphin[no description available]medium10
alpha,beta-methyleneadenosine 5'-triphosphate[no description available]medium10nucleoside triphosphate analogue
histidine[no description available]medium10amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
phenylpiperazine[no description available]medium10
zopiclone[no description available]medium10monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
nordazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
cl 218872[no description available]medium10pyridazines;
ring assembly
dihydroalprenolol[no description available]medium10
9,10-dihydroergosine[no description available]medium10
gaboxadol[no description available]medium10oxazole
isoxazoles[no description available]medium10isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
lithium chloride[no description available]medium10inorganic chloride;
lithium salt		antimanic drug;
geroprotector
cosyntropin[no description available]medium10
carbidopa, levodopa drug combination[no description available]medium10
nsd 1034[no description available]medium10
dimethylphenylpiperazinium iodide[no description available]medium10N-arylpiperazine;
organic iodide salt;
piperazinium salt;
quaternary ammonium salt		nicotinic acetylcholine receptor agonist
n-benzyl-n,n-dimethylamine[no description available]medium10
iron tetraphenylporphyrin[no description available]medium10
etoprine[no description available]medium10
isoquinoline[no description available]medium10azaarene;
isoquinolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene
quinpirole[no description available]medium10pyrazoloquinolinedopamine agonist
bicuculline methiodide[no description available]medium10
peptide phi[no description available]medium10
fibrin[no description available]medium10peptide
fibrinogen[no description available]medium40iditolfungal metabolite
fpl-52694[no description available]medium10
4-(5,6-dimethyl-2-benzofuranyl)piperidine[no description available]medium10
toluene[no description available]medium10methylbenzene;
toluenes;
volatile organic compound		cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent
oxyphenonium[no description available]medium20acylcholine
kynurenine[no description available]medium10aromatic ketone;
non-proteinogenic alpha-amino acid;
substituted aniline		human metabolite
nad[no description available]medium10organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
nadp[no description available]medium10
chlorine[no description available]medium40diatomic chlorine;
gas molecular entity		bleaching agent
bromine[no description available]medium30diatomic bromine
acid phosphatase[no description available]medium10
cobalt[no description available]medium10cobalt group element atom;
metal allergen		micronutrient
nitrites[no description available]medium10monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
scandium[no description available]medium10d-block element atom;
rare earth metal atom;
scandium group element atom
lead[no description available]medium10carbon group element atom;
elemental lead;
metal atom		neurotoxin
phlorhizin[no description available]medium10aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		antioxidant;
plant metabolite
mercury[no description available]medium10elemental mercury;
zinc group element atom		neurotoxin
tremorine[no description available]medium30N-alkylpyrrolidine
hydrochloric acid[no description available]medium10chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite
eledoisin[no description available]medium10peptide
glycopyrrolate[no description available]medium10organic bromide salt;
quaternary ammonium salt
camphor, (+-)-isomer[no description available]medium10bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite
rutin[no description available]medium10disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
neodymium[no description available]medium10f-block element atom;
lanthanoid atom
hyaluronoglucosaminidase[no description available]medium10
strontium[no description available]medium10alkaline earth metal atom
psilocybin[no description available]medium20organic phosphate;
tertiary amino compound;
tryptamine alkaloid		fungal metabolite;
hallucinogen;
prodrug;
serotonergic agonist
xenon[no description available]medium10monoatomic xenon;
noble gas atom;
p-block element atom
methylcellulose[no description available]medium10
biguanides[no description available]medium10guanidines
uric acid[no description available]medium10uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
levallorphan[no description available]medium10morphinane alkaloid
dextromoramide[no description available]medium10morpholines;
N-acylpyrrolidine		opioid analgesic
chlorisondamine[no description available]medium10isoindoles
gold[no description available]medium10copper group element atom;
elemental gold
thymidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
chlorphentermine[no description available]medium10amphetamines
agar[no description available]medium10
fluorine[no description available]medium10diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
hydrogen carbonate[no description available]medium10carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pentolinium tartrate[no description available]medium10tartrate saltantihypertensive agent
isomethyleugenol[no description available]medium20isomethyleugenol
phenylephrine hydrochloride[no description available]medium43hydrochloride
fomesafen[no description available]medium250aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
eye[no description available]medium41
trolamine salicylate[no description available]medium30
s,n,n'-tripropylthiocarbamate[no description available]medium20tertiary amine
jaw[no description available]medium10indolecarboxamide
4-methoxyamphetamine[no description available]medium10
benzquinamide[no description available]low00monocarboxylic acid amideantiemetic;
antipsychotic agent;
H1-receptor antagonist;
muscarinic antagonist;
sedative
bromodiphenhydramine[no description available]low00organobromine compound;
tertiary amino compound		antimicrobial agent;
H1-receptor antagonist;
muscarinic antagonist
emedastine[no description available]low00benzimidazolesanti-allergic agent;
antipruritic drug;
H1-receptor antagonist
methapyrilene[no description available]low00ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
promethazine hydrochloride[no description available]low00hydrochlorideanti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative
methapyrilene hydrochloride[no description available]low00hydrochlorideanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
orphenadrine hydrochloride[no description available]low00hydrochlorideantiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
clopenthixol[no description available]low00N-alkylpiperazine;
primary alcohol;
thioxanthenes		alpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
azelastine hydrochloride[no description available]low00hydrochlorideanti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
trazodone hydrochloride[no description available]low00hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
diphenylpyraline hydrochloride[no description available]low00hydrochloridecholinergic antagonist;
H1-receptor antagonist
orphenadrine citrate[no description available]low00citrate saltH1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
clemizolpenicillin[no description available]low00clemizole(1+) saltH1-receptor antagonist
tau 284[no description available]low00organosulfonate saltanti-allergic agent;
H1-receptor antagonist
clemastine fumarate[no description available]low00fumarate saltanti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
ketotifen fumarate[no description available]low00organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
carbinoxamine maleate[no description available]low00maleate saltanti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
zuclopenthixol[no description available]low00clopenthixolalpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
triprolidine hydrochloride anhydrous[no description available]low00hydrochlorideH1-receptor antagonist
cyclizine hydrochloride[no description available]low00hydrochlorideantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist
dexbrompheniramine maleate[no description available]low00brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
demethylmirtazapine[no description available]low00benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
human xenobiotic metabolite;
serotonergic antagonist
alcaftadine[no description available]medium00aldehyde;
imidazobenzazepine;
piperidines;
tertiary amino compound		anti-allergic agent;
H1-receptor antagonist
(S)-carbinoxamine maleate[no description available]low00carbinoxamine maleateanti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
aripiprazole lauroxil[no description available]low00aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist
propiomazine[no description available]low00aromatic ketone;
phenothiazines;
tertiary amino compound		dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
sedative;
serotonergic antagonist
setiptiline[no description available]low00tertiary amino compound;
tetracyclic antidepressant		alpha-adrenergic antagonist;
serotonergic antagonist
thiethylperazine[no description available]low00N-methylpiperazine;
phenothiazines		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
dotarizine[no description available]low00cyclic ketal;
dioxolane;
N-alkylpiperazine		calcium channel blocker;
serotonergic antagonist;
vasodilator agent
alosetron hydrochloride[no description available]low00hydrochlorideantiemetic;
serotonergic antagonist
tramadol hydrochloride[no description available]low00hydrochlorideadrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor
spiramide[no description available]medium00aromatic ether;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
serotonergic antagonist
clomipramine hydrochloride[no description available]low00hydrochlorideanticoronaviral agent;
antidepressant;
serotonergic antagonist;
serotonergic drug
amperozide[no description available]low00diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas		anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
amperozide hydrochloride[no description available]low00hydrochlorideanxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine[no description available]low00hydrobromideserotonergic antagonist
gr 113808[no description available]medium00indolyl carboxylate ester;
piperidines;
sulfonamide		serotonergic antagonist
fk 1052[no description available]low00imidazoles;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
lurasidone[no description available]low001,2-benzisothiazole;
bridged compound;
dicarboximide;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea[no description available]low001,2-thiazoles;
indoles;
ureas		receptor modulator;
serotonergic antagonist
sb-224289[no description available]low001,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound		serotonergic antagonist
brl 15572[no description available]low00monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol		geroprotector;
serotonergic antagonist
LY-310762[no description available]medium00aromatic ketone;
monofluorobenzenes;
oxindoles;
piperidines;
tertiary amino compound		receptor modulator;
serotonergic antagonist
ly 367265[no description available]low00dihydropyridine;
fluoroindole;
tertiary amino compound;
thiadiazoloquinoline		antidepressant;
geroprotector;
serotonergic antagonist;
serotonin uptake inhibitor
flibanserin[no description available]low00benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound		antidepressant;
serotonergic agonist;
serotonergic antagonist
rs 25259-197[no description available]low00hydrochlorideantiemetic;
serotonergic antagonist
vortioxetine[no description available]low00aryl sulfide;
N-arylpiperazine		antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist
pimavanserin[no description available]medium00aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas		5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist
lurasidone hydrochloride[no description available]low00hydrochlorideadrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
GR 127935 hydrochloride[no description available]low00hydrochlorideserotonergic antagonist
pipamperone dihydrochloride[no description available]low00hydrochloridedopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
brl 15572[no description available]low00hydrochlorideprodrug;
serotonergic antagonist
1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one[no description available]low00hydrochloridereceptor modulator;
serotonergic antagonist
rs 39604[no description available]low00hydrochlorideserotonergic antagonist
3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid[no description available]low0011-oxo steroid;
3alpha-hydroxy steroid;
7-oxo steroid;
monocarboxylic acid;
steroid acid		antineoplastic agent;
cholinergic antagonist;
metabolite;
serotonergic antagonist
crotamiton[no description available]low00enamide;
tertiary carboxamide		antipruritic drug;
scabicide
ethyl chloride[no description available]low00chloroethanesantipruritic drug;
inhalation anaesthetic;
local anaesthetic
diflorasone diacetate[no description available]low0011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug;
antipruritic drug
flumethasone pivalate[no description available]low0011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
pivalate ester;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
quercetin 3-o-glucopyranoside[no description available]low00beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
clocortolone pivalate[no description available]low0011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
pivalate ester		anti-inflammatory drug;
antipruritic drug
desoximetasone[no description available]low0011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
amlexanox[no description available]low00monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
scoparone[no description available]low00aromatic ether;
coumarins		anti-allergic agent;
anti-inflammatory agent;
antihypertensive agent;
antilipemic drug;
immunosuppressive agent;
plant metabolite
nedocromil[no description available]low00dicarboxylic acid;
organic heterotricyclic compound		anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug
hydrangenol[no description available]low00dihydroisocoumarins;
phenols		anti-allergic agent;
plant metabolite
glycyrrhetyl 3-monoglucuronide[no description available]low00beta-D-glucosiduronic acid;
enone;
monosaccharide derivative;
oxo dicarboxylic acid;
pentacyclic triterpenoid;
triterpenoid saponin		anti-allergic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
human xenobiotic metabolite;
plant metabolite;
sweetening agent
secoxyloganin[no description available]low00beta-D-glucoside;
dicarboxylic acid monoester;
enoate ester;
methyl ester;
monosaccharide derivative;
pyrans;
secoiridoid glycoside		anti-allergic agent;
antioxidant;
plant metabolite
davidigenin[no description available]low00dihydrochalcones;
polyphenol		anti-allergic agent;
anti-asthmatic agent;
antioxidant;
metabolite
fluticasone propionate[no description available]low0011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
rhapontin[no description available]low00rhaponticinangiogenesis inhibitor;
anti-allergic agent;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
hypoglycemic agent;
neuroprotective agent;
plant metabolite
naringenin chalcone[no description available]low00chalcones;
polyphenol		anti-allergic agent;
anti-inflammatory agent;
metabolite
brompheniramine maleate[no description available]low00maleate saltanti-allergic agent
petasin[no description available]low00alicyclic ketone;
enoate ester;
enone;
sesquiterpenoid		anti-allergic agent;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} activator;
plant metabolite;
vasodilator agent
myricitrin[no description available]low00alpha-L-rhamnoside;
glycosyloxyflavone;
monosaccharide derivative;
pentahydroxyflavone		anti-allergic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite
rottlerin[no description available]low00aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
sappanchalcone[no description available]low00catechols;
chalcones;
monomethoxybenzene		anti-allergic agent;
anti-inflammatory agent;
antioxidant;
metabolite
jaceosidin[no description available]low00dimethoxyflavone;
trihydroxyflavone		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
metabolite
5,4'-dihydroxy-7,3'-dimethoxyflavone[no description available]low00dihydroxyflavone;
dimethoxyflavone		anti-allergic agent;
anti-inflammatory agent;
antibacterial agent;
antioxidant;
melanin synthesis inhibitor;
plant metabolite
rhodiocyanoside a[no description available]low00aliphatic nitrile;
beta-D-glucoside;
cyanogenic glycoside;
monosaccharide derivative		anti-allergic agent;
metabolite
capsiate[no description available]low00carboxylic ester;
monomethoxybenzene;
phenols		angiogenesis inhibitor;
anti-allergic agent;
anti-inflammatory agent;
antioxidant;
capsaicin receptor agonist;
hypoglycemic agent;
plant metabolite
ginsenoside m1[no description available]low0012beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
hepatoprotective agent;
plant metabolite
fluticasone furoate[no description available]low0011beta-hydroxy steroid;
2-furoate ester;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
steroid ester;
thioester		anti-allergic agent;
anti-asthmatic drug;
prodrug
abt-737[no description available]low00aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
tixocortol pivalate[no description available]low00corticosteroid;
pivalate ester;
tertiary alpha-hydroxy ketone;
thioester		allergen;
anti-allergic agent;
glucocorticoid receptor agonist
betazole[no description available]low00primary amino compound;
pyrazoles		diagnostic agent;
gastrointestinal drug;
histamine agonist
alpha-methylene gamma-butyrolactone[no description available]low00butan-4-olideanti-ulcer drug;
gastrointestinal drug
aurapten[no description available]low00coumarins;
monoterpenoid		antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
dopaminergic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
gamma-secretase modulator;
gastrointestinal drug;
hepatoprotective agent;
matrix metalloproteinase inhibitor;
neuroprotective agent;
plant metabolite;
PPARalpha agonist;
vulnerary
sofalcone[no description available]low00aromatic ether;
chalcones;
monocarboxylic acid		anti-ulcer drug;
antibacterial agent;
gastrointestinal drug;
plant metabolite
16,16-dimethylprostaglandin e2[no description available]low00cyclopentanones;
monocarboxylic acid;
prostanoid;
secondary allylic alcohol		anti-ulcer drug;
gastrointestinal drug;
radiation protective agent
eluxadoline[no description available]low00amino acid amide;
benzamides;
imidazoles;
L-phenylalanine derivative;
methoxybenzoic acid		delta-opioid receptor antagonist;
gastrointestinal drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist
ceruletide[no description available]low00oligopeptidediagnostic agent;
gastrointestinal drug
ceruletide diethylamine[no description available]low00organoammonium saltdiagnostic agent;
gastrointestinal drug
cycrimine[no description available]low00piperidines;
tertiary alcohol;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
dyclonine[no description available]low00aromatic ketone;
piperidines		topical anaesthetic
eperisone[no description available]low00aromatic ketone;
piperidines
ethyl piperidinoacetylaminobenzoate[no description available]low00benzoate ester;
piperidines
mazaticol[no description available]low00piperidines
mefloquine hydrochloride[no description available]low00organofluorine compound;
piperidines;
quinolines;
secondary alcohol
methixene[no description available]low00piperidines;
thioxanthenes		antiparkinson drug;
histamine antagonist;
muscarinic antagonist
sb 220025[no description available]low00aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines		angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
vesamicol[no description available]low00piperidines
diphemanil methylsulfate[no description available]low00piperidines;
quaternary ammonium salt		bronchodilator agent;
muscarinic antagonist;
parasympatholytic
pempidine[no description available]low00piperidines
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester[no description available]low00piperidines
2-methylpiperidine[no description available]low00piperidines
piperidine[no description available]low00azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine		base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent
jervine[no description available]low00piperidines
phenoperidine[no description available]low00piperidines
piminodine[no description available]low00piperidines
dexetimide[no description available]low00piperidines
4-(4-chlorophenyl)-4-hydroxypiperidine[no description available]low00piperidines
levocabastine[no description available]low00piperidines
preclamol[no description available]low00piperidines
tzu 0460[no description available]low00piperidines
eliprodil[no description available]low00monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound
3-methylfentanyl[no description available]low00monocarboxylic acid amide;
piperidines		mu-opioid receptor agonist;
opioid analgesic;
sedative
f 7302[no description available]low00piperidines
4-fluorofentanyl[no description available]low00monocarboxylic acid amide;
organofluorine compound;
piperidines
tenocyclidine[no description available]low00piperidines;
tertiary amino compound;
thiophenes		central nervous system stimulant;
hallucinogen;
neuroprotective agent;
NMDA receptor antagonist
terikalant[no description available]low00piperidines
sufotidine[no description available]low00piperidines
fagomine[no description available]low00piperidines
1-(4-nitrophenyl)piperidine[no description available]low00piperidines
fentanyl isothiocyanate[no description available]low00piperidines
ritalinic acid[no description available]low00monocarboxylic acid;
piperidines		drug metabolite;
marine xenobiotic metabolite
fenpropidine[no description available]low00piperidines;
tertiary amine
sk&f 95282[no description available]low00piperidines
biperiden hydrochloride[no description available]low00hydrochloride;
piperidines;
tertiary alcohol		antiparkinson drug;
muscarinic antagonist;
parasympatholytic
phenglutarimide[no description available]low00piperidines
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol[no description available]low00piperidines
alphaprodine[no description available]low00piperidines
lofentanil[no description available]low00methyl ester;
piperidines;
tertiary amino compound;
tertiary carboxamide		mu-opioid receptor agonist;
opioid analgesic
1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine[no description available]low001-benzothiophenes;
piperidines;
tertiary amino compound		dopamine uptake inhibitor
picaridin[no description available]low00carboxylic acid;
piperidines
5-(4-piperidyl)isoxazol-3-ol[no description available]low00piperidines
ku 1257[no description available]low00piperidines
l 733060[no description available]low00piperidines
n-(n-benzylpiperidin-4-yl)-4-iodobenzamide[no description available]low00piperidines
l 741626[no description available]low00piperidines
aminopotentidine[no description available]low00aromatic ether;
benzamides;
guanidines;
nitrile;
piperidines;
substituted aniline		H2-receptor antagonist
migalastat[no description available]low00piperidines
zanapezil[no description available]low00piperidines
anacoline iodide[no description available]low00dioxolane;
piperidines
norfentanyl[no description available]low00anilide;
monocarboxylic acid amide;
piperidines		drug metabolite;
opioid analgesic
magellanine[no description available]low00piperidines
tecomine[no description available]low00piperidines
isofagomine[no description available]low00piperidines
efinaconazole[no description available]low00conazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
N-(1,3-benzodioxol-5-yl)-1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinecarboxamide[no description available]low00piperidines
N-(1-adamantyl)-4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinecarboxamide[no description available]low00piperidines
2-[(1,3-dimethyl-2,6-dioxo-7-propyl-8-purinyl)thio]-N-[2-(1-piperidinyl)phenyl]acetamide[no description available]low00piperidines
4-methyl-N-[3-[1-(phenylmethyl)-4-piperidinyl]-2,4-dihydro-1H-1,3,5-triazin-6-yl]benzenesulfonamide[no description available]low00piperidines
4-(2-benzamidoethylamino)-1-piperidinecarboxylic acid ethyl ester[no description available]low00carboxylic acid;
piperidines
N-[3-(dimethylamino)-2,2-dimethylpropyl]-1-[(2-hydroxyphenyl)methyl]-4-piperidinecarboxamide[no description available]low00piperidines
N-(2-ethoxyphenyl)-1-[4-(1-pyrrolidinylsulfonyl)phenyl]-4-piperidinecarboxamide[no description available]low00piperidines
1-(4,6-dimethyl-2-pyrimidinyl)-4-piperidinecarboxylic acid[no description available]low00carboxylic acid;
piperidines
N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamide[no description available]low00acetamides;
piperidines;
pyridines;
sulfonamide
1-(1-oxo-2-thiophen-2-ylethyl)-4-piperidinecarboxylic acid ethyl ester[no description available]low00carboxylic acid;
piperidines
4-Piperidinobenzoic acid[no description available]low00piperidines
N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine[no description available]low00piperidines;
quinazolines;
tertiary amino compound;
toluenes
2-(2-methylphenoxy)-N-[2-(4-methyl-1-piperidinyl)phenyl]acetamide[no description available]low00piperidines
2-(phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile[no description available]low00piperidines
1-(phenylmethyl)-N'-(2,4,6-trimethylphenyl)sulfonyl-4-piperidinecarbohydrazide[no description available]low00piperidines
1-[2-[(4-methyl-2-oxo-1-benzopyran-7-yl)oxy]-1-oxoethyl]-4-phenyl-4-piperidinecarboxylic acid[no description available]low00piperidines
3-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-1,3-diazaspiro[4.6]undecane-2,4-dione[no description available]low00piperidines
1-[1-(phenylmethyl)-4-piperidinyl]-3-(2,4,4-trimethylpentan-2-yl)thiourea[no description available]low00piperidines
4-[4-(phenylmethyl)-1-piperidinyl]thieno[2,3-d]pyrimidine[no description available]low00piperidines;
thienopyrimidine
cyclohexanecarboxylic acid [2-oxo-2-[4-(1-piperidinyl)anilino]ethyl] ester[no description available]low00piperidines
1-[1-(phenylmethyl)-4-piperidinyl]-3-(2-propan-2-ylphenyl)thiourea[no description available]low00piperidines
1-(4-ethylphenyl)-3-[1-(phenylmethyl)-4-piperidinyl]thiourea[no description available]low00piperidines
tempo[no description available]low00aminoxyls;
piperidines		catalyst;
ferroptosis inhibitor;
radical scavenger
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl[no description available]low00aminoxyls;
dicarboximide;
maleimides;
piperidines		radical scavenger;
spin label
N-(4-bromophenyl)-4-(2-methoxyphenyl)-1-piperidinecarbothioamide[no description available]low00piperidines
N1-(1-benzyl-4-piperidyl)-4-chlorobenzene-1-sulfonamide[no description available]low00piperidines
3,3-dimethyl-1-[4-(trifluoromethoxy)phenyl]piperidine-2,6-dione[no description available]low00piperidines
1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]piperidine[no description available]low00piperidines
4-(benzenesulfonyl)-1-[(4-chlorophenyl)methyl]-4-piperidinecarboxylic acid ethyl ester[no description available]low00piperidines
2-benzyl-6-hydroxy-2-azabicyclo[2.2.2]octan-3-one[no description available]low00piperidines
5-methyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-thieno[2,3-d]pyrimidinamine[no description available]low00piperidines;
thienopyrimidine
N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N'-(4-fluorophenyl)urea[no description available]low00piperidines
[4-(2-methoxyphenyl)-1-piperidinyl]-(5-methyl-1-phenyl-4-pyrazolyl)methanone[no description available]low00piperidines
4-acetamidobenzenesulfonic acid [2-(1-piperidinyl)phenyl] ester[no description available]low00piperidines
1-(3-phenylpropanoyl)-4-piperidinecarboxylic acid[no description available]low00carboxylic acid;
piperidines
4-fluoro-N-[2-(1-piperidinyl)phenyl]benzenesulfonamide[no description available]low00piperidines
1-(2-fluorophenyl)-3-[2-(1-piperidinyl)phenyl]urea[no description available]low00piperidines
4-(1-piperidinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonylamino]benzoic acid ethyl ester[no description available]low00piperidines
1-[(3-chlorophenyl)methyl]-N,N-diethyl-3-piperidinecarboxamide[no description available]low00piperidines
3-hydroxy-5-nitro-2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-triazolimine[no description available]low00piperidines
1-(3-chlorophenyl)-3-[[1-[(2,5-dimethoxyphenyl)methyl]-4-piperidinyl]methyl]urea[no description available]low00piperidines
1-[2-hydroxy-3-[4-(2-methylbutan-2-yl)phenoxy]propyl]-4-piperidinecarboxylic acid ethyl ester[no description available]low00carboxylic acid;
piperidines
femoxetine[no description available]low00piperidines
4-phenyl-1-(4-phenylbutyl)piperidine[no description available]low00piperidines
4-(1h-imidazol-4-ylmethyl)piperidine[no description available]low00piperidines
tandutinib[no description available]low00aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
6-phenylspiro[7-oxa-1-azabicyclo[2.2.1]heptane-2,1'-cyclopentane][no description available]low00piperidines
3,5-dimethyl-2,6-bis(4-methylphenyl)-4-piperidinone[no description available]low00piperidines
1-[2-[(4-chlorophenyl)thio]-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester[no description available]low00carboxylic acid;
piperidines
1-[9-[(4-fluorophenyl)methyl]-9-azabicyclo[3.3.1]nonan-3-yl]-3-(2-phenylphenyl)urea[no description available]low00piperidines
4-(2-fluorophenyl)-1-[[1-[(4-methoxyphenyl)methyl]-5-tetrazolyl]methyl]-4-piperidinol[no description available]low00piperidines
1-(3-methylphenyl)-3-[[1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinyl]methyl]urea[no description available]low00piperidines
1-(2-methylphenyl)-3-[[1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinyl]methyl]urea[no description available]low00piperidines
1-[2-[3-(N-ethylanilino)propylamino]-3,4-dioxo-1-cyclobutenyl]-4-piperidinecarboxylic acid ethyl ester[no description available]low00carboxylic acid;
piperidines
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[(3,4-dimethoxyphenyl)methyl]-N-methyl-3-piperidinecarboxamide[no description available]low00piperidines
4-[[2-(3-ethylanilino)-3,4-dioxo-1-cyclobutenyl]amino]-1-piperidinecarboxylic acid ethyl ester[no description available]low00carboxylic acid;
piperidines
1,4-dimethyl-6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]quinoxaline-2,3-dione[no description available]low00piperidines
1-[(3-chlorophenyl)methyl]-N-methyl-N-(phenylmethyl)-3-piperidinecarboxamide[no description available]low00piperidines
4-[4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-piperidinyl]-3-nitrobenzoic acid methyl ester[no description available]low00piperidines
benzoic acid [[1-(4-nitrophenyl)-4-piperidinylidene]amino] ester[no description available]low00piperidines
1-[(4-chlorophenyl)methyl]-4-(4-chlorophenyl)sulfonyl-4-piperidinecarboxylic acid ethyl ester[no description available]low00piperidines
1-[3-[(2-methoxyphenyl)sulfamoyl]-4-(1-piperidinyl)phenyl]-3-(3-methylphenyl)urea[no description available]low00piperidines
1-[(6-hydroxy-2-methyl-5-thiazolo[3,2-b][1,2,4]triazolyl)-(3,4,5-trimethoxyphenyl)methyl]-4-piperidinecarboxylic acid methyl ester[no description available]low00carboxylic acid;
piperidines
1-pyrrolidinyl-[1-[(2,3,4-trimethoxyphenyl)methyl]-3-piperidinyl]methanone[no description available]low00piperidines
2-[1-[4-(diethylamino)phenyl]-4a-hydroxy-1,3,4,5,6,7,8,8a-octahydroisoquinolin-2-yl]-N-phenylacetamide[no description available]low00piperidines
2-(hexylamino)-1-[4-(phenylmethyl)-1-piperidinyl]ethanone[no description available]low00piperidines
5-(4-morpholinylsulfonyl)-2-(1-piperidinyl)benzoic acid [2-[[(3-methylbutylamino)-oxomethyl]amino]-2-oxoethyl] ester[no description available]low00piperidines
2-methyl-2,6-diphenyl-7-oxa-1-azabicyclo[2.2.1]heptane[no description available]low00piperidines
N-(3-isoxazolyl)-3-nitro-4-(1-piperidinyl)benzamide[no description available]low00piperidines
N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide[no description available]low00piperidines
2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-quinazolinamine[no description available]low00piperidines
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine[no description available]low00aromatic amine;
piperidines;
pyridines;
quinazolines;
secondary amino compound;
tertiary amino compound
1-(4-carbamoyl-2-nitrophenyl)-4-piperidinecarboxylic acid methyl ester[no description available]low00piperidines
N-(1,3-benzodioxol-5-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide[no description available]low00piperidines
5-[2-furanyl-[4-(phenylmethyl)-1-piperidinyl]methyl]-6-thiazolo[3,2-b][1,2,4]triazolol[no description available]low00piperidines
5-nitro-6-(3-nitrophenyl)-2-piperidinone[no description available]low00piperidines
3-nitro-4-[2-[1-(phenylmethyl)-4-piperidinylidene]hydrazinyl]benzenesulfonamide[no description available]low00piperidines
pibutidine[no description available]low00aromatic ether;
cyclobutenones;
olefinic compound;
piperidines;
primary amino compound;
pyridines;
secondary amino compound		anti-ulcer drug;
H2-receptor antagonist
N-[4-[(4-methyl-1-piperidinyl)methyl]phenyl]-1-[5-(1-pyrrolyl)-1,3,4-thiadiazol-2-yl]-4-piperidinecarboxamide[no description available]low00piperidines
palbociclib[no description available]low00aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
1-(2-chlorophenyl)-3-[4-(1-piperidinylmethyl)phenyl]urea[no description available]low00piperidines
opc-67683[no description available]low00piperidines
ro 25-6981[no description available]low00benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound		anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist
pd 174494[no description available]low00piperidines
2-ethoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide[no description available]low00piperidines
n-demethylloperamide[no description available]low00monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		drug metabolite
bms201038[no description available]low00(trifluoromethyl)benzenes;
benzamides;
fluorenes;
piperidines		anticholesteremic drug;
MTP inhibitor
casopitant[no description available]low00piperidines
rolapitant[no description available]low00azaspiro compound;
ether;
organofluorine compound;
piperidines;
pyrrolidin-2-ones		antiemetic;
neurokinin-1 receptor antagonist
at 7867[no description available]low00monochlorobenzenes;
piperidines;
pyrazoles		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
at 7519[no description available]low00dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
alogliptin[no description available]low00nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
azd 8931[no description available]low00aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
pf 00299804[no description available]low00enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
dorsomorphin[no description available]low00aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
6-o-desmethyl donepezil[no description available]low00piperidines
nvp-tae684[no description available]low00piperidines
[3-[(2-methylphenyl)methyl]-1-[(5-methyl-2-thiophenyl)methyl]-3-piperidinyl]methanol[no description available]low00piperidines
2-(2-fluoro-5-methoxyphenyl)-5-methyl-4-[(4-phenyl-1-piperidinyl)methyl]oxazole[no description available]low00piperidines
[3-[(3-chlorophenyl)methyl]-1-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-3-piperidinyl]methanol[no description available]low00piperidines
2-[4-[1-(2-fluorophenyl)-4-piperidinyl]-1-[(3-methoxyphenyl)methyl]-2-piperazinyl]ethanol[no description available]low00piperidines
[1-[(1,2-dimethyl-3-indolyl)methyl]-4-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]methanol[no description available]low00piperidines
[1-(2-benzofuranylmethyl)-4-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]methanol[no description available]low00piperidines
1-(5-isoquinolinylmethyl)-4-[(3-methoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester[no description available]low00piperidines
3-[[4-[(4-chlorophenyl)methyl]-4-(hydroxymethyl)-1-piperidinyl]-oxomethyl]-4,5-dihydro-1H-pyridazin-6-one[no description available]low00piperidines
1-(2-chloro-4-methylphenyl)-3-[[1-[(3-chlorophenyl)methyl]-4-piperidinyl]methyl]urea[no description available]low00piperidines
1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]thiourea[no description available]low00piperidines
3-hydroxy-2-(3-methylphenyl)-5-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-4-triazolimine[no description available]low00piperidines
4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine[no description available]low00piperidines
gdc-0973[no description available]low00aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
gsk690693[no description available]low001,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
WAY-316606[no description available]low00(trifluoromethyl)benzenes;
piperidines;
secondary amino compound;
sulfonamide;
sulfone		secreted frizzled-related protein 1 inhibitor
N-butyl-4-(phenylmethyl)-1-piperidinecarbothioamide[no description available]low00piperidines
N-(2-methylpropyl)-4-(phenylmethyl)-1-piperidinecarbothioamide[no description available]low00piperidines
4-(phenylmethyl)-N-prop-2-enyl-1-piperidinecarbothioamide[no description available]low00piperidines
N-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-4-piperidinyl]-3-pyrazolyl]-4-phenylbutanamide[no description available]low00piperidines
4-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinecarboxylic acid[no description available]low00carboxylic acid;
piperidines
2-(2,6-dimethylphenoxy)-N-[2-(1-piperidinyl)phenyl]acetamide[no description available]low00piperidines
niraparib[no description available]low00benzenes;
indazoles;
piperidines;
primary carboxamide		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ipi-926[no description available]low00piperidines
asp3026[no description available]low00aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
bix 01294[no description available]low00piperidines
pf 3845[no description available]low00piperidines
glasdegib[no description available]low00benzimidazoles;
nitrile;
phenylureas;
piperidines		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
1-[3-methoxy-4-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]-4-piperidinol[no description available]low00piperidines
1-[4-[[4-amino-5-chloro-6-(2-propan-2-ylsulfonylanilino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-piperidinecarboxamide[no description available]low00piperidines
2,3-dimethoxy-N-[4-(1-piperidinyl)phenyl]aniline[no description available]low00piperidines
ulixacaltamide[no description available]low00benzamides;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary carboxamide		non-narcotic analgesic;
T-type calcium channel blocker
Mps1-IN-2[no description available]low00piperidines
gilteritinib[no description available]low00aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alectinib[no description available]low00aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ceritinib[no description available]low00aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gsk2879552[no description available]low00benzenes;
benzoic acids;
cyclopropanes;
monocarboxylic acid;
piperidines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor
ldc4297[no description available]low00aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
PF-06446846[no description available]low00benzamides;
monochloropyridine;
piperidines;
tertiary carboxamide;
triazolopyridine		antilipemic drug;
EC 3.4.21.61 (kexin) inhibitor
trimethylamine[no description available]low00methylamines;
tertiary amine		Escherichia coli metabolite;
human xenobiotic metabolite
butenafine[no description available]low00naphthalenes;
tertiary amine		antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor
n(6),n(6)-dimethyladenine[no description available]low00tertiary amine
triallate[no description available]low00tertiary amine
n,n-dimethylcyclohexylamine[no description available]low00tertiary amine
tripropylamine[no description available]low00tertiary amine
tributylamine[no description available]low00tertiary amine
triethylamine[no description available]low00tertiary amine
eptc[no description available]low00tertiary amine
pebulate[no description available]low00tertiary amine
3-quinuclidinol[no description available]low00quinuclidines;
secondary alcohol;
tertiary amine
butylate[no description available]low00tertiary amine
difenoxin[no description available]low00nitrile;
piperidinemonocarboxylic acid;
tertiary amine		antidiarrhoeal drug
naftifine[no description available]low00allylamine antifungal drug;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor
1-(1-phenylcyclohexyl)pyrrolidine[no description available]low00pyrrolidines;
tertiary amine		general anaesthetic;
hallucinogen;
NMDA receptor antagonist
disperse blue 124[no description available]low001,3-thiazoles;
monoazo compound;
tertiary amine		allergen;
dye;
hapten
lupanine[no description available]low00delta-lactam;
quinolizidine alkaloid;
tertiary amine
lobeline[no description available]low00aromatic ketone;
piperidine alkaloid;
tertiary amine		nicotinic acetylcholine receptor agonist
ay 25545[no description available]low00acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine		antimicrobial agent;
antineoplastic agent;
bacterial metabolite
otonecine[no description available]low00tertiary amine
di-allate[no description available]low00tertiary amine
2-(4-(dimethylamino)styryl)-1-methylpyridinium[no description available]low00organic iodide salt;
pyridinium salt;
tertiary amine		fluorochrome
4-(4-dihexadecylaminostyryl)-n-methylpyridium[no description available]low00pyridinium ion;
tertiary amine		fluorochrome
lumefantrine[no description available]low00fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine		antimalarial
fm1 43[no description available]low00organic bromide salt;
pyridinium salt;
quaternary ammonium salt;
tertiary amine		fluorochrome
ceratamine a[no description available]low00alkaloid;
aromatic ether;
cyclic ketone;
organic heterobicyclic compound;
organobromine compound;
secondary amino compound;
tertiary amine		antimitotic;
metabolite
picogreen[no description available]low00benzothiazoles;
cyanine dye;
quinolines;
tertiary amine		fluorescent dye
sybr green i[no description available]low00benzothiazolium ion;
cyanine dye;
quinolines;
tertiary amine		fluorescent dye
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease0low20
2019 Novel Coronavirus Infection0low20
2019-nCoV Disease0low20
2019-nCoV Infection0low20
Abdomen, Acute0low10
Abdominal Cramps0low20
Abdominal Migraine0medium569
Abdominal Neoplasms0low10
Abnormal Deep Tendon Reflex0medium21
Abnormal Reflex0medium21
Abnormal Reflexes0medium21
Abnormalities, Autosome0low60
Abnormalities, Chromosomal0low60
Abnormalities, Chromosome0low60
Abnormalities, Drug-Induced0low10
Abnormalities, Multiple0low10
Abortion, Habitual0low40
Abortion, Recurrent0low40
Abortion, Spontaneous0low20
Abortion, Threatened0low10
Abortion, Tubal0low20
Absence of Corpus Callosum0low10
Absence Seizure0low120
Absence Seizures0low120
Acanthosis Nigricans0low20
Acathisia, Drug-Induced0medium42
Ache0low190
Acidosis0low10
Acne Rosacea0low10
Acromegaly0medium122
ACTH Syndrome, Ectopic0low10
Action Tremor0medium81
Active Hyperemia0low20
Acute Confusional Migraine0medium569
Acute Confusional Senile Dementia0low20
Acute Disease0low130
Acute Edematous Pancreatitis0low40
Acute Liver Injury, Drug-Induced0low70
Acute Myelogenous Leukemia0low10
Acute Myeloid Leukemia0low10
Acute Myeloid Leukemia with Maturation0low10
Acute Myeloid Leukemia without Maturation0low10
Acute Pancreatitis0low40
Acute Peripheral Vestibulopathy0low10
Acute Post-Traumatic Stress Disorder0medium52
Acute Respiratory Distress Syndrome0low20
Acute Vestibular Neuritis0low10
ADDH0medium51
Addison Disease0low20
Addison's Disease0low20
Adenocarcinoma0low30
Adenocarcinoma of Lung0low10
Adenocarcinoma, Basal Cell0low30
Adenocarcinoma, Granular Cell0low30
Adenocarcinoma, Mucinous0low10
Adenocarcinoma, Oxyphilic0low30
Adenocarcinoma, Tubular0low30
Adenohypophyseal Diseases0low20
Adenohypophyseal Hyposecretion0medium21
Adenoma0low190
Adenoma, Acidophil0low10
Adenoma, Acidophilic0low10
Adenoma, Basal Cell0low190
Adenoma, Basophil0low10
Adenoma, Basophilic0low10
Adenoma, beta-Cell0low20
Adenoma, Chromophobe0low10
Adenoma, Eosinophil0low10
Adenoma, Eosinophilic0low10
Adenoma, Follicular0low190
Adenoma, Malignant0low30
Adenoma, Microcystic0low190
Adenoma, Monomorphic0low190
Adenoma, Papillary0low190
Adenoma, Prolactin-Secreting, Pituitary0low10
Adenoma, Trabecular0low190
Adjustment Disorder0low20
Adjustment Disorders0low20
Adjuvant Arthritis0low10
Adrenal Cancer0low70
Adrenal Cortex Cancer0low20
Adrenal Cortex Neoplasms0low20
Adrenal Gland Cancer0low70
Adrenal Gland Hyperfunction0low10
Adrenal Gland Hypofunction0low10
Adrenal Gland Neoplasms0low70
Adrenal Hyperplasia, Congenital0low10
Adrenal Insufficiency0low10
Adrenal Neoplasm0low70
Adrenocortical Cancer0low20
Adrenocortical Hyperfunction0low10
Adult Respiratory Distress Syndrome0low20
Adverse Drug Event0low40
Adverse Drug Reaction0low40
Affective Disorders0low20
Affective Psychosis, Bipolar0low30
Afibrinogenemia0low10
Afibrinogenemia, Congenital0low10
African Lymphoma0low10
African Swine Fever0low10
African Swine Fever Virus Infection0low10
Age-Related Memory Disorders0low10
Agenesis of Corpus Callosum0low10
Ageusia0low10
Ageusia, Hysterical0low10
Aggression0low90
Aging0low100
Agnogenic Myeloid Metaplasia0low10
Agranulocytosis0low10
AIDS Seroconversion0low10
AIDS Seropositivity0low10
Airway Hyper-Responsiveness0medium41
Akathisia, Drug-Induced0medium42
Akathisia, Tardive0medium42
Akinetic-Rigid Variant of Huntington Disease0medium11
Alarm Clock Headache0low10
Alcohol Abuse0low40
Alcohol Addiction0low40
Alcohol Dependence0low40
Alcohol Drinking0medium51
Alcohol Use Disorder0low40
Alcoholic Intoxication, Chronic0low40
Aldosteronism0low30
Aldrich Syndrome0low10
Allergic Conjunctivitis0medium73
Allergic Contact Dermatitis0low20
Allergic Encephalomyelitis0low30
Allergic Encephalomyelitis, Experimental0low30
Allergic Reaction0medium372
Allergic Rhinitis0medium82
Allergy0medium372
Allergy, Drug0medium41
Allergy, Food0low30
Allodynia0low20
Allodynia, Mechanical0low20
Allodynia, Tactile0low20
Allodynia, Thermal0low20
Alloxan Diabetes0low100
Altered Level of Consciousness0low10
Altitude Hypoxia0low10
Altitude Sickness0low10
Alveolitis, Fibrosing0low20
Alzheimer Dementia0low20
Alzheimer Disease0low20
Alzheimer Disease, Early Onset0low20
Alzheimer Disease, Late Onset0low20
Alzheimer Sclerosis0low20
Alzheimer Syndrome0low20
Alzheimer Type Senile Dementia0low20
Alzheimer-Type Dementia (ATD)0low20
Alzheimer's Disease0low20
Alzheimer's Disease, Focal Onset0low20
Alzheimer's Diseases0low20
Ambulation Disorders, Neurologic0low10
Amenorrhea0low60
American Trypanosomiasis0low10
Amnesia0low10
Amnesia-Memory Loss0low10
Amnesia, Dissociative0low10
Amnesia, Global0low10
Amnesia, Hysterical0low10
Amnesia, Pre-Ictal0low10
Amnesia, Retrograde0low10
Amnesia, Tactile0low10
Amnesia, Temporary0low10
Amnesic Shellfish Poisoning0low10
Amnestic State0low10
Amyotonia Congenita0low10
Anaphylactic Reaction0low240
Anaphylactoid Reaction0low240
Anaphylactoid Shock0low240
Anaphylaxis0low240
Anasarca0low500
Androgenization0low20
Anemia, Fanconi0low10
Anemia, Hypochromic0low10
Anemia, Iron-Deficiency0low10
Anemias, Iron-Deficiency0low10
Anesthesia0low90
Angina Pectoris, Variant0low20
Angioedema0low80
Angiomatosis0low10
Angioneurotic Edema0low80
Angiospasm, Intracranial0low10
Anguilluliasis0low10
Animal Mammary Carcinoma0low10
ANLL0low10
Anniversary Reaction0low20
Anochlesia0low60
Anorectal Diseases0low10
Anorectal Disorders0low10
Anorexia0medium236
Anorexia Nervosa0medium349
Anoxemia0low40
Anoxia0low40
ANS (Autonomic Nervous System) Diseases0low10
ANS Diseases0low10
Anterior Choroidal Artery Infarction0low10
Anterior Circulation Transient Ischemic Attack0low20
Anterior Pituitary Diseases0low20
Anterior Pituitary Hyposecretion Syndrome0medium21
Anti-HIV Positivity0low10
Antral Vascular Ectasia0low10
Anxiety0low80
Anxiety Disorders0low20
Anxiety Neuroses0low20
Anxiety States, Neurotic0low20
Aortic Diseases0low10
Aortic Stenosis0low10
Aortic Valve Stenosis0low10
Apoplexy0medium21
Appetite Disorders0medium4316
Apudoma0low20
Aqueductal Stenosis0low10
Arachnidism0low10
ARDS, Human0low20
Argentaffinoma0medium232
Arrhythmia0low80
Arrhythmias, Cardiac0low80
Arrythmia0low80
ARSB Deficiency0low10
Arterial Hyperemia0low20
Arteriosclerosis0low20
Arteriosclerosis Obliterans0low10
Arthritis0low30
Arthritis, Adjuvant0low10
Arthritis, Adjuvant-Induced0low10
Arthritis, Collagen-Induced0low10
Arthritis, Experimental0low10
Arthritis, Rheumatoid0medium41
Arthus Phenomenon0low20
Arthus Reaction0low20
Arylsulfatase B Deficiency0low10
As If Personality0low10
Asfivirus Infection0low10
Asialia0low10
Asthenia0low20
Asthma0medium143
Asthma, Bronchial0medium143
Asthma, Exercise-Induced0low10
Astigmatism0low10
Astrocytoma, Grade IV0low20
Asymmetric Diabetic Proximal Motor Neuropathy0low20
Asystole0low10
Ataxia0low10
Ataxia, Appendicular0low10
Ataxia, Limb0low10
Ataxia, Motor0low10
Ataxia, Sensory0low10
Ataxia, Truncal0low10
Ataxy0low10
Atherogenesis0low10
Atherosclerosis0low10
Athetoid Movements0low10
Athetosis0low10
Atonic Absence Seizure0low120
Atonic Absence Seizures0low120
Atonic Seizure0low120
Atonic Seizures0low120
Atopic Hypersensitivity0medium135
Attention Deficit Disorder0medium51
Attention Deficit Disorder with Hyperactivity0medium51
Attention Deficit Disorders with Hyperactivity0medium51
Attention Deficit Hyperactivity Disorder0medium51
Attention Deficit Hyperactivity Disorders0medium51
Attention Deficit-Hyperactivity Disorder0medium51
Atypical Cluster Headache0low20
Audiogenic Epilepsy0low20
Aura0low40
Auricular Cancer0low10
Auricular Neoplasms0low10
Autism0medium21
Autism, Early Infantile0medium21
Autism, Infantile0medium21
Autistic Disorder0medium21
Autoimmune Diabetes0low10
Autoimmune Disease0low10
Autoimmune Diseases0low10
Autoimmune Encephalomyelitis, Experimental0low30
Autoimmune Experimental Encephalomyelitis0low30
Autoimmune Urticaria0medium11
Autonomic Central Nervous System Diseases0low10
Autonomic Diseases0low10
Autonomic Nervous System Diseases0low10
Autonomic Nervous System Disorders0low10
Autonomic Peripheral Nervous System Diseases0low10
Autosomal Chromosome Disorders0low10
Autosomal Dominant Juvenile Parkinson Disease0low10
Autosomal Dominant Juvenile Parkinsonism0low10
Autosomal Dominant Parkinsonism0low10
Autosomal Recessive Juvenile Parkinson Disease0low10
Autosomal Recessive Juvenile Parkinsonism0low10
Autosomal Recessive Parkinsonism0low10
Autosome Abnormalities0low60
Avoidant Personality Disorder0low10
Awakening Epilepsy0low40
B-Cell Leukemia0low10
B-Lymphocytic Leukemia0low10
Basal Ganglia Diseases0medium11
Basal Ganglia Disorders0medium11
Behavior Disorders0medium62
Bends0low20
Benign Cough Headache0low10
Benign Exertional Headache0low10
Benign Intracranial Hypertension0low10
Benign Neoplasms0medium207
Benign Neoplasms, Brain0low10
Benign Paroxysmal Positional Vertigo0low10
Benign Recurrent Vertigo0low10
beta-Cell Tumor0low20
Bewilderment0low30
BH4 Deficiency0low20
Bilateral Headache0medium182
Bilateral Nasal Obstruction0medium11
Bile Duct Obstruction0low20
Bilharziasis0low10
Biliary Stasis0low20
Bilirubinemia0low10
Binge Eating0low30
Bipolar Disorder0low30
Bipolar Mood Disorder0low30
Birth Weight0low10
Bladder Cancer0low10
Bladder Disorder, Neurogenic0low10
Bladder Neoplasms0low10
Bladder Neurogenesis0low10
Bladder Tumors0low10
Bladder, Neurogenic0low10
Blastocyst Disintegration0low10
Bleb0low20
Bleeding0low70
Blepharoptosis0low10
Blepharospasm0low20
Blister0low20
Blood Clot0low50
Blood Poisoning0low20
Blood Pressure, High0low160
Blood Pressure, Low0low70
Blood Protein Disorders0low10
Bloodstream Infection0low20
Body Rocking0low10
Body Weight0medium8926
Bone Marrow Diseases0low30
Bone Marrow Fibrosis0low10
Bowel Incontinence0low10
Brachial Paresis0low10
Bradyarrhythmia0low20
Bradyarrhythmias0low20
Bradycardia0low20
Brain Cancer0low10
Brain Diseases0low10
Brain Disorders0low10
Brain Dysfunction, Minimal0medium51
Brain Edema0low10
Brain Embolism and Thrombosis0low10
Brain Ischemia0low20
Brain Metastases0low10
Brain Neoplasm, Primary0low10
Brain Neoplasms0low10
Brain Neoplasms, Benign0low10
Brain Neoplasms, Malignant0low10
Brain Neoplasms, Malignant, Primary0low10
Brain Neoplasms, Primary Malignant0low10
Brain Stem Ischemia, Transient0low20
Brain Stem Transient Ischemic Attack0low20
Brain Swelling0low10
Brain TIA0low20
Brain Tumor, Primary0low10
Brain Tumor, Recurrent0low10
Brain Tumors0low10
Brainstem Ischemia, Transient0low20
Brainstem Transient Ischemic Attack0low20
Break-Bone Fever0medium21
Breakbone Fever0medium21
Bright Disease0low40
Briquet Syndrome0low10
Bronchial Asthma0medium143
Bronchial Neoplasms0low20
Bronchial Spasm0medium41
Bronchitis0low10
Bronchospasm0medium41
Bronchospasm, Exercise-Induced0low10
Bulbocavernosus Reflex, Decreased0medium21
Bulbocavernousus Reflex Absent0medium21
Bulimia0low30
Bulla0low20
Bullae0low20
Bullous Lesion0low20
Bunostomiasis0low10
Burkitt Cell Leukemia0low10
Burkitt Leukemia0low10
Burkitt Lymphoma0low10
Burkitt Tumor0low10
Burkitt's Leukemia0low10
Burkitt's Lymphoma0low10
Burkitt's Tumor0low10
Burns0low20
C gattii Infection0low10
C neoformans Infection0low10
C. gattii Infection0low10
C. neoformans Infection0low10
Cachexia0medium115
Cadaver0medium21
Caisson Disease0low20
Calcification, Pathologic0low20
Calcinosis0low20
Calcinosis, Tumoral0low20
Cancer0medium207
Cancer of Adrenal Cortex0low20
Cancer of Bladder0low10
Cancer of Brain0low10
Cancer of Colon0low40
Cancer of Ear0low10
Cancer of Ear Auricle0low10
Cancer of Gastrointestinal Tract0low10
Cancer of ILEUM0low10
Cancer of Intestines0low60
Cancer of Liver0low80
Cancer of Lung0low40
Cancer of Ovary0low10
Cancer of Pancreas0low20
Cancer of Pituitary0low310
Cancer of Prostate0low10
Cancer of Stomach0medium51
Cancer of Testis0low10
Cancer of the Adrenal Cortex0low20
Cancer of the Adrenal Gland0low70
Cancer of the Bladder0low10
Cancer of the Brain0low10
Cancer of the Colon0low40
Cancer of the Ear0low10
Cancer of the Gastrointestinal Tract0low10
Cancer of the ILEUM0low10
Cancer of the Intestines0low60
Cancer of the Liver0low80
Cancer of the Lung0low40
Cancer of the Ovary0low10
Cancer of the Pancreas0low20
Cancer of the Pituitary0low310
Cancer of the Prostate0low10
Cancer of the Stomach0medium51
Cancer of the Testes0low10
Cancer of the Testis0low10
Cancer of the Thymus0low10
Cancer of Thymus0low10
Cancer, Hepatocellular0low80
Cancer, Ileal0low10
Canine Diseases0medium73
Carcinoid0medium232
Carcinoid Heart Disease0low20
Carcinoid Tumor0medium232
Carcinoid, Goblet Cell0medium232
Carcinoma, Colloid0low10
Carcinoma, Cribriform0low30
Carcinoma, Epidermoid0low10
Carcinoma, Granular Cell0low30
Carcinoma, Hepatocellular0low40
Carcinoma, Mucinous0low10
Carcinoma, Non-Small Cell Lung0low10
Carcinoma, Non-Small-Cell Lung0low10
Carcinoma, Ovarian Epithelial0low10
Carcinoma, Planocellular0low10
Carcinoma, Squamous0low10
Carcinoma, Squamous Cell0low10
Carcinoma, Thymic0low20
Carcinoma, Tubular0low30
Cardiac Arrest0low10
Cardiac Arrhythmia0low80
Cardiac Arrhythmias0low80
Cardiac Diseases0low10
Cardiac Disorders0low10
Cardiac Dysrhythmia0low80
Cardiac Remodeling, Ventricular0low10
Cardiopulmonary Arrest0low10
Cardiovascular Stroke0low20
Carotid Artery Thrombosis0low10
Carotid Circulation Transient Ischemic Attack0low20
Carotid Thrombosis0low10
Cat Diseases0medium71
Catalepsy0low60
Catarrh0medium53
Cell Transformation, Neoplastic0low10
Cellulitis0low20
Central Autonomic Nervous System Diseases0low10
Central Hypothyroidism0low20
Central Nervous System Disease0medium31
Central Nervous System Diseases0medium31
Central Nervous System Disorder0medium31
Central Nervous System Disorders0medium31
Central Nervous System Disorders, Intracranial0low10
Central Nervous System Intracranial Disorders0low10
Centrala nervsystemets sjukdomar@sv0medium31
Cephalalgia0medium182
Cephalgia0medium182
Cephalgia, Vascular0medium81
Cephalodynia0medium182
Cerea Flexibilitas0low60
Cerebral Angiospasm0low10
Cerebral Artery Spasm0low10
Cerebral Edema0low10
Cerebral Edema, Cytotoxic0low10
Cerebral Edema, Vasogenic0low10
Cerebral Embolism and Thrombosis0low10
Cerebral Infarct0low10
Cerebral Infarction0low10
Cerebral Infarction, Left Hemisphere0low10
Cerebral Infarction, Right Hemisphere0low10
Cerebral Ischemia0low20
Cerebral Ischemia, Transient0low20
Cerebral Palsy0low20
Cerebral Palsy, Athetoid0low20
Cerebral Palsy, Atonic0low20
Cerebral Palsy, Congenital0low20
Cerebral Palsy, Diplegic, Infantile0low20
Cerebral Palsy, Dyskinetic0low20
Cerebral Palsy, Dystonic-Rigid0low20
Cerebral Palsy, Hypotonic0low20
Cerebral Palsy, Mixed0low20
Cerebral Palsy, Monoplegic, Infantile0low20
Cerebral Palsy, Quadriplegic, Infantile0low20
Cerebral Palsy, Rolandic Type0low20
Cerebral Palsy, Spastic0low20
Cerebral Stroke0medium21
Cerebral Vasospasm0low10
Cerebral Ventriculomegaly0low10
Cerebral, Left Hemisphere, Infarction0low10
Cerebral, Right Hemisphere, Infarction0low10
Cerebrovascular Accident0medium21
Cerebrovascular Accident, Acute0medium21
Cerebrovascular Apoplexy0medium21
Cerebrovascular Spasm0low10
Cerebrovascular Stroke0medium21
Cervical Migraine Syndrome0medium569
Chagas Disease0low10
Chagas' Disease0low10
Charcot Gait0low10
Charcot's Gait0low10
Chemical and Drug Induced Liver Injury0low70
Chemical Dependence0low100
Chemically-Induced Liver Toxicity0low70
Child Behavior Disorders0low10
Childhood Behavior Disorders0low10
Chlorosis0low10
Choked Disk0low10
Cholecystoduodenal Fistula0low20
Cholera Infantum0low40
Cholestasis0low20
Choline Deficiency0low10
Chondrodystrophic Myotonia0low10
Chondroma0low10
Chorea0low10
Chorea Disorders0low10
Chorea Syndromes0low10
Chorea, Benign Hereditary0low10
Chorea, Chronic Progressive0low10
Chorea, Chronic Progressive Hereditary (Huntington)0medium11
Chorea, Rheumatic0low10
Chorea, Senile0low10
Chorea, Sydenham0low10
Choreatic Disorders0low10
Choreatic Syndromes0low10
Choreic Movement0low10
Choreiform Movement0low10
Choroby OUN@pl0medium31
Chromosomal Aberrations0low60
Chromosomal Disorders0low10
Chromosome 6-Linked Autosomal Recessive Parkinsonism0low10
Chromosome Aberrations0low60
Chromosome Abnormalities0low60
Chromosome Abnormality Disorders0low10
Chromosome Disorders0low10
Chronic Autoimmune Urticaria0medium11
Chronic Cluster Headache0low20
Chronic Disease0medium4120
Chronic Idiopathic Myelofibrosis0low10
Chronic Idiopathic Urticaria0medium11
Chronic Illness0medium4120
Chronic Inducible Urticaria0medium11
Chronic Insomnia0low10
Chronic Kidney Failure0low20
Chronic Motor and Vocal Tic Disorder0low10
Chronic Post-Traumatic Stress Disorder0medium52
Chronic Progressive Hereditary Chorea (Huntington)0medium11
Chronic Spontaneous Urticaria0medium11
Chronic Urticaria0medium11
Chronically Ill0medium4120
Ciliary Neuralgia0low20
CIndU0medium11
Circulatory Collapse0low20
Circulatory Failure0low20
Cirrhosis0low20
Cirrhosis, Liver0medium11
Clasp-Knife Spasticity0medium104
Classical Dengue0medium21
Classical Dengue Fever0medium21
Clonic Seizure0low120
Clonic Seizures0low120
Cluster Headache0low20
Cluster Headache Syndrome0low20
CNS Disease0medium31
CNS Diseases0medium31
CNS Disorders, Intracranial0low10
Coagulation, Disseminated Intravascular0low20
Coarse Tremor0medium81
Cold Fingers, Hereditary0low10
Cold, Common0medium53
Colic0low20
Colicky Pain0medium61
Colitis Gravis0low10
Colitis, Granulomatous0low10
Colitis, Mucous0low10
Colitis, Ulcerative0low10
Collagen Arthritis0low10
Colon Cancer0low40
Colon Neoplasms0low40
Colon, Irritable0low10
Colonic Cancer0low40
Colonic Neoplasms0low40
Colorectal Cancer0medium11
Colorectal Carcinoma0medium11
Colorectal Neoplasms0medium11
Colorectal Tumors0medium11
Colovesical Fistula0low20
Coma0low10
Comatose0low10
Combined Multiple Motor and Vocal Tic Disorder0low10
Combined Vocal and Multiple Motor Tic Disorder0low10
Common Carotid Artery Thrombosis0low10
Common Cold0medium53
Common Migraine0low10
Communicating Hydrocephalus0low10
Community Acquired Infection0low10
Community-Acquired Infection0low10
Community-Acquired Infections0low10
Compensatory Hyperinsulinemia0low10
Complex Partial Seizure0low120
Complex Partial Seizures0low120
Complication, Intraoperative0low10
Complication, Peroperative0low10
Complication, Postoperative0medium52
Complications, Labor0medium21
Complications, Pregnancy0low30
Concomitant Strabismus0low10
Confusion0low30
Confusion, Post-Ictal0low30
Confusion, Reactive0low30
Confusional State0low30
Congenital Adrenal Hyperplasia0low10
Congenital Afibrinogenaemia0low10
Congenital Afibrinogenemia0low10
Congenital Cerebral Palsy0low20
Congenital Hydrocephalus0low10
Congenital Poikiloderma0low10
Congenital Thrombotic Thrombocytopenic Purpura0low20
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Conjugate Nystagmus0low10
Conjunctivitis, Allergic0medium73
Conjunctivitis, Atopic0medium73
Conjunctivitis, Giant Papillary0medium73
Conjunctivitis, Vernal0medium73
Conn Syndrome0low30
Conn's Syndrome0low30
Connective Tissue Diseases0low10
Consciousness Disorders0low10
Consciousness, Level Altered0low10
Consciousness, Level Depressed0low10
Consumption Coagulopathy0low20
Contact Dermatitis0medium72
Continuous Tremor0medium81
Conus Medullaris Syndrome0low20
Convergence Nystagmus0low10
Convergent Comitant Strabismus0low10
Convulsion0low120
Convulsion, Non-Epileptic0low120
Convulsions0low120
Convulsive Seizure0low120
Convulsive Seizures0low120
Coordination Impairment0low10
Coronary Artery Vasospasm0low10
Coronary Disease0low10
Coronary Heart Disease0low10
Coronary Thrombosis0low10
Coronary Vasospasm0low10
Coronavirus Disease 20190low20
Coronavirus Disease-190low20
Corpse0medium21
Corpus Callosum Agenesis0low10
Corpus Callosum Dysgenesis0low10
Corpus Callosum Hypogenesis0low10
Corpus Callosum Malformation0low10
Corpus Callosum, Agenesis Of0low10
Coryza, Acute0medium53
Cough0medium21
Cough Headache0low10
COVID-190low20
COVID-19 Pandemic0low20
COVID-19 Pandemics0low20
COVID-19 Virus Disease0low20
COVID-19 Virus Infection0low20
COVID190low20
CP (Cerebral Palsy)0low20
Cramp0medium11
Cramp-Fasciculation Syndrome0low10
Cranial Pain0medium182
Crescendo Transient Ischemic Attacks0low20
Crohn Disease0low10
Crohn's Disease0low10
Crohn's Enteritis0low10
Crural Paresis0low10
Cruveilhier-Baumgarten Syndrome0low10
Cryptococcosis0low10
Cryptococcus gattii Infection0low10
Cryptococcus Infection0low10
Cryptococcus Infections0low10
Cryptococcus neoformans Infection0low10
Curling Ulcer0medium52
Curling's Ulcer0medium52
Cursive Epilepsy0low20
Cushing Syndrome0medium824
Cushing's Syndrome0medium824
Cutaneous Mastocytosis0medium21
CVA (Cerebrovascular Accident)0medium21
Cyanosis0low10
Cystic Fibrosis0medium73
Cystic Fibrosis of Pancreas0medium73
Cytogenetic Aberrations0low60
Cytogenetic Abnormalities0low60
Cytotoxic Brain Edema0low10
Cytotoxic Cerebral Edema0low10
Darkness Tremor0medium81
Death, Sudden0low20
Decerebrate Posturing0low80
Decerebrate State0low80
Decision Making Reflex Epilepsy0low20
Decompression Sickness0low20
Decorticate Rigidity0low80
Decorticate State0low80
Decreased Intraocular Pressure-Associated Papilledema0low10
Deficiency Disease, Dihydropteridine Reductase0low20
Deficiency Disease, Ornithine Carbamoyltransferase0low10
Deficiency Disease, Ornithine Transcarbamylase0low10
Deficiency Disease, Phenylalanine Hydroxylase0low20
Deficiency Disease, Phenylalanine Hydroxylase, Severe0low20
Deficiency, Choline0low10
Deficiency, Factor II0low10
Deficiency, Fibrinogen0low10
Deficiency, IgG0low10
Deficiency, Mental0low10
Deficiency, Oxygen0low40
Deficiency, Thiamine0low10
Dehiscence, Surgical Wound0low10
Delayed Effects, Prenatal Exposure0low10
Delayed Hypersensitivity0low30
Delayed Onset Post-Traumatic Stress Disorder0medium52
Delirium0medium31
Delirium of Mixed Origin0medium31
Dementia Praecox0medium137
Dementia, Alzheimer Type0low20
Dementia, Presenile0low20
Dementia, Primary Senile Degenerative0low20
Dementia, Senile0low20
Dengue0medium21
Dengue Fever0medium21
Dengue Hemorrhagic Fever0medium11
Dengue Shock Syndrome0medium11
Depressed Level of Consciousness0low10
Depression0medium132
Depression, Bipolar0low30
Depression, Endogenous0medium183
Depression, Involutional0low10
Depression, Neurotic0medium183
Depression, Reactive0low20
Depression, Unipolar0medium183
Depressive Disorder0medium183
Depressive Disorder, Major0low10
Depressive Syndrome0medium183
Dermatitis0low80
Dermatitis Herpetiformis0low20
Dermatitis Medicamentosa0low40
Dermatitis Seborrheica0low10
Dermatitis Venenata0medium72
Dermatitis, Adverse Drug Reaction0low40
Dermatitis, Allergic Contact0low20
Dermatitis, Allergic Eczematous0low20
Dermatitis, Atopic0medium146
Dermatitis, Contact0medium72
Dermatitis, Contact, Allergic0low20
Dermatitis, Eczematous0medium72
Dermatitis, Seborrheic0low10
Dermatomycoses0low10
Dermatomycosis0low10
Dermatophyte Infection0low10
Dermatoses0medium81
Dermatosis0medium81
DHPR Deficiency0low20
Diabetes Mellitus0medium72
Diabetes Mellitus, Adult-Onset0low10
Diabetes Mellitus, Brittle0low10
Diabetes Mellitus, Experimental0low100
Diabetes Mellitus, Insulin-Dependent0low10
Diabetes Mellitus, Insulin-Dependent, 10low10
Diabetes Mellitus, Juvenile-Onset0low10
Diabetes Mellitus, Ketosis-Prone0low10
Diabetes Mellitus, Ketosis-Resistant0low10
Diabetes Mellitus, Maturity-Onset0low10
Diabetes Mellitus, Non Insulin Dependent0low10
Diabetes Mellitus, Non-Insulin-Dependent0low10
Diabetes Mellitus, Noninsulin Dependent0low10
Diabetes Mellitus, Noninsulin-Dependent0low10
Diabetes Mellitus, Slow-Onset0low10
Diabetes Mellitus, Stable0low10
Diabetes Mellitus, Sudden-Onset0low10
Diabetes Mellitus, Type 10low10
Diabetes Mellitus, Type 20low10
Diabetes Mellitus, Type I0low10
Diabetes Mellitus, Type II0low10
Diabetes, Autoimmune0low10
Diabetic Amyotrophy0low20
Diabetic Asymmetric Polyneuropathy0low20
Diabetic Autonomic Neuropathy0low20
Diabetic Glomerulosclerosis0low10
Diabetic Kidney Disease0low10
Diabetic Mononeuropathy0low20
Diabetic Mononeuropathy Simplex0low20
Diabetic Nephropathies0low10
Diabetic Nephropathy0low10
Diabetic Neuralgia0low20
Diabetic Neuropathies0low20
Diabetic Neuropathy, Painful0low20
Diabetic Polyneuropathy0low20
Diagnosis, Psychiatric0medium62
Diaphragmatic Paralysis0low10
Diarrhea0low100
Diarrhetic Shellfish Poisoning0low10
Diathesis0low30
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated0low10
Diffuse Myofascial Pain Syndrome0low10
Dihydropteridine Reductase Deficiency0low20
Dihydropteridine Reductase Deficiency Disease0low20
DIMS (Disorders of Initiating and Maintaining Sleep)0low10
Diplegia, Spastic0low20
Diplegic Infantile Cerebral Palsy0low20
Disability, Intellectual0low10
Disease Exacerbation0medium31
Disease Models, Animal0low420
Disease Progression0medium31
Disease Susceptibility0low30
Disease, Pulmonary0low20
Diseases of Endocrine System0medium11
Diseases of Immune System0low30
Diseases, Metabolic0low20
Diseases, Pulmonary0low20
Disintegration of Blastocyst0low10
Disintegration of Embryo0low10
Disorders of Initiating and Maintaining Sleep0low10
Disorders of the Autonomic Nervous System0low10
Disorientation0low30
Disseminated Coagulation, Intravascular0low20
Disseminated Intravascular Coagulation0low20
Dissociated Nystagmus0low10
Dissociated Vertical Deviation0low10
Diverticulum, Meckel0low10
Doenu00E7as do Sistema Nervoso Central@pt0medium31
Dog Diseases0medium73
Drop Attack0low10
Dropsy0low500
Drug Abuse0low100
Drug Addiction0low100
Drug Allergy0medium41
Drug Dependence0low100
Drug Eruptions0low40
Drug Habituation0low100
Drug Hypersensitivity0medium41
Drug Overdose0low80
Drug Side Effects0low40
Drug Toxicity0low40
Drug Use Disorders0low100
Drug Withdrawal Symptoms0medium161
Drug-Induced Abnormalities0low10
Drug-Induced Acute Liver Injury0low70
Drug-Induced Akathisia0medium42
Drug-Induced Liver Disease0low70
Drug-Induced Liver Injury0low70
Drug-Related Side Effects and Adverse Reactions0low40
Duck Gait0low10
Duhring Disease0low20
Duhring's Disease0low20
Dumping Syndrome0low50
Duncan Disease0low10
Duncan's Syndrome0low10
Duodenal Ulcer0medium52
Dyschondroplasia0low10
Dyschondroplasias0low10
Dyscoordination0low10
Dysesthesia0low10
Dysgammaglobulinemia0low10
Dyskinesia Syndromes0low70
Dyskinesia, Drug-Induced0medium92
Dyskinesia, Medication-Induced0medium92
Dyskinesias, Paroxysmal0low10
Dyspepsia0low10
Dyssynergia0low10
Dystonia0low10
Dystonia, Diurnal0low10
Dystonia, Limb0low10
Dystonia, Paroxysmal0low10
E coli Infections0low10
E. coli Infection0low10
Ear Cancer0low10
Ear Infection0low10
Ear Inflammation0low10
Ear Neoplasms0low10
Early Awakening0low10
Early Onset Alzheimer Disease0low20
Early Pregnancy Loss0low20
Eating and Feeding Disorders0medium4316
Eating Disorders0medium4316
Eating-Induced Epilepsy0low20
Ebola Hemorrhagic Fever0low10
Ebola Infection0low10
Ebola Virus Disease0low10
Ebola Virus Infection0low10
Ebolavirus Infection0low10
EBS-DM0medium11
EBS, Acral Form0medium11
EBS, Generalized0medium11
Ecchymosis0low10
Ectopic ACTH Syndrome0low10
Ectopic Hormone Syndromes0low10
Eczema0medium72
Eczema-Thrombocytopenia-Immunodeficiency Syndrome0low10
Eczema, Atopic0medium146
Eczema, Contact0medium72
Eczema, Infantile0medium146
Edema0low500
Edema of the Optic Disc0low10
Edema of the Optic Disk0low10
Edema-Proteinuria-Hypertension Gestosis0low10
Edema, Pulmonary0low10
Edemas, Pulmonary0low10
EHS Tumor0low20
Electrocardiogram QT Prolonged0medium31
Electrolytes0low10
Emaciation0medium61
Embolism0low20
Embolism and Thrombosis, Brain0low10
Embolism, Pulmonary0low40
Embolisms, Pulmonary0low40
Embolus0low20
Embryo Death0low10
Embryo Disintegration0low10
Embryo Loss0low10
Embryo Resorption0low10
Emergencies0low20
Emesis0medium112
Encephalomyelitis, Allergic0low30
Encephalomyelitis, Autoimmune, Experimental0low30
Encephalomyelitis, Experimental Autoimmune0low30
Encephalon Diseases0low10
Encephalopathy0low10
Encephalopathy, Ischemic0low20
Encephalopathy, Toxic0low20
Enchondroma0low10
End-Stage Kidney Disease0low20
End-Stage Renal Disease0low20
Endocrine Diseases0medium11
Endocrine System Diseases0medium11
Endogenous Hyperinsulinism0low10
Endosteal Hyperostosis, Autosomal Recessive0low10
Endotoxin Shock0low70
Enfermedades del Sistema Nervioso Central@es0medium31
Enteritis, Granulomatous0low10
Enteritis, Regional0low10
Enterocutaneous Fistula0low20
Eosinophilia0low20
Eosinophilia, Pulmonary0low20
Eosinophilia, Tropical0low20
Eosinophilias, Pulmonary0low20
Eosinophilic Pneumonia0low20
EPH Complex0low10
EPH Gestosis0low10
EPH Toxemias0low10
Epidemic Neurolabyrinthitis0low10
Epidermolysis Bullosa Herpetiformis Dowling Meara0medium11
Epidermolysis Bullosa Herpetiformis Dowling-Meara0medium11
Epidermolysis Bullosa Herpetiformis, Dowling-Meara0medium11
Epidermolysis Bullosa Herpetiformis, Dowling-Meara Type0medium11
Epidermolysis Bullosa of Hands and Feet0medium11
Epidermolysis Bullosa Simplex0medium11
Epidermolysis Bullosa Simplex Kobner0medium11
Epidermolysis Bullosa Simplex, Cockayne-Touraine Type0medium11
Epidermolysis Bullosa Simplex, Dowling-Meara Type0medium11
Epidermolysis Bullosa Simplex, Generalized0medium11
Epidermolysis Bullosa Simplex, Koebner Type0medium11
Epidermolysis Bullosa Simplex, Localized0medium11
Epidermolysis Bullosa Simplex, Weber-Cockayne Type0medium11
Epilepsy0low40
Epilepsy, Cryptogenic0low40
Epilepsy, Photogenic0low20
Epilepsy, Reading0low20
Epilepsy, Reflex0low20
Epileptic Seizure0low120
Epileptic Seizures0low120
Epileptiform Neuralgia0low10
Episodic Cluster Headache0low20
Episodic Recurrent Vertigo0low10
Epithelial Ovarian Cancer0low10
Epithelial Ovarian Carcinoma0low10
Epstein-Barr Virus Infection, Familial Fatal0low10
Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males0low10
Epulides0low10
Epulis0low10
Equine Diseases0low50
Erectile Dysfunction0low20
Erythema0medium61
Erythema Multiforme0medium11
Erythematotelangiectatic Rosacea0low10
Erythermalgia0low10
Erythermalgia, Primary0low10
Erythremia0low10
Erythrocytosis0low10
Erythromelalgia0low10
Erythromelalgia, Familial0low10
Erythromelalgia, Primary0low10
Escherichia coli Infections0low10
Esophageal Reflux0low10
ESRD0low20
Etat Marbre0low70
Ethanol Abuse0low40
Exanthem0low30
Exanthema0low30
Exercise-Induced Asthma0low10
Exercise-Induced Bronchospasm0low10
Exogenous Hyperinsulinism0low10
Experimental Allergic Encephalomyelitis0low30
Experimental Autoimmune Encephalomyelitis0low30
Experimental Diabetes Mellitus0low100
Experimental Lung Inflammation0low20
Experimental Mammary Neoplasms0low10
Experimental Neoplasms0low50
Experimental Parkinson Disease0low10
Experimental Parkinsonism0low10
Experimental Parkinsonism, MPTP-Induced0low10
Experimental Radiation Injuries0low20
Experimental Sarcoma0low20
Experimental Sarcomas0low20
External Carotid Artery Thrombosis0low10
External Ophthalmoplegia0low30
Extramedullary Spinal Cord Compression0low20
Extrapyramidal Disorders0medium11
Extravascular Hemolysis0low10
Eye Diseases0low30
Eye Disorders0low30
Eyelid Diseases0low10
Facial Dermatoses0low10
Facial Dermatosis0low10
Factor II Deficiency0low10
Failure to Thrive0low20
Fainting0low10
Familial Afibrinogenemia0low10
Familial Alzheimer Disease (FAD)0low20
Familial Benign Recurrent Vertigo0low10
Familial Erythromelalgia0low10
Familial Fatal Epstein-Barr Infection0low10
Familial Juvenile Parkinsonism0low10
Familial Parkinson Disease, Autosomal Recessive0low10
Familial Precocious Puberty0low10
Familial Thrombotic Thrombocytopenia Purpura0low20
Familial Thrombotic Thrombocytopenic Purpura0low20
Familial Vestibulopathy0low10
Familial Waldenstrom's Macroglobulinaemia0low10
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
Farsightedness0low10
Fasciculation-Cramp Syndrome, Benign0low10
Fasting Hypoglycemia0medium101
Fatigable Positional Nystagmus0low10
Fatty Liver0medium11
Favre-Racouchot Syndrome0low10
Fecal Incontinence0low10
Fecal Soiling0low10
Feeding and Eating Disorders0medium4316
Feeding Disorders0medium4316
Feline Diseases0medium71
Fetal Cerebral Ventriculomegaly0low10
Fetal Death0low20
Fetal Demise0low20
Fetal Mummification0low20
Fetal Resorption0low20
Fever0low150
Fever, Zika0low10
Fibrinogen Deficiency0low10
Fibrocystic Disease of Pancreas0medium73
Fibromyalgia0low10
Fibromyalgia-Fibromyositis Syndrome0low10
Fibromyalgia, Primary0low10
Fibromyalgia, Secondary0low10
Fibromyositis-Fibromyalgia Syndrome0low10
Fibrosarcoma0low20
Fibroses, Pulmonary0low20
Fibrosis0low20
Fibrosis, Bone Marrow0low10
Fibrosis, Liver0medium11
Fibrosis, Pulmonary0low20
Fibrositis0low10
Fine Tremor0medium81
Flaccid Quadriplegia0low20
Flaccid Tetraplegia0low20
Flexibility, Waxy0low60
Flushing0low10
Focal Neurologic Deficits0low10
Focal Onset Alzheimer's Disease0low20
Foley-Denny-Brown Syndrome0low10
Folliculitis0low10
Folling Disease0low20
Folling's Disease0low20
Food Allergy0low30
Food Hypersensitivity0low30
Foot Diseases0low10
Formication0low10
Fothergill Disease0low10
Frigidity0low110
Froehlich's Syndrome0medium31
Functional Gastrointestinal Disorders0low40
Fungal Diseases0low10
Fungal Infections0low10
Fungal Lung Diseases0low10
Fungal Skin Diseases0low10
Fungus Diseases0low10
Fungus Infections0low10
Gait Disorder, Sensorimotor0low10
Gait Disorders, Neurologic0low10
Gait Dysfunction, Neurologic0low10
Gait, Athetotic0low10
Gait, Broadened0low10
Gait, Drop Foot0low10
Gait, Festinating0low10
Gait, Frontal0low10
Gait, Hemiplegic0low10
Gait, Hysterical0low10
Gait, Reeling0low10
Gait, Rigid0low10
Gait, Scissors0low10
Gait, Shuffling0low10
Gait, Spastic0low10
Gait, Stumbling0low10
Gait, Unsteady0low10
Gait, Widebased0low10
Galactorrhea0low60
Gangrene0low10
Gastric Acid Reflux0low10
Gastric Acid Reflux Disease0low10
Gastric Antral Vascular Ectasia0low10
Gastric Cancer0medium51
Gastric Cancer, Familial Diffuse0medium51
Gastric Diseases0low20
Gastric Neoplasms0medium51
Gastric Ulcer0medium92
Gastritis0low10
Gastro-Esophageal Reflux0low10
Gastro-Esophageal Reflux Disease0low10
Gastro-oesophageal Reflux0low10
Gastroduodenal Ulcer0low50
Gastroesophageal Reflux0low10
Gastroesophageal Reflux Disease0low10
Gastrointestinal Cancer0low10
Gastrointestinal Diseases0low40
Gastrointestinal Disorders0low40
Gastrointestinal Disorders, Functional0low40
Gastrointestinal Hemorrhage0low10
Gastrointestinal Neoplasms0low10
Generalized Absence Seizure0low120
Generalized Absence Seizures0low120
Generalized Headache0medium182
Generalized Tonic-Clonic Seizures0low120
Genetic Predisposition0low20
Genetic Predisposition to Disease0low20
Genetic Susceptibility0low20
GERD0low10
Gestosis, EPH0low10
Giant Cell Glioblastoma0low20
Gigantism0low10
Gilles de la Tourette Disorder0low10
Gilles de la Tourette Syndrome0low10
Gilles de la Tourette's Disease0low10
Gilles De La Tourette's Syndrome0low10
Gingival Diseases0low10
Gingivosis0low10
Glandular Fever0low10
Glaucoma0low20
Glioblastoma0low20
Glioblastoma Multiforme0low20
Glomerulonephritis0low40
Glomerulosclerosis, Diabetic0low10
Gout0low10
Granulocytopenia0low10
Granuloma0low40
Granulomas0low40
Granulomatous Rosacea0low10
Growth Disorders0medium52
Growth Hormone Insensitivity Syndrome0low10
Growth Hormone Receptor Defect0low10
Growth Hormone Receptor Deficiency0low10
Haemolysis0low10
Hallucination of Body Sensation0low50
Hallucinations0low50
Hallucinations, Auditory0low50
Hallucinations, Dissociative0low50
Hallucinations, Elementary0low50
Hallucinations, Formed, of People0low50
Hallucinations, Gustatory0low50
Hallucinations, Hypnagogic0low50
Hallucinations, Hypnapompic0low50
Hallucinations, Internal Body Sensation0low50
Hallucinations, Kinesthetic0low50
Hallucinations, Mood Congruent0low50
Hallucinations, Mood Incongruent0low50
Hallucinations, Olfactory0low50
Hallucinations, Organic0low50
Hallucinations, Reflex0low50
Hallucinations, Sensory0low50
Hallucinations, Somatic0low50
Hallucinations, Tactile0low50
Hallucinations, Verbal Auditory0low50
Hallucinations, Visual0low50
Hallucinations, Visual, Formed0low50
Hallucinations, Visual, Unformed0low50
Hammond Disease0low10
Hammond's Disease0low10
Hay Fever0medium5535
Hayfever0medium5535
Head Banging0low10
Head Pain0medium182
Headache0medium182
Headache Disorders, Primary0low10
Headache, Cluster0low20
Headache, Migraine0medium569
Headache, Thunderclap0low10
Headache, Vascular0medium81
Heart Arrest0low10
Heart Attack0low20
Heart Disease, Ischemic0low10
Heart Diseases0low10
Heart Disorders0low10
Heart Valve Diseases0low20
Heart Valvular Disease0low20
Hemarthrosis0low10
Hematochezia0low10
Hematuria0low30
Hemicrania0medium182
Hemicrania Migraine0medium569
Hemiparesis0low10
Hemolysis0low10
Hemorrhage0low70
Hemorrhage, Gastrointestinal0low10
Hemorrhage, Peptic Ulcer0low30
Hemorrhage, Retinal0low10
Hemorrhage, Subarachnoid0low20
Hemorrhagic Dengue0medium11
Hemorrhagic Fever with Renal Syndrome0low10
Hemorrhagic Fever, Dengue0medium11
Hemorrhagic Fever, Ebola0low10
Hemorrhagic Fever, Epidemic0low10
Hemorrhagic Fever, Korean0low10
Hemorrhagic Nephroso-Nephritis0low10
Hemorrhagic Shock0low40
Hepatic Cancer0low80
Hepatic Cirrhosis0medium11
Hepatic Neoplasms0low80
Hepatitis0medium11
Hepatitis B0low10
Hepatitis B Virus Infection0low10
Hepatitis, Drug-Induced0low70
Hepatitis, Toxic0low70
Hepatocellular Cancer0low80
Hepatocellular Carcinoma0low40
Hepatoma0low40
Hereditary Chorea0low10
Hereditary Hemorrhagic Telangiectasia0low10
Hereditary Progressive Chorea Without Dementia0low10
Heroin Abuse0low10
Heroin Addiction0low10
Heroin Dependence0low10
Heroin Smoking0low10
HFRS0low10
Histamine Cephalgia0low20
HIV Antibody Positivity0low10
HIV Coinfection0medium11
HIV Infections0medium11
HIV Seroconversion0low10
HIV Seropositivity0low10
Hives0medium7624
Hoffman's Reflex0medium21
Hookworm Infections0low10
Horizontal Nystagmus0low10
Horse Diseases0low50
Horton Syndrome0low20
Horton's Syndrome0low20
Hospital-Acquired Condition0low10
HPABH4C0low20
HTLV-III Infections0medium11
HTLV-III Seroconversion0low10
HTLV-III Seropositivity0low10
HTLV-III-LAV Infections0medium11
Human Trichinellosis0low10
Huntington Chorea0medium11
Huntington Chronic Progressive Hereditary Chorea0medium11
Huntington Disease0medium11
Huntington Disease, Akinetic-Rigid Variant0medium11
Huntington Disease, Juvenile0medium11
Huntington Disease, Juvenile-Onset0medium11
Huntington Disease, Late Onset0medium11
Huntington's Chorea0medium11
Huntington's Disease0medium11
Hydrocephalus0low10
Hydrocephalus Ex-Vacuo0low10
Hydrocephaly0low10
Hydrops0low500
Hydrosyringomyelia0low10
Hyperactivity, Motor0low10
Hyperadrenalism0low10
Hyperadrenocorticism0low10
Hyperaldosteronism0low30
Hyperalgesia0low20
Hyperalgesia, Mechanical0low20
Hyperalgesia, Primary0low20
Hyperalgesia, Secondary0low20
Hyperalgesia, Tactile0low20
Hyperalgesia, Thermal0low20
Hyperalgesic Sensations0low20
Hyperalgia0low20
Hyperalgia, Mechanical0low20
Hyperalgia, Primary0low20
Hyperalgia, Secondary0low20
Hyperbilirubinemia0low10
Hypercalcemia0low10
Hypercorticism0low10
Hypercortisolism0medium824
Hyperemia0low20
Hyperesthesia0low10
Hyperesthesia, Tactile0low10
Hyperesthesia, Thermal0low10
Hyperesthetic Sensations0low10
Hyperglycemia0low60
Hyperglycemia, Postprandial0low60
Hyperhidrosis0low80
Hyperidrosis0low80
Hyperinsulinemia0low10
Hyperinsulinism0low10
Hyperkinesia0low10
Hyperkinesia, Generalized0low10
Hyperkinesis0low10
Hyperkinetic Movements0low10
Hyperkinetic Syndrome0medium51
Hyperlipemia0low20
Hyperlipidemia0low20
Hyperlipidemias0low20
Hypermetropia0low10
Hypermyotonia0low10
Hyperopia0low10
Hyperostosis Corticalis Generalisata0low10
Hyperparathyroidism0low10
Hyperphagia0medium84
Hyperphenylalaninaemia0low20
Hyperphenylalaninemia Caused by a Defect in Biopterin Metabolism0low20
Hyperphenylalaninemia, BH4-Deficient, C0low20
Hyperphenylalaninemia, Non-Phenylketonuric0low20
Hyperphenylalaninemia, Tetrahydrobiopterin-Deficient, Due To DHPR Deficiency0low20
Hyperphosphatasemia Tarda0low10
Hyperplasia0low40
Hyperplasia, Congenital Adrenal0low10
Hyperprolactinaemia0low20
Hyperprolactinemia0low20
Hyperreflexia0medium21
Hypersensitivity, Atopic0medium135
Hypersensitivity, Contact0medium72
Hypersensitivity, Delayed0low30
Hypersensitivity, Drug0medium41
Hypersensitivity, Food0low30
Hypersensitivity, Immediate0medium135
Hypersensitivity, Respiratory0medium41
Hypersensitivity, Tuberculin-Type0low30
Hypersensitivity, Type I0medium135
Hypersensitivity, Type III0low30
Hypersensitivity, Type IV0low30
Hypertension0low160
Hypertension-Edema-Proteinuria Gestosis0low10
Hypertension, Portal0low10
Hypertension, Pulmonary0low20
Hyperthermia0low10
Hypertonia, Detrusor Muscle0low10
Hypertonia, Infantile0low10
Hypertonia, Neonatal0low10
Hypertonia, Sphincter0low10
Hypertonia, Transient0low10
Hypertropia0low10
Hyperventilation0low10
Hypnic Headache0low10
Hypnic Headache Syndrome0low10
Hypoactive Sexual Desire Disorder0low110
Hypoadrenalism0low10
Hypofibrinogenemia, Congenital0low10
Hypogalactia0low10
Hypogeusia0low10
Hypoglycemia0medium101
Hypokalemia0low10
Hypophyseal Disorders0low20
Hypopituitarism0medium21
Hypopotassemia0low10
Hypoprothrombinemia0low10
Hypoprothrombinemias0low10
Hyporeflexia0medium21
Hyposalivation0low10
Hyposecretion Syndrome, Anterior Pituitary0medium21
Hyposecretion, Adenohypophyseal0medium21
Hypotension0low70
Hypotension, Orthostatic0medium31
Hypotension, Postural0medium31
Hypotension, Vascular0low70
Hypothalamic Diseases0medium31
Hypothalamic Dysfunction Syndromes0medium31
Hypothalamic Dysinhibition Syndrome0medium31
Hypothalamic Overactivity Syndrome0medium31
Hypothalamic Pseudopuberty0medium31
Hypothalamic-Adenohypophyseal Disorders0medium31
Hypothalamic-Neurohypophyseal Disorders0medium31
Hypothermia0low110
Hypothermia, Accidental0low110
Hypothyroidism0low20
Hypovolemic Shock0low20
Hypoxemia0low40
Hypoxia0low40
Iatrogenic Disease0low10
Ice-Pick Headache0low10
Ichthyosis0low10
Icterus0low30
IDDM0low10
Idiocy0low10
Idiopathic Chronic Urticaria0medium11
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0low20
Idiopathic Intracranial Hypertension0low10
Idiopathic Myelofibrosis0low10
Idiopathic Parkinson Disease0medium42
Idiopathic Parkinson's Disease0medium42
Idiopathic Proctocolitis0low10
Idiopathic Sexual Precocity0low10
IgE-Mediated Hypersensitivity0medium135
IgG Deficiency0low10
Ileal Cancer0low10
Ileal Neoplasms0low10
Ileitis, Regional0low10
Ileitis, Terminal0low10
Ileocolitis0low10
Imd20low10
Immersion Related Epilepsy0low20
Immune Complex Diseases0low30
Immune Diseases0low30
Immune Disorders0low30
Immune System Diseases0low30
Immune System Disorders0low30
Immunodeficiency 20low10
Immunodeficiency 50low10
Immunodeficiency, X-Linked Progressive Combined Variable0low10
Immunologic Diseases0low30
Immunological Diseases0low30
Impotence0low20
Impulse-Ridden Personality0low10
Inadequate Personality0low10
Inadequate Sleep0low20
Inappropriate GH Secretion Syndrome (Acromegaly)0medium122
Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)0medium122
Inappropriate Prolactin Secretion0low20
Inappropriate Prolactin Secretion Syndrome0low20
Incoordination0low10
Increased Intracranial Pressure-Associated Papilledema0low10
Indigestion0low10
Infant Malnutrition0low30
Infant Nutrition Disorders0low30
Infant Overnutrition0low30
Infantile Cerebral Palsy, Diplegic0low20
Infantile Cerebral Palsy, Monoplegic0low20
Infantile Cerebral Palsy, Quadriplegic0low20
Infantile Colic0low20
Infantile Malnutrition0low30
Infarction, Cerebral0low10
Infarction, Cerebral, Left Hemisphere0low10
Infarction, Cerebral, Right Hemisphere0low10
Infarction, Left Hemisphere, Cerebral0low10
Infarction, Right Hemisphere, Cerebral0low10
Infections, Community-Acquired0low10
Infections, E coli0low10
Infections, Escherichia coli0low10
Infections, Hookworm0low10
Infections, Nematode0low10
Infections, Orthomyxoviridae0low10
Infections, Orthomyxovirus0low10
Infections, Plasmodium0medium62
Infections, Pneumococcal0low10
Infections, Streptococcus pneumoniae0low10
Infections, Taenia0low10
Infectious Mononucleosis0low10
Infertility, Female0low10
Inflammation0medium311
Inflammatory Bowel Disease 10low10
Inflammatory Bowel Disease, Ulcerative Colitis Type0low10
Injuries0low10
Injuries and Wounds0low10
Injuries, Experimental Radiation0low20
Injuries, Spinal Cord0medium146
Injuries, Surgical0low10
Injuries, Wounds0low10
Injury, Myocardial Reperfusion0low20
Innate Inflammatory Response0medium311
Insect Bites0medium31
Insect Bites and Stings0medium31
Insect Stings0medium31
Insomnia0low10
Insomnia Disorder0low10
Insufficient Sleep0low20
Insufficient Sleep Syndrome0low20
Insulin-Dependent Diabetes Mellitus 10low10
Insulinoma0low20
Insuloma0low20
Intellectual Development Disorder0low10
Intellectual Disability0low10
Intention Tremor0medium81
Intermittent Tremor0medium81
Internal Carotid Artery Thrombosis0low10
Internal Ophthalmoplegia0low30
Intertrigo0low10
Intestinal Cancer0low60
Intestinal Diseases0low20
Intestinal Fistula0low20
Intestinal Neoplasms0low60
Intestinal Obstruction0low20
Intestinal Perforation0low20
Intestinal Polyps0low10
Intestines Cancer0low60
Intestines Neoplasms0low60
Intracapillary Glomerulosclerosis0low10
Intracranial Angiospasm0low10
Intracranial Central Nervous System Disorders0low10
Intracranial CNS Disorders0low10
Intracranial Edema0low10
Intracranial Embolism and Thrombosis0low10
Intracranial Hypertension, Benign0low10
Intracranial Hypertension, Idiopathic0low10
Intracranial Neoplasms0low10
Intracranial Vascular Spasm0low10
Intracranial Vasospasm0low10
Intradural-Extramedullary Spinal Cord Neoplasms0low10
Intramedullary Spinal Cord Neoplasms0low10
Intramedullary Spinal Cord Neoplasms, Primary0low10
Intraocular Pressure0low10
Intraoperative Complications0low10
Intravascular Coagulation, Disseminated0low20
Intravascular Disseminated Coagulation0low20
Intravascular Hemolysis0low10
Involuntary Quiver0medium81
Iron-Deficiency Anemia0low10
Iron-Deficiency Anemias0low10
Irritable Bowel Syndrome0low10
Ischemia0low40
Ischemia, Cerebral0low20
Ischemia, Myocardial0low10
Ischemic Attack, Transient0low20
Ischemic Encephalopathy0low20
Ischemic Heart Disease0low10
Itching0medium3615
Jacksonian Seizure0low120
Jaundice0low30
Jaundice, Hemolytic0low30
Jerk Nystagmus0low10
Juvenile Huntington Disease0medium11
Juvenile Parkinson Disease0low10
Juvenile Parkinson Disease, Autosomal Dominant0low10
Juvenile Parkinson Disease, Autosomal Recessive0low10
Juvenile Parkinsonism, Autosomal Dominant0low10
Juvenile Parkinsonism, Autosomal Recessive0low10
Juvenile-Onset Diabetes0low10
Juvenile-Onset Huntington Disease0medium11
Kahler Disease0low30
Kanner's Syndrome0medium21
Katayama Fever0low10
Keratoconjunctivitis0low10
Keratoconjunctivitis, Vernal0medium73
Keskushermoston sairaudet@fi0medium31
Kidney Diseases0low30
Kidney Failure, Chronic0low20
Kidney Scarring0low40
Kimmelstiel-Wilson Disease0low10
Kimmelstiel-Wilson Syndrome0low10
Labor Complications0medium21
Lack of Coordination0low10
Lactation Disorders0low10
Lactotroph Adenoma0low10
Laron Dwarfism0low10
Laron Syndrome0low10
Laron Type Dwarfism I0low10
Laryngitis0low10
Late Effects, Prenatal Exposure0low10
Late Onset Alzheimer Disease0low20
Late-Onset Huntington Disease0medium11
Late-Onset Spondyloepiphyseal Dysplasia0low10
Leanness0medium84
Left Hemisphere, Cerebral Infarction0low10
Left Hemisphere, Infarction, Cerebral0low10
Left Ventricle Remodeling0low10
Left Ventricular Remodeling0low10
Lenticulostriate Disorders0medium11
Leukemia, Acute Myelogenous0low10
Leukemia, Acute Myeloid0low10
Leukemia, B-Cell0low10
Leukemia, Lymphoblastic, Burkitt-Type0low10
Leukemia, Lymphocytic, B Cell0low10
Leukemia, Lymphocytic, B-Cell0low10
Leukemia, Lymphocytic, L30low10
Leukemia, Myeloblastic, Acute0low10
Leukemia, Myelocytic, Acute0low10
Leukemia, Myelogenous, Acute0low10
Leukemia, Myeloid, Acute0low10
Leukemia, Myeloid, Acute, M10low10
Leukemia, Myeloid, Acute, M20low10
Leukemia, Nonlymphoblastic, Acute0low10
Leukemia, Nonlymphocytic, Acute0low10
Leukocytopenia0low10
Leukocytosis0low10
Leukopenia0low10
Lewy Body Parkinson Disease0medium42
Lewy Body Parkinson's Disease0medium42
Libman-Sacks Disease0low10
Lichen Planus0low20
Lichen Ruber Planus0low20
Lichen Rubra Planus0low20
Lichen Simplex Chronicus0low10
Limb Cramp0medium11
Lipemia0low20
Lipidemia0low20
Little Disease0low20
Little's Disease0low20
Liver Cancer0low80
Liver Cancer, Adult0low40
Liver Cell Carcinoma0low40
Liver Cell Carcinoma, Adult0low40
Liver Cirrhosis0medium11
Liver Diseases0medium21
Liver Dysfunction0medium21
Liver Fibrosis0medium11
Liver Injury, Drug-Induced0low70
Liver Injury, Drug-Induced, Acute0low70
Liver Neoplasms0low80
Liver Steatosis0medium11
Lobar Pneumonia0low20
Local Neoplasm Recurrence0medium11
Local Neoplasm Recurrences0medium11
Locomotion Disorders, Neurologic0low10
Locoregional Neoplasm Recurrence0medium11
Loeffler Syndrome0low20
Long QT Syndrome0medium31
Long Sleeper Syndrome0medium82
Loss of Taste0low10
Low Blood Pressure0low70
Lower Extremity Paresis0low10
Lung Adenocarcinoma0low10
Lung Cancer0low40
Lung Diseases0low20
Lung Diseases, Fungal0low10
Lung Inflammation0low20
Lung Neoplasms0low40
Lupus Erythematosus Disseminatus0low10
Lupus Erythematosus, Chronic Cutaneous0low10
Lupus Erythematosus, Cutaneous, Chronic0low10
Lupus Erythematosus, Discoid0low10
Lupus Erythematosus, Systemic0low10
Lymphocytic Leukemia, B-Cell0low10
Lymphocytic Leukemia, L30low10
Lymphocytic Lymphoma, Diffuse, Poorly Differentiated0low10
Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated0low10
Lymphoma, Burkitt0low10
Lymphoma, Centrocytic Small-Cell0low10
Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated0low10
Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated0low10
Lymphoma, Lymphocytic, Intermediate0low10
Lymphoma, Lymphocytic, Plasmacytoid0low10
Lymphoma, Lymphoplasmacytoid0low10
Lymphoma, Mantle-Cell0low10
Lymphoma, Small-Cell, Centrocytic0low10
Lymphoproliferative Disease, X-Linked0low10
Lymphoproliferative Disorders0low10
Lymphoproliferative Syndrome, X-Linked, 10low10
Macroglobulinemia0low10
Macroprolactinoma0low10
Maculopapular Cutaneous Mastocytosis0low50
Maculopapular Drug Eruption0low40
Maculopapular Exanthem0low40
Major Depressive Disorder0low10
Maladie du systu00E8me nerveux central@fr0medium31
Malaria0medium62
Malaria, Falciparum0low10
Malattie del sistema nervoso centrale@it0medium31
Male Impotence0low20
Male Sexual Impotence0low20
Malignancy0medium207
Malignant Carcinoid Syndrome0medium223
Malignant Neoplasms0medium207
Malignant Neoplasms, Brain0low10
Malignant Primary Brain Neoplasms0low10
Malignant Primary Brain Tumors0low10
Malignant Tumor of Urinary Bladder0low10
Malnourishment0medium41
Malnutrition0medium41
Malnutrition in Infant0low30
Malnutrition, Infant0low30
Mammary Carcinoma, Animal0low10
Mammary Neoplasms0low10
Mammary Neoplasms, Animal0low10
Mammary Neoplasms, Experimental0low10
Manic Depression0low30
Manic Disorder0low30
Manic-Depressive Psychosis0low30
Manifestations, Neurologic0low10
Manifestations, Neurological0low10
Mantle-Cell Lymphoma0low10
Mantle-Zone Lymphoma0low10
Marburg Disease0low10
Marburg Hemorrhagic Fever0low10
Marburg Virus Disease0low10
Marche a Petit Pas0low10
Marginal Ulcer0low50
Maroteaux-Lamy Syndrome0low10
Marsh Fever0medium62
Massive Tremor0medium81
Mast Cell Activation Disease0low20
Mast Cell Activation Syndrome0low20
Mast Cell Activation Syndromes0low20
Mast Cell Disease0low20
Mast-Cell Disease0low20
Mastocytosis0low20
Mastocytosis, Bullous0medium21
Mastocytosis, Cutaneous0medium21
Mastocytosis, Diffuse Cutaneous0medium21
Maturity-Onset Diabetes0low10
Maturity-Onset Diabetes Mellitus0low10
Mechanical Allodynia0low20
Mechanical Hyperalgesia0low20
Mechanical Strabismus0low10
Meckel Diverticulum0low10
Meckel's Diverticulum0low10
Medically Unexplained Syndrome0low10
Medically Unexplained Syndromes0low10
Medication-Induced Dyskinesia0medium92
Melancholia0medium183
Melancholia, Involutional0low10
Melnick-Needles Osteodysplasty0low10
Melnick-Needles Syndrome0low10
Memory Deficits0low10
Memory Disorder, Semantic0low10
Memory Disorder, Spatial0low10
Memory Disorders0low10
Memory Disorders, Age-Related0low10
Memory Loss0low10
Memory Loss, Retrograde0low10
Meningitis, Tuberculous0low10
Menopause0low10
Mental Deficiency0low10
Mental Disorders0medium62
Mental Disorders, Severe0medium62
Mental Illness0medium62
Mental Retardation0low10
Mental Retardation, Psychosocial0low10
Metabolic Acidosis0low10
Metabolic Diseases0low20
Metastase0low80
Metastases, Neoplasm0low80
Metastasis0low80
Metastasis, Neoplasm0low80
Microangiopathic Hemolytic Anemia, Congenital0low20
Microcalcification0low20
Microcalcinosis0low20
Microglossia0low10
Microprolactinoma0low10
Middle Ear Inflammation0low10
Migraine0medium569
Migraine Disorders0medium569
Migraine Headache0medium569
Migraine Variant0medium569
Migraine without Aura0low10
Migraine, Common0low10
Miliaria0low10
Miliaria Rubra0low10
Milk-Alkali Syndrome0low10
Minimal Brain Dysfunction0medium51
Miscarriage0low20
Miscarriage, Recurrent0low40
Mitral Incompetence0low10
Mitral Insufficiency0low10
Mitral Regurgitation0low10
Mitral Valve Incompetence0low10
Mitral Valve Regurgitation0low10
MODY0low10
Mononeuropathy, Diabetic0low20
Mononucleosis, Infectious0low10
Monoparesis0low10
Monoplegic Cerebral Palsy0low20
Monoplegic Infantile Cerebral Palsy0low20
Mood Disorders0low20
Moral Injury0medium52
Morbilliform Drug Reaction0low40
Morbilliform Exanthem0low40
Morphine Abuse0low70
Morphine Addiction0low70
Morphine Dependence0low70
Morvan Disease0low10
Morvan's Disease0low10
Moschcowitz Disease0low20
Moschkowitz Disease0low20
Mountain Sickness0low10
Mouth Diseases0low10
Mouth Dryness0low10
Movement Disorder Syndromes0low70
Movement Disorder, Stereotypic0low10
Movement Disorders0low70
MPTP-Induced Experimental Parkinsonism0low10
MS (Multiple Sclerosis)0medium11
Mucopolysaccharidosis 60low10
Mucopolysaccharidosis Type 60low10
Mucopolysaccharidosis Type VI0low10
Mucopolysaccharidosis VI0low10
Mucositis, Oral0medium11
Mucoviscidosis0medium73
Multidirectional Nystagmus0low10
Multiple Abnormalities0low10
Multiple Epiphyseal Dysplasia0low10
Multiple Motor and Vocal Tic Disorder, Combined0low10
Multiple Myeloma0low30
Multiple Sclerosis0medium11
Multiple Sclerosis, Acute Fulminating0medium11
Muscle Contraction0medium492
Muscle Cramp0medium11
Muscle Disorders0low20
Muscle Dystonia0low10
Muscle Hypertonia0low10
Muscle Paresis0low10
Muscle Relaxation0low30
Muscle Spasm0low10
Muscle Spasticity0medium104
Muscle Tone Increased0low10
Muscular Cramp0medium11
Muscular Diseases0low20
Muscular Dystrophies0low10
Muscular Dystrophy0low10
Muscular Dystrophy, Animal0low30
Muscular Hypertonicity0low10
Muscular Paresis0low10
Muscular Spasm0low10
Musicogenic Epilepsy0low20
Mycoses0low10
Mydriasis0low10
Myeloblastic Leukemia, Acute0low10
Myelocytic Leukemia, Acute0low10
Myelofibrosis0low10
Myelofibrosis With Myeloid Metaplasia0low10
Myelogenous Leukemia, Acute0low10
Myeloid Leukemia, Acute0low10
Myeloid Leukemia, Acute, M10low10
Myeloid Leukemia, Acute, M20low10
Myeloid Metaplasia0low10
Myeloma-Multiple0low30
Myeloma, Multiple0low30
Myeloma, Plasma-Cell0low30
Myelomatosis0low30
Myelopathy0low10
Myelopathy, Compressive0low20
Myelopathy, Traumatic0medium146
Myeloproliferative Disorders0low10
Myelosclerosis0low10
Myelosis, Nonleukemic0low10
Myelosyringosis0low10
Myocardial Infarct0low20
Myocardial Infarction0low20
Myocardial Ischemia0low10
Myocardial Ischemic Reperfusion Injury0low20
Myocardial Remodeling, Ventricular0low10
Myocardial Reperfusion Injury0low20
Myoclonic Jerk0low60
Myoclonic Jerking0low60
Myoclonic Seizure0low120
Myoclonic Seizures0low120
Myoclonus0low60
Myoclonus Simplex0low60
Myoclonus, Action0low60
Myoclonus, Eyelid0low60
Myoclonus, Intention0low60
Myoclonus, Lower Extremity0low60
Myoclonus, Nocturnal0low60
Myoclonus, Oculopalatal0low60
Myoclonus, Palatal0low60
Myoclonus, Segmental0low60
Myoclonus, Sleep0low60
Myoclonus, Upper Extremity0low60
Myodystrophica0low10
Myodystrophy0low10
Myofascial Pain Syndrome, Diffuse0low10
Myopathic Conditions0low20
Myopathies0low20
Myopia0low10
Myotonic Chondrodystrophy0low10
Myotonic Myopathy, Dwarfism, Chondrodystrophy, And Ocular And Facial Abnormalities0low10
N-Acetylgalactosamine-4-Sulfatase Deficiency0low10
Narcissistic Personality Disorder0low10
Nasal Airway Obstruction0medium11
Nasal Blockage0medium11
Nasal Catarrh0low50
Nasal Obstruction0medium11
Nausea0medium31
Nearsightedness0low10
Necrosis0low60
Necrotic Arachnidism0low10
Nelson Syndrome0medium121
Nematode Infections0low10
nemoci centru00E1lnu00EDho nervovu00E9ho systu00E9mu@cs0medium31
Neoplasia0medium207
Neoplasm0medium207
Neoplasm Metastases0low80
Neoplasm Metastasis0low80
Neoplasm Recurrence, Local0medium11
Neoplasm Recurrence, Locoregional0medium11
Neoplasm Recurrences, Local0medium11
Neoplasms0medium207
Neoplasms of Ear Auricle0low10
Neoplasms, Adrenal Cortex0low20
Neoplasms, Adrenal Gland0low70
Neoplasms, Auricular0low10
Neoplasms, Benign0medium207
Neoplasms, Bladder0low10
Neoplasms, Brain0low10
Neoplasms, Brain, Benign0low10
Neoplasms, Brain, Malignant0low10
Neoplasms, Brain, Primary0low10
Neoplasms, Bronchial0low20
Neoplasms, Colonic0low40
Neoplasms, Colorectal0medium11
Neoplasms, Ear0low10
Neoplasms, Experimental0low50
Neoplasms, Experimental Mammary0low10
Neoplasms, Gastric0medium51
Neoplasms, Gastrointestinal0low10
Neoplasms, Hepatic0low80
Neoplasms, Intestinal0low60
Neoplasms, Intracranial0low10
Neoplasms, Liver0low80
Neoplasms, Lung0low40
Neoplasms, Mammary0low10
Neoplasms, Nervous System0medium11
Neoplasms, Ovarian0low10
Neoplasms, Pancreatic0low20
Neoplasms, Prostate0low10
Neoplasms, Prostatic0low10
Neoplasms, Pulmonary0low40
Neoplasms, Spinal Cord0low10
Neoplasms, Stomach0medium51
Neoplasms, Testicular0low10
Neoplasms, Testis0low10
Neoplasms, Thymic0low10
Neoplasms, Thymus0low10
Neoplastic Cell Transformation0low10
Neoplastic Transformation, Cell0low10
Nephritis0low10
Nephropathia Epidemica0low10
Nerve Pain0low10
Nervous System Diseases, Autonomic0low10
Nervous System Diseases, Parasympathetic0low10
Nervous System Diseases, Sympathetic0low10
Nervous System Neoplasms0medium11
Nervous System Poisoning0low20
Nervous System Tumors0medium11
Neuralgia0low10
Neuralgia, Atypical0low10
Neuralgia, Diabetic0low20
Neuralgia, Iliohypogastric Nerve0low10
Neuralgia, Ilioinguinal0low10
Neuralgia, Perineal0low10
Neuralgia, Stump0low10
Neuralgia, Supraorbital0low10
Neuralgia, Vidian0low10
Neuralgic Migraine0low20
Neuritis, Vestibular0low10
Neuroblastoma0low10
Neurodermatitis0low10
Neurodermatitis, Atopic0medium146
Neurodermatitis, Circumscribed0low10
Neurodermatitis, Disseminated0medium146
Neurodermatitis, Localized0low10
Neurodynia0low10
Neuroendocrine Tumors0low10
Neurogenic Bladder0low10
Neurogenic Bladder Disorder0low10
Neurogenic Bladder, Atonic0low10
Neurogenic Bladder, Spastic0low10
Neurogenic Bladder, Uninhibited0low10
Neurogenic Dysfunction of the Urinary Bladder0low10
Neurogenic Urinary Bladder Disorder0low10
Neurogenic Urinary Bladder, Atonic0low10
Neurogenic Urinary Bladder, Spastic0low10
Neurogenic Urinary Bladder, Uninhibited0low10
Neurohypophyseal Diseases0low20
Neuroleptic Malignant Syndrome0low30
Neuroleptic-Induced Neuroleptic Malignant Syndrome0low30
Neuroleptic-Malignant Syndrome, Neuroleptic Induced0low30
Neurologic Ambulation Disorders0low10
Neurologic Deficits0low10
Neurologic Dysfunction0low10
Neurologic Findings0low10
Neurologic Locomotion Disorders0low10
Neurologic Manifestation0low10
Neurologic Manifestations0low10
Neurologic Signs0low10
Neurologic Signs and Symptoms0low10
Neurologic Symptoms0low10
Neurologic Voice Disorder0low10
Neurological Manifestations0low10
Neuromuscular Diseases0low10
Neuronitis, Vestibular0low10
Neuropathic Bladder0low10
Neuropathic Pain0low10
Neuroretinitis0low10
Neuroses0low10
Neuroses, Anxiety0low20
Neuroses, Post-Traumatic0medium52
Neuroses, Posttraumatic0medium52
Neurosis, Depressive0medium183
Neurotic Disorders0low10
Neurotoxic Disorders0low20
Neurotoxic Shellfish Poisoning0low10
Neurotoxicity Syndromes0low20
Neurotoxin Diseases0low20
Neurotoxin Disorders0low20
NIDDM0low10
NMS (Neuroleptic Malignant Syndrome)0low30
Nodular Elastoidosis0low10
Nodular Elastosis0low10
Nodular Glomerulosclerosis0low10
Non-communicable Chronic Diseases0low10
Non-communicable Diseases0low10
Non-Concomitant Strabismus0low10
Non-Epileptic Seizure0low120
Non-Epileptic Seizures0low120
Non-Fatigable Positional Nystagmus0low10
Non-infectious Diseases0low10
Non-Phenylketonuric Hyperphenylalaninemia0low20
Non-Small Cell Lung Cancer0low10
Non-Small Cell Lung Carcinoma0low10
Non-Small-Cell Lung Carcinoma0low10
Noncommunicable Diseases0low10
Nonconcomitant Strabismus0low10
Nonepileptic Seizure0low120
Nonepileptic Seizures0low120
Noninfectious Diseases0low10
Noninsulin-Dependent Diabetes Mellitus0low10
Nonlymphoblastic Leukemia, Acute0low10
Nonlymphocytic Leukemia, Acute0low10
Nonorganic Insomnia0low10
Nonsmall Cell Lung Cancer0low10
Nutrition Disorders0medium21
Nutrition Disorders, Infant0low30
Nutritional Deficiency0medium41
Nutritional Disorders0medium21
Nystagmus, Pathologic0low10
Obesity0low60
Obstetric Labor Complications0medium21
Obstructive Hydrocephalus0low10
Ocular Headache0medium182
Ocular Rosacea0low10
Oculomotor Paralysis0low30
Odontalgia0low20
Oligophrenia Phenylpyruvica0low20
Onchocerciasis0medium22
Ophthalmoparesis0low30
Ophthalmoplegia0low30
Oppenheim Disease0low10
Oppenheim's Disease0low10
Optic Disc Edema0low10
Optic Disk Edema0low10
Optic Nerve Papillitis0low10
Optic Papilla Edema0low10
Oral Mucositis0medium11
Organic Mental Disorders, Substance-Induced0low100
Orgasmic Disorder0low110
Ornithine Carbamoyltransferase Deficiency0low10
Ornithine Carbamoyltransferase Deficiency Disease0low10
Ornithine Transcarbamylase Deficiency0low10
Ornithine Transcarbamylase Deficiency Disease0low10
Ornithine Transcarbamylase Deficiency, Hyperammonemia Due To0low10
Oromucositis0medium11
Orthomyxoviridae Infections0low10
Orthomyxovirus Infections0low10
Orthostatic Headache0medium182
Orthostatic Hypotension0medium31
Osler-Rendu Disease0low10
Osler-Rendu-Weber Disease0low10
Osler-Vaquez Disease0low10
Osler-Weber-Rendu Syndrome0low10
Osler's Disease0low10
Osteochondrodysplasias0low10
Osteodysplasty of Melnick and Needles0low10
Osteomyelitis0low10
OTC Deficiency0low10
Otitis0low10
Otitis Media0low10
Ovarian Cancer0low10
Ovarian Cancer, Epithelial0low10
Ovarian Diseases0low10
Ovarian Epithelial Cancer0low10
Ovarian Epithelial Carcinoma0low10
Ovarian Neoplasms0low10
Ovary Cancer0low10
Ovary Neoplasms0low10
Overeating0medium84
Overweight0low10
Oxyesthesia0low10
Oxygen Deficiency0low40
P carinii Pneumonia0low10
P. carinii Pneumonia0low10
P. jirovecii Pneumonia0low10
PAH Deficiency0low20
Pain0low190
Pain Disorder0low10
Pain, Burning0low190
Pain, Crushing0low190
Pain, Migratory0low190
Pain, Radiating0low190
Pain, Splitting0low190
Palmo-Mental Reflex0medium21
Palmoplantaris Pustulosis0low20
Palsy0low20
Paludism0medium62
Pancreas Cancer0low20
Pancreas Neoplasms0low20
Pancreatic Cancer0low20
Pancreatic Cystic Fibrosis0medium73
Pancreatic Diseases0low10
Pancreatic Neoplasms0low20
Pancreatic Parenchyma with Edema0low40
Pancreatic Parenchymal Edema0low40
Pancreatitis0low40
Pancreatitis, Acute0low40
Pancreatitis, Acute Edematous0low40
Panniculitis, Nodular Nonsuppurative0low10
Papilledema0low10
Papilledema Associated with Decreased Intraocular Pressure0low10
Papilledema Associated with Increased Intracranial Pressure0low10
Papillitis0low10
Papillitis, Optic0low10
Papulopustular Rosacea0low10
Paralysis0low20
Paralysis Agitans0medium42
Paralysis, Legs0medium42
Paralysis, Lower Extremities0medium42
Paralysis, Lower Limbs0medium42
Paralysis, Respiratory Muscle0low10
Paralysis, Spinal, Quadriplegic0low20
Paralytic Shellfish Poisoning0low10
Paraneoplastic Endocrine Syndromes0low10
Paranoia0low10
Paranoid Disorders0low10
Paranoid Psychoses0low10
Paraphrenia, Involutional0low10
Paraplegia0medium42
Paraplegia, Ataxic0medium42
Paraplegia, Cerebral0medium42
Paraplegia, Flaccid0medium42
Paraplegia, Spastic0medium42
Paraplegia, Spinal0medium42
Parasite Infections0low10
Parasitemia0low20
Parasitic Diseases0low10
Parasitic Infections0low10
Parasympathetic Nervous System Diseases0low10
Paresis0low10
Paresthesia0low10
Paresthesia, Distal0low10
Paresthesia, Painful0low10
Parkinson Disease0medium42
Parkinson Disease 20low10
Parkinson Disease 2, Autosomal Recessive Juvenile0low10
Parkinson Disease Autosomal Recessive, Early Onset0low10
Parkinson Disease, Autosomal Dominant. Juvenile0low10
Parkinson Disease, Experimental0low10
Parkinson Disease, Familial, Autosomal Recessive0low10
Parkinson Disease, Idiopathic0medium42
Parkinson Disease, Juvenile0low10
Parkinson Disease, Juvenile, Autosomal Dominant0low10
Parkinson Disease, Juvenile, Autosomal Recessive0low10
Parkinson's Disease0medium42
Parkinson's Disease, Idiopathic0medium42
Parkinson's Disease, Lewy Body0medium42
Parkinsonian Diseases0low10
Parkinsonian Disorders0low10
Parkinsonian Syndrome0low10
Parkinsonian Syndromes0low10
Parkinsonism0low10
Parkinsonism, Early Onset, with Diurnal Fluctuation0low10
Parkinsonism, Early-Onset, With Diurnal Fluctuation0low10
Parkinsonism, Experimental0low10
Parkinsonism, Juvenile0low10
Parkinsonism, Juvenile, Autosomal Dominant0low10
Parkinsonism, Juvenile, Autosomal Recessive0low10
Paroxysmal Dyskinesias0low10
Paroxysmal Nerve Pain0low10
Paroxysmal Reciprocal Tachycardia0low10
Partial Seizure0low120
Partial Seizures0low120
Passive Hyperemia0low20
Passive Tremor0medium81
Pathologic Calcification0low20
PCP Infection0low10
PCP Pneumonia0low10
Pediatric Respiratory Distress Syndrome0low20
Pendular Nystagmus0low10
Peptic Ulcer0low50
Peptic Ulcer Hemorrhage0low30
Perinatal Subarachnoid Hemorrhage0low20
Periodic Alternating Nystagmus0low10
Periorbital Headache0medium182
Peripancreatic Fat Necrosis0low40
Peripheral Autonomic Nervous System Diseases0low10
Permanent Nystagmus0low10
Peroperative Complications0low10
Persistent Tremor0medium81
Personality Disorders0low10
Petechiae0low10
Petit Mal Convulsion0low120
Phenylalanine Hydroxylase Deficiency0low20
Phenylalanine Hydroxylase Deficiency Disease0low20
Phenylalanine Hydroxylase Deficiency Disease, Severe0low20
Phenylketonuria0low20
Phenylketonuria I0low20
Phenylketonuria II0low20
Phenylketonuria Type 20low20
Phenylketonuria, Atypical0low20
Phenylketonuria, Classical0low20
Phenylketonurias0low20
Pheochromocytoma0low10
Pheochromocytoma, Extra-Adrenal0low10
Philippine Hemorrhagic Fever0medium11
Phlegmon0low20
Phorias0low10
Photosensitive Epilepsy0low20
Phymatous Rosacea0low10
Pill Rolling Tremor0medium81
Pituitary Adenoma0low310
Pituitary Adenoma, Prolactin-Secreting0low10
Pituitary Cancer0low310
Pituitary Carcinoma0low310
Pituitary Diencephalic Syndrome0medium31
Pituitary Diseases0low20
Pituitary Disorders0low20
Pituitary Dwarfism II0low10
Pituitary Gigantism0low10
Pituitary Gland Diseases0low20
Pituitary Insufficiency0medium21
Pituitary Neoplasms0low310
Pituitary Tumors0low310
Pityriasis0low10
PKU, Atypical0low20
Plant Poisoning0low10
Plasma Cell Myeloma0low30
Plasmodium falciparum Malaria0low10
Plasmodium Infections0medium62
Plegia0low20
Pleocytosis0low10
Pleural Effusion0low10
Pleurisy0low70
Pleuritis0low70
Pneumococcal Diseases0low10
Pneumococcal Infections0low10
Pneumocystis carinii Pneumonia0low10
Pneumocystis jirovecii Pneumonia0low10
Pneumocystis Pneumonia0low10
Pneumocystosis0low10
Pneumonia0low20
Pneumonia, Eosinophilic0low20
Pneumonia, Interstitial Plasma Cell0low10
Pneumonia, Lobar0low20
Pneumonia, Pneumocystis0low10
Pneumonia, Pneumocystis carinii0low10
Pneumonitis0low20
Poikiloderma Atrophicans and Cataract0low10
Poikiloderma Congenitale0low10
Poikiloderma Congenitale of Rothmund-Thomson0low10
Poikiloderma of Rothmund-Thomson0low10
Poisoning0low20
Poisoning, Blood0low20
Poisoning, Nervous System0low20
Poisoning, Plant0low10
Pollen Allergy0medium5535
Pollinosis0medium5535
Polyarthritis0low30
Polycythemia0low10
Polycythemia Ruba Vera0low10
Polycythemia Rubra Vera0low10
Polycythemia Vera0low10
Polydystrophic Dwarfism0low10
Polymyoclonus0low60
Polyphagia0medium84
Post Traumatic Stress Disorder0medium52
Post-operative Vasoplegic Syndrome0low10
Post-Traumatic Hydrocephalus0low10
Post-Traumatic Myelopathy0medium146
Post-Traumatic Stress Disorders0medium52
Postabsorptive Hypoglycemia0medium101
Posterior Choroidal Artery Infarction0low10
Posterior Circulation Transient Ischemic Attack0low20
Posterior Pituitary Diseases0low20
Postgastrectomy Syndromes0low10
Postoperative Complications0medium52
Postoperative Vasoplegic Syndrome0low10
Postpartum Amenorrhea0low60
Postpartum Hypopituitarism0medium21
Postpartum Panhypopituitarism0medium21
Postpartum Pituitary Insufficiency0medium21
Postprandial Hyperglycemia0low60
Postprandial Hypoglycemia0medium101
Posttraumatic Stress Disorders0medium52
Poultry Diseases0low10
Pre-Eclampsia0low10
Pre-Ictal Memory Loss0low10
Precocious Puberty0low10
Precocious Puberty, Central0low10
Precocious Puberty, Male Limited0low10
Precocious Puberty, Male-Limited0low10
Prediabetes0medium21
Prediabetic State0medium21
Predisposition, Genetic0low20
Preeclampsia0low10
Preeclampsia Eclampsia 10low10
Pregnancy0medium441
Pregnancy Complications0low30
Pregnancy Toxemias0low10
Prenatal Exposure Delayed Effects0low10
Presbyopia0low10
Prescription Drug Abuse0low100
Presenile Alzheimer Dementia0low20
Presyncope0low10
Priapism0low10
Prickly Heat0low10
Primary Adrenal Insufficiency0low20
Primary Adrenocortical Insufficiency0low20
Primary Brain Neoplasms0low10
Primary Cough Headache0low10
Primary Erythermalgia0low10
Primary Erythromelalgia0low10
Primary Exertional Headache0low10
Primary GH Resistance0low10
Primary Growth Hormone Resistance0low10
Primary Headache Disorders0low10
Primary Hyperaldosteronism0low30
Primary Hypoadrenalism0low20
Primary Hypothyroidism0low20
Primary Insomnia0low10
Primary Intramedullary Spinal Cord Neoplasms0low10
Primary Macroglobulinemia0low10
Primary Malignant Brain Neoplasms0low10
Primary Malignant Brain Tumors0low10
Primary Myelofibrosis0low10
Primary Parkinsonism0medium42
Primary Polycythemia0low10
Primary Senile Degenerative Dementia0low20
Primary Spinal Cord Neoplasms, Intramedullary0low10
Primary Stabbing Headache0low10
Primary Thunderclap Headache0low10
Prinzmetal Angina0low20
Prinzmetal's Angina0low20
PRL-Secreting Pituitary Adenoma0low10
Progressive Chorea, Chronic Hereditary (Huntington)0medium11
Progressive Chorea, Hereditary, Chronic (Huntington)0medium11
Prolactin Hypersecretion Syndrome0low20
Prolactin-Producing Pituitary Adenoma0low10
Prolactin-Secreting Pituitary Adenoma0low10
Prolactin, Inappropriate Secretion0low20
Prolactinoma0low10
Prolactinoma, Familial0low10
Prostate Cancer0low10
Prostate Neoplasms0low10
Prostatic Cancer0low10
Prostatic Neoplasms0low10
Proteinuria0low40
Proteinuria-Edema-Hypertension Gestosis0low10
Prothrombin Deficiency0low10
Prurigo0low10
Pruritis0medium3615
Pruritus0medium3615
Pruritus Ani0low10
Pruritus Vulvae0low10
Pseudoakathisia0medium42
Pseudocoma0low10
Pseudotumor Cerebri0low10
Psoriasis0low20
Psychiatric Diagnosis0medium62
Psychiatric Diseases0medium62
Psychiatric Disorders0medium62
Psychiatric Illness0medium62
Psychoneuroses0low10
Psychophysiologic Disorders0low20
Psychophysiological Disorders0low20
Psychophysiological Insomnia0low10
Psychoses0medium11
Psychoses, Drug0low70
Psychoses, Manic-Depressive0low30
Psychoses, Paranoid0low10
Psychoses, Substance-Induced0low70
Psychoses, Toxic0low70
Psychosexual Disorders0low110
Psychosexual Dysfunctions0low110
Psychosis0medium11
Psychosis, Brief Reactive0medium11
Psychosis, Involutional0low10
Psychosis, Manic-Depressive0low30
Psychosomatic Disorders0low20
Psychotic Disorders0medium11
Ptosis, Eyelid0low10
PTSD0medium52
Pubertas Praecox0low10
Puberty, Precocious0low10
Pulmonary Cancer0low40
Pulmonary Consumption0medium11
Pulmonary Cystic Fibrosis0medium73
Pulmonary Disease0low20
Pulmonary Diseases0low20
Pulmonary Edema0low10
Pulmonary Edemas0low10
Pulmonary Embolism0low40
Pulmonary Embolisms0low40
Pulmonary Eosinophilia0low20
Pulmonary Eosinophilias0low20
Pulmonary Fibroses0low20
Pulmonary Fibrosis0low20
Pulmonary Fungal Diseases0low10
Pulmonary Fungal Infections0low10
Pulmonary Hypertension0low20
Pulmonary Inflammation0low20
Pulmonary Neoplasms0low40
Pulmonary Phthisis0medium11
Pulmonary Thromboembolism0low40
Pulmonary Thromboembolisms0low40
Pulmonary Tuberculoses0medium11
Pulmonary Tuberculosis0medium11
Purpura0low10
Purpura, Thrombocytopenic0low10
Purpura, Thrombopenic0low10
Purpura, Thrombotic Thrombocytopenic0low20
Purpura, Thrombotic Thrombopenic0low20
Purtilo Syndrome0low10
Pustular Psoriasis of Palms and Soles0low20
Pustulosis of Palms and Soles0low20
Pustulosis Palmaris et Plantaris0low20
Pyaemia0low20
Pyemia0low20
Pyohemia0low20
Pyrexia0low150
QDPR Deficiency0low20
Quadriparesis0low20
Quadriplegia0low20
Quadriplegic Infantile Cerebral Palsy0low20
Quincke's Edema0low80
Quinoid Dihydropteridine Reductase Deficiency0low20
Radiation Injuries, Experimental0low20
Ramsay Hunt Paralysis Syndrome0low10
Rapid Fatigue of Gait0low10
Rash0low30
Raynaud Disease0low10
Raynaud Phenomenon0low10
Raynaud's Disease0low10
Reactive Disorders0low20
Reactive Hyperemia0low20
Reactive Hypoglycemia0medium101
Reading Epilepsy0low20
Rebound Insomnia0low10
Rebound Nystagmus0low10
Recrudescence0medium174
Rectal Diseases0low10
Rectal Disorders0low10
Recurrence0medium174
Recurrence, Local Neoplasm0medium11
Recurrence, Locoregional Neoplasm0medium11
Recurrences, Local Neoplasm0medium11
Recurrent Early Pregnancy Loss0low40
Recurrent Vestibular Neuritis0low10
Recurrent Vestibulopathy0low10
Reflex Epilepsy0low20
Reflex Epilepsy, Audiogenic0low20
Reflex Epilepsy, Cursive (Running)0low20
Reflex Epilepsy, Eating-Induced0low20
Reflex Epilepsy, Musicogenic0low20
Reflex Epilepsy, Photosensitive0low20
Reflex Epilepsy, Reading0low20
Reflex Epilepsy, Visual Pattern0low20
Reflex, Abnormal0medium21
Reflex, Absent0medium21
Reflex, Acoustic, Abnormal0medium21
Reflex, Anal, Absent0medium21
Reflex, Anal, Decreased0medium21
Reflex, Ankle, Abnormal0medium21
Reflex, Ankle, Absent0medium21
Reflex, Ankle, Decreased0medium21
Reflex, Biceps, Abnormal0medium21
Reflex, Biceps, Absent0medium21
Reflex, Biceps, Decreased0medium21
Reflex, Corneal, Absent0medium21
Reflex, Corneal, Decreased0medium21
Reflex, Decreased0medium21
Reflex, Deep Tendon, Abnormal0medium21
Reflex, Deep Tendon, Absent0medium21
Reflex, Gag, Absent0medium21
Reflex, Gag, Decreased0medium21
Reflex, Knee, Abnormal0medium21
Reflex, Knee, Decreased0medium21
Reflex, Moro, Asymmetric0medium21
Reflex, Pendular0medium21
Reflex, Triceps, Abnormal0medium21
Reflex, Triceps, Absent0medium21
Reflex, Triceps, Decreased0medium21
Reflexes, Abnormal0medium21
Reflux, Gastroesophageal0low10
Regional Enteritis0low10
Relapse0medium174
REM Sleep Deprivation0low20
Remission, Spontaneous0low40
Remittent Fever0medium62
Renal Disease, End-Stage0low20
Renal Failure, Chronic0low20
Renal Failure, End-Stage0low20
Rendu-Osler-Weber Disease0low10
Reperfusion Injury, Myocardial0low20
Research-Related Injuries0low10
Respiratory Distress Syndrome0low20
Respiratory Distress Syndrome, Acute0low20
Respiratory Distress Syndrome, Adult0low20
Respiratory Distress Syndrome, Pediatric0low20
Respiratory Hypersensitivity0medium41
Respiratory Paralysis0low10
Respiratory Syndrome, Acute, Severe0low10
Respiratory Syndrome, Severe Acute0low10
Respiratory Tract Diseases0low10
Rest Tremor0medium81
Resting Tremor0medium81
Restless Leg Syndrome0low20
Restless Legs0low20
Restless Legs Syndrome0low20
Retardation, Mental0low10
Retention Disorders, Cognitive0low10
Retinal Edema0low10
Retinal Hemorrhage0low10
Retinitis0low10
Retraction Nystagmus0low10
Retro-Ocular Headache0medium182
Retrograde Amnesia0low10
Retroperitoneal Neoplasms0low10
Rhabdomyolysis0low10
Rheumatic Chorea0low10
Rheumatism, Muscular0low10
Rheumatoid Arthritis0medium41
Rhinitis0low50
Rhinitis, Allergic0medium82
Rhinitis, Allergic, Nonseasonal0medium2512
Rhinitis, Allergic, Perennial0medium2512
Rhinitis, Allergic, Seasonal0medium5535
Rhinitis, Vasomotor0low10
Right Hemisphere, Cerebral Infarction0low10
Right Hemisphere, Infarction, Cerebral0low10
Rigidity, Decerebrate0low80
Rigidity, Decorticate0low80
Rolandic Type Cerebral Palsy0low20
Rosacea0low10
Rotary Nystagmus0low10
Rotational Nystagmus0low10
Rothmund-Thomson Syndrome0low10
Russell Silver Syndrome0low10
Russell-Silver Syndrome0low10
SAH (Subarachnoid Hemorrhage)0low20
Sarcoma0low10
Sarcoma, Engelbreth-Holm-Swarm0low20
Sarcoma, Epithelioid0low10
Sarcoma, Experimental0low20
Sarcoma, Jensen0low20
Sarcoma, Soft Tissue0low10
Sarcoma, Spindle Cell0low10
Sarcomas, Experimental0low20
SARS (Severe Acute Respiratory Syndrome)0low10
SARS Coronavirus 2 Infection0low20
SARS-CoV-2 Infection0low20
Saturnine Tremor0medium81
Schistoma Infection0low10
Schistosomiasis0low10
Schizoaffective Disorder0medium11
Schizophrenia0medium137
Schizophrenic Disorders0medium137
Schizophreniform Disorders0medium11
Schulman-Upshaw Syndrome0low20
Schwartz Jampel Aberfeld syndrome0low10
Schwartz-Jampel Syndrome0low10
Schwartz-Jampel Syndrome, Type 10low10
Schwartz-Jampel-Aberfeld Syndrome0low10
Sclerosis, Disseminated0medium11
Seasonal Allergic Rhinitis0medium5535
Seborrhea0low10
Seborrheic Dermatitis0low10
Secondary Hypothyroidism0low20
Secondary Insomnia0low10
Secondary Trigeminal Neuralgia0low10
SED Tarda0low10
See-Saw Nystagmus0low10
Segmental Autonomic Dysfunction0low10
Seizure0low120
Seizure Disorder0low40
Seizures0low120
Seizures, Auditory0low120
Seizures, Clonic0low120
Seizures, Convulsive0low120
Seizures, Epileptic0low120
Seizures, Focal0low120
Seizures, Generalized0low120
Seizures, Gustatory0low120
Seizures, Motor0low120
Seizures, Olfactory0low120
Seizures, Sensory0low120
Seizures, Somatosensory0low120
Seizures, Tonic0low120
Seizures, Tonic-Clonic0low120
Seizures, Vertiginous0low120
Seizures, Vestibular0low120
Seizures, Visual0low120
Semantic Memory Disorder0low10
Semiconsciousness0low10
Senile Chorea0low10
Senile Dementia, Acute Confusional0low20
Senile Dementia, Alzheimer Type0low20
Senile Tremor0medium81
Sensitivity and Specificity0medium91
Sensitivity, Contact0medium72
Sensorimotor Gait Disorder0low10
Sepsis0low20
Septic Shock0low70
Septicemia0low20
Serotonin Syndrome0low290
Serum Sickness0low10
Severe Dengue0medium11
Severe GH Insensitivity0low10
Severe Sepsis0low20
Sex Disorders0low40
Sexual Arousal Disorder0low110
Sexual Aversion Disorder0low110
Sexual Disorders, Physiological0low40
Sexual Dysfunction, Physiological0low40
Sexual Dysfunctions, Physiological0low40
Sexual Dysfunctions, Psychological0low110
Sexual Precocity0low10
Sharp Headache0medium182
Sheehan Syndrome0medium21
Sheehan's Syndrome0medium21
Shellfish Poisoning0low10
Shock0low20
Shock Lung0low20
Shock, Anaphylactic0low240
Shock, Endotoxic0low70
Shock, Hemorrhagic0low40
Shock, Septic0low70
Shock, Toxic0low70
Short Sleep Phenotype0medium82
Short Sleeper Syndrome0medium82
Sick Headache0medium569
Side Effects of Drugs0low40
Silver Russell Dwarfism0low10
Silver-Russell Dwarfism0low10
Silver-Russell Syndrome0low10
Simmonds Disease0medium21
Simmonds' Disease0medium21
Simple Pulmonary Eosinophilia0low20
Singapore Hemorrhagic Fever0medium11
Single Seizure0low120
Sinus Infections0low10
Sinusitis0low10
SJA Syndrome0low10
Skin and Subcutaneous Tissue Disorders0medium81
Skin Diseases0medium81
Skin Diseases, Fungal0low10
Skin Mastocytosis0medium21
Skin Rash0low30
Sleep Debt0low20
Sleep Deprivation0low20
Sleep Disorders0medium82
Sleep Fragmentation0low20
Sleep Initiation and Maintenance Disorders0low10
Sleep Initiation Dysfunction0low10
Sleep Insufficiency0low20
Sleep Wake Disorders0medium82
Sleep-Related Neurogenic Tachypnea0medium82
Sleepiness0medium11
Sleeplessness0low10
Sneezing0medium53
Somatization Disorder0low10
Somatoform Disorders0low10
Somatotropin Hypersecretion Syndrome (Acromegaly)0medium122
Somnolence0medium11
Sost Sclerosing Bone Dysplasia0low10
Sost-Related Sclerosing Bone Dysplasia0low10
Spasm0low10
Spasm, Ciliary Body0low10
Spasm, Generalized0low10
Spastic0medium104
Spastic Diplegia0low20
Spastic Paraplegia0medium42
Spastic Quadriplegia0low20
Spastic Tetraplegia0low20
Spatial Memory Disorder0low10
Spider Bites0low10
Spider Veins0low20
Spinal Cord Compression0low20
Spinal Cord Compression, Extramedullary0low20
Spinal Cord Contusion0medium146
Spinal Cord Diseases0low10
Spinal Cord Disorders0low10
Spinal Cord Injuries0medium146
Spinal Cord Laceration0medium146
Spinal Cord Neoplasms0low10
Spinal Cord Neoplasms, Benign0low10
Spinal Cord Neoplasms, Intradural-Extramedullary0low10
Spinal Cord Neoplasms, Intramedullary0low10
Spinal Cord Neoplasms, Malignant0low10
Spinal Cord Neoplasms, Primary Intramedullary0low10
Spinal Cord Transection0medium146
Spinal Cord Trauma0medium146
Spondylo-Epimetaphyseal Dysplasia With Myotonia0low10
Spondyloepiphyseal Dysplasia0low10
Spondyloepiphyseal Dysplasia Tarda, X-Linked0low10
Spondyloepiphyseal Dysplasia, Late0low10
Spontaneous Abortion0low20
Spontaneous Ocular Nystagmus0low10
Squamous Cell Carcinoma0low10
Squint0low10
SREDIu0160NJI u017DIVu010CANI SUSTAV, BOLESTI@hr0medium31
St. Vitus's Dance0low10
Stabbing Headache0low10
Starvation0low20
Stasis Ulcer0low10
Static Tremor0medium81
Status Marmoratus0low70
Status Migrainosus0medium569
Steatohepatitis0medium11
Steatosis of Liver0medium11
Stereotypic Movement Disorder0low10
Sterility, Female0low10
Sterility, Postpartum0low10
Stomach Cancer0medium51
Stomach Diseases0low20
Stomach Neoplasms0medium51
Stomach Ulcer0medium92
Stomatitis0medium11
Strabismus0low10
Strabismus, Comitant0low10
Strabismus, Noncomitant0low10
Streptococcus pneumoniae Infections0low10
Streptozocin Diabetes0low100
Streptozotocin Diabetes0low100
Stress Disorder, Post Traumatic0medium52
Stress Disorders, Post-Traumatic0medium52
Stress Disorders, Posttraumatic0medium52
Stroke, Acute0medium21
Strongyloidiasis0low10
Stunted Growth0medium52
Stunting0medium52
Sub-Fertility, Female0low10
Subacute Delirium0medium31
Subacute Vestibular Neuritis0low10
Subarachnoid Hemorrhage0low20
Subarachnoid Hemorrhage, Aneurysmal0low20
Subarachnoid Hemorrhage, Intracranial0low20
Subarachnoid Hemorrhage, Spontaneous0low20
Subcortical Infarction0low10
Subfertility, Female0low10
Substance Abuse0low100
Substance Addiction0low100
Substance Dependence0low100
Substance Use0low100
Substance Use Disorders0low100
Substance Withdrawal Syndrome0medium161
Substance-Induced Psychoses0low70
Substance-Related Disorders0low100
Subwakefullness Syndrome0medium82
Sudden Death0low20
Suffering, Physical0low190
Suicidal Ideation0medium11
Sunburn0low10
Surgical Injuries0low10
Surgical Wound Dehiscence0low10
Susceptibility, Disease0low30
Susceptibility, Genetic0low20
Swine Fever, African0low10
Swine Influenza0low10
Sycosis0low10
Sydenham Chorea0low10
Sydenham's Chorea0low10
Sykdommer i sentralnervesystemet@no0medium31
Symmetric Diabetic Proximal Motor Neuropathy0low20
Sympathetic Nervous System Diseases0low10
Symptom Cluster0low190
Symptomatic Nystagmus0low10
Syncopal Episode0low10
Syncopal Vertigo0low10
Syncope0low10
Syncope, Cardiogenic0low10
Syncope, Carotid Sinus0low10
Syncope, Convulsive0low10
Syncope, Deglutitional0low10
Syncope, Effort0low10
Syncope, Hyperventilation0low10
Syncope, Micturition0low10
Syncope, Postural0low10
Syncope, Situational0low10
Syncope, Stokes-Adams0low10
Syncope, Tussive0low10
Syndrome0low190
Syringomyelia0low10
Syringomyelus0low10
Systemic Lupus Erythematosus0low10
T-Lymphotropic Virus Type III Infections, Human0medium11
Tachyarrhythmia0low30
Tachycardia0low30
Tachycardia, Paroxysmal0low10
Tactile Allodynia0low20
Tactile Reflex Epilepsy0low20
Taenia brauni Infection0low10
Taenia glomeratus Infection0low10
Taenia Infections0low10
Taenia multiceps Infection0low10
Taenia serialis Infection0low10
Taenia solium Infection0low10
Taeniasis0low10
Taste-Blindness0low10
TB Meningitis0low10
Telangiectasia0low20
Telangiectasia, Hereditary Hemorrhagic0low10
Telangiectasia, Hereditary Hemorrhagic, of Rendu, Osler, and Weber0low10
Telangiectasia, Hereditary Hemorrhagic, Type 10low10
Telangiectasis0low20
Temporary Nystagmus0low10
Testicular Cancer0low10
Testicular Neoplasm0low10
Testicular Neoplasms0low10
Testicular Tumor0low10
Testicular Tumors0low10
Testis Cancer0low10
Testis Neoplasms0low10
Testotoxicosis0low10
Tetrahydrobiopterin Deficiency0low20
Tetraplegia0low20
Thai Hemorrhagic Fever0medium11
Thermal Allodynia0low20
Thesaurismosis0low20
Thiamine Deficiency0low10
Thinness0medium84
Threatened Miscarriage0low10
Throbbing Headache0medium182
Thrombocytopenia0low10
Thromboembolism, Pulmonary0low40
Thromboembolisms, Pulmonary0low40
Thrombopenia0low10
Thrombosis0low50
Thrombosis, Carotid0low10
Thrombosis, Carotid Artery0low10
Thrombosis, Common Carotid Artery0low10
Thrombosis, Coronary0low10
Thrombosis, External Carotid Artery0low10
Thrombosis, Internal Carotid Artery0low10
Thrombotic Microangiopathy, Familial0low20
Thrombotic Thrombocytopenic Purpura0low20
Thrombotic Thrombocytopenic Purpura, Congenital0low20
Thrombotic Thrombocytopenic Purpura, Familial0low20
Thrombus0low50
Thunderclap Headache0low10
Thymic Cancer0low10
Thymic Neoplasms0low10
Thymic Tumors0low10
Thymoma0low20
Thymus Cancer0low10
Thymus Neoplasms0low10
Thymus Tumors0low10
Thyroid Diseases0low20
Thyroid-Stimulating Hormone Deficiency0low20
TIA (Transient Ischemic Attack)0low20
Tic Disorder, Combined Vocal and Multiple Motor0low10
Tic Doloureux0low10
Tic Douloureux0low10
Todd Paralysis0low20
Todd's Paralysis0low20
Tongue Diseases0low10
Tonic Clonic Seizure0low120
Tonic Seizure0low120
Tonic Seizures0low120
Tonic-Clonic Seizure0low120
Tonic-Clonic Seizures0low120
Toothache0low20
Torsade de Pointes0low20
Torsades de Pointes0low20
Torulosis0low10
Tourette Disease0low10
Tourette Disorder0low10
Tourette Syndrome0low10
Tourette's Disease0low10
Tourette's Disorder0low10
Tourette's Syndrome0low10
Toxemia0low10
Toxemia Of Pregnancy0low10
Toxemias, Pregnancy0low10
Toxic Encephalitis0low20
Toxic Hepatitis0low70
Toxic Psychoses0low70
Toxic Shock0low70
Toxic Shock Syndrome0low70
Toxicity, Drug0low40
Transformation, Neoplastic Cell0low10
Transient Insomnia0low10
Transient Ischemic Attack0low20
Transient Ischemic Attack, Anterior Circulation0low20
Transient Ischemic Attack, Brain Stem0low20
Transient Ischemic Attack, Brainstem0low20
Transient Ischemic Attack, Carotid Circulation0low20
Transient Ischemic Attack, Posterior Circulation0low20
Transient Ischemic Attack, Vertebrobasilar Circulation0low20
Transient Ischemic Attacks, Crescendo0low20
Transient Situational Disturbance0low20
Trauma0low10
Tremor0medium81
Tremor, Limb0medium81
Tremor, Muscle0medium81
Tremor, Neonatal0medium81
Tremor, Nerve0medium81
Tremor, Perioral0medium81
Tremor, Rubral0low10
Tremor, Semirhythmic0medium81
Trichinelliasis0low10
Trichinellosis0low10
Trichinosis0low10
Trichostrongyloidiasis0low10
Trifacial Neuralgia0low10
Trigeminal Neuralgia0low10
Trigeminal Neuralgia, Idiopathic0low10
Trigeminal Neuralgia, Secondary0low10
Trombiculiasis0low10
Tropical Eosinophilia0low20
Tropical Eosinophilic Pneumonia0low20
Trypanosoma cruzi Infection0low10
Trypanosomiasis, South American0low10
TSH Deficiency0low20
Tubercular Meningitis0low10
Tuberculin-Type Hypersensitivity0low30
Tuberculoses, Pulmonary0medium11
Tuberculosis Meningitis0low10
Tuberculosis, Meningeal0low10
Tuberculosis, Pulmonary0medium11
Tuberculous Hypertrophic Pachymeningitis0low10
Tumor of Rete Testis0low10
Tumorigenic Transformation0low10
Tumors0medium207
Tumors of the Nervous System0medium11
Tumors, Spinal Cord0low10
Type 1 Diabetes0low10
Type 1 Diabetes Mellitus0low10
Type 2 Diabetes0low10
Type 2 Diabetes Mellitus0low10
Type I Hypersensitivity0medium135
Type III Hypersensitivity0low30
Type IV Hypersensitivity0low30
u041Du0415u0420u0412u041Du041Eu0419 u0421u0418u0421u0422u0415u041Cu042B u0426u0415u041Du0422u0420u0410u041Bu042Cu041Du041Eu0419 u0411u041Eu041Bu0415u0417u041Du0418@ru0medium31
u4E2Du67A2u795Eu7D4Cu7CFBu75BEu60A3@ja0medium31
Ulcer0low10
Ulcerative Colitis0low10
Undernutrition0medium41
Underweight0medium84
Unidirectional Nystagmus0low10
Unilateral Headache0medium182
Unilateral Nasal Obstruction0medium11
Unipolar Depression0medium183
Upper Extremity Paresis0low10
Upshaw Factor, Deficiency of0low20
Upshaw-Schulman Syndrome0low20
Urinary Bladder Cancer0low10
Urinary Bladder Disorder, Neurogenic0low10
Urinary Bladder Neoplasms0low10
Urinary Bladder Neurogenesis0low10
Urinary Bladder Neurogenic Dysfunction0low10
Urinary Bladder, Neurogenic0low10
Urinary Incontinence0low10
Urinary Retention0low20
Urination Disorders0low10
Urticaria0medium7624
Urticaria Pigmentosa0low50
Urticaria, Giant0low80
Uveitis0low20
Valvular Heart Diseases0low20
Van Buchem Disease0low10
Varicose Ulcer0low10
Vascular Accident, Brain0medium21
Vascular Diseases0low40
Vascular Headache0medium81
Vascular Headaches0medium81
Vascular Hypotension0low70
Vasogenic Brain Edema0low10
Vasogenic Cerebral Edema0low10
Vasomotor Rhinitis0low10
Vasoplegia0low10
Vasoplegic Syndrome0low10
Vasospasm, Intracranial0low10
Venous Congestion0low20
Venous Engorgement0low20
Venous Hypertension Ulcers0low10
Venous Stasis Ulcers0low10
Venous Ulcer0low10
Ventricle Remodeling0low10
Ventricular Remodeling0low10
Vertebrobasilar Circulation Transient Ischemic Attack0low20
Vertex Headache0medium182
Vertical Nystagmus0low10
Vertigo, Benign Paroxysmal Positional0low10
Vertigo, Benign Recurrent0low10
Vesication0low20
Vestibular Diseases0low10
Vestibular Nerve Inflammation0low10
Vestibular Nerve Neuritis0low10
Vestibular Neuritis0low10
Vestibular Neuronitis0low10
Vestibular Neuropathy0low10
Vestibulopathy, Familial0low10
Virilism0low20
Virilization0low20
Visceral Steatosis0medium11
Visual Pattern Reflex Epilepsy0low20
Voice Disorder, Neurologic0low10
Voice Disorders0low10
Voice Disturbance0low10
Voice Fatigue0low10
Vomiting0medium112
Waldenstrom Macroglobulinemia0low10
Waldenstrom's Macroglobulinaemia0low10
Waldenstrom's Macroglobulinemia0low10
Wart-Hog Disease0low10
Watermelon Stomach0low10
Weber-Christian Disease0low10
Weber-Cockayne Syndrome0medium11
Weber-Cockayne Type Epidermolysis Bullosa Simplex0medium11
Weber-Osler Disease0low10
Weber-Osler Syndrome0low10
Weight Gain0medium143
Weight Loss0low30
Weight Reduction0low30
Wet Lung0low10
Willis Ekbom Disease0low20
Willis Ekbom Syndrome0low20
Willis-Ekbom Disease0low20
Willis-Ekbom Syndrome0low20
Wiskott Syndrome0low10
Wiskott-Aldrich Syndrome0low10
Withdrawal Symptoms0medium161
Wittmaack Ekbom Syndrome0low20
Wittmaack-Ekbom Syndrome0low20
Wound Dehiscence, Surgical0low10
Wounds0low10
Wounds and Injuries0low10
Wounds and Injury0low10
Wounds, Injury0low10
Writing-Induced Reflex Epilepsy0low20
X-Linked Lymphoproliferative Disease0low10
X-Linked Lymphoproliferative Disorder0low10
X-Linked Lymphoproliferative Syndrome0low10
X-Linked SED0low10
X-Linked SEDT0low10
X-Linked Spondyloepiphyseal Dysplasia Tarda0low10
Xeroderma0low10
Xerostomia0low10
Zentralnervensystemkrankheiten@de0medium31
Ziekte, centraalzenuwstelsel-@nl0medium31
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (34)

ArticleYear
Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats.
Environmental science and pollution research international, Volume: 29, Issue: 26		2022
Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.
Journal of dermatological science, Volume: 94, Issue: 3		2019
Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Allergology international : official journal of the Japanese Society of Allergology, Volume: 68, Issue: 2		2019
Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Allergology international : official journal of the Japanese Society of Allergology, Volume: 68, Issue: 1		2019
Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments-Comparison With the Previous White Caucasian Thorough QT Study.
Clinical pharmacology in drug development, Volume: 7, Issue: 1		2018
Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
PloS one, Volume: 11, Issue: 9		2016
Rupatadine: global safety evaluation in allergic rhinitis and urticaria.
Expert opinion on drug safety, Volume: 15, Issue: 10		2016
A retrospective review of cyproheptadine for feeding intolerance in children less than three years of age: effects and side effects.
Acta paediatrica (Oslo, Norway : 1992), Volume: 105, Issue: 8		2016
Acute Vilazodone Toxicity in a Pediatric Patient.
The Journal of emergency medicine, Volume: 49, Issue: 3		2015
Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
AIDS patient care and STDs, Volume: 27, Issue: 3		2013
Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children.
The Journal of pediatrics, Volume: 163, Issue: 1		2013
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, Volume: 7, Issue: 12		2011
Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety.
Journal of drugs in dermatology : JDD, Volume: 10, Issue: 12		2011
Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety.
Archives of otolaryngology--head & neck surgery, Volume: 136, Issue: 8		2010
Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome.
European journal of pharmacology, Aug-01, Volume: 615, Issue: 1-3		2009
Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
Drug safety, Volume: 32, Issue: 1		2009
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Clinical therapeutics, Volume: 30, Issue: 9		2008
Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis.
Primary care respiratory journal : journal of the General Practice Airways Group, Volume: 18, Issue: 2		2009
Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.
European journal of pharmacology, Jul-07, Volume: 588, Issue: 2-3		2008
A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Journal of investigational allergology & clinical immunology, Volume: 14, Issue: 1		2004
[Adverse effects: priapism caused by paroxetine].
Annales medico-psychologiques, Volume: 154, Issue: 2		1996
[Side effects of various drugs acting on the eye].
Fortschritte der Medizin, Jun-01, Volume: 90, Issue: 16		1972
Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis.
Annals of allergy, Volume: 58, Issue: 6		1987
Antihistamines and driving safety.
Cutis, Oct-27, Volume: 42, Issue: 4A		1988
Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis.
The Journal of allergy and clinical immunology, Volume: 81, Issue: 5 Pt 1		1988
Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis.
Allergy, Volume: 44, Issue: 6		1989
Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis.
The Journal of allergy and clinical immunology, Volume: 83, Issue: 2 Pt 1		1989
Role of serotonin in the regulation of human natural killer cell cytotoxicity.
Journal of immunology (Baltimore, Md. : 1950), Aug-01, Volume: 139, Issue: 3		1987
Nonsedating antihistamines: pharmacology, clinical efficacy and adverse effects.
American family physician, Volume: 45, Issue: 3		1992
[Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)].
Monatsschrift fur Kinderheilkunde, Volume: 126, Issue: 3		1978
Evaluation of the cytotoxicity of dihydroxytryptamines and 5-hydroxytryptamine antagonists as cytotoxic agents in dimethylhydrazine-induced adenocarcinomata.
Cancer chemotherapy and pharmacology, Volume: 1, Issue: 4		1978
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (13)

ArticleYear
[USEFULNESS OF RUPATADINE FOR PRURITUS OF PATIENTS WITH ATOPIC DERMATITIS].
Arerugi = [Allergy], Volume: 69, Issue: 3		2020
Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats.
Journal of psychopharmacology (Oxford, England), Volume: 21, Issue: 2		2007
[The effect of the one-time and long-term administration of preparations acting on biogenic amine metabolism on the blood level of pressor peptide hormones].
Likars'ka sprava, Issue: 9		1993
Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian).
Postgraduate medical journal, Volume: 71, Issue: 834		1995
Pharmacological characterization of serotonin receptors in the facial motor nucleus: a microiontophoretic study.
European journal of pharmacology, Jul-25, Volume: 65, Issue: 2-3		1980
Chronic treatment with some atypical antidepressants increases the brain level of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rats.
Psychopharmacology, Volume: 74, Issue: 2		1981
Cyproheptadine in the control of Cushing's disease.
The Johns Hopkins medical journal, Volume: 149, Issue: 2		1981
Cyproheptadine dependence associated with an atypical somatoform disorder.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, Volume: 32, Issue: 2		1987
Chronic treatment with antidepressants decreases the number of [3H]SCH 23390 binding sites in the rat striatum and limbic system.
European journal of pharmacology, Jul-09, Volume: 139, Issue: 2		1987
Effect of serotonergic drugs on negative contrast in consummatory behavior.
Pharmacology, biochemistry, and behavior, Volume: 36, Issue: 4		1990
The effect of cyproheptadine and human growth hormone on adrenocortical function in children with hypopituitarism.
The Journal of pediatrics, Volume: 92, Issue: 3		1978
Deanol acetamidobenzoate (Deaner) in tardive dyskinesia.
Diseases of the nervous system, Volume: 38, Issue: 12 Pt 2		1977
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (17)

ArticleYear
Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.
PloS one, Volume: 12, Issue: 4		2017
Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
PloS one, Volume: 11, Issue: 9		2016
Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis, Volume: 111		2015
CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
European journal of drug metabolism and pharmacokinetics, Volume: 41, Issue: 2		2016
Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study.
Journal of investigational allergology & clinical immunology, Volume: 19, Issue: 6		2009
Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers.
Journal of pharmaceutical and biomedical analysis, Feb-20, Volume: 49, Issue: 2		2009
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Clinical therapeutics, Volume: 30, Issue: 9		2008
High performance liquid chromatography-tandem mass spectrometric determination of rupatadine in human plasma and its pharmacokinetics.
Journal of pharmaceutical and biomedical analysis, Aug-05, Volume: 47, Issue: 4-5		2008
Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Human psychopharmacology, Volume: 21, Issue: 1		2006
A comparison of the pharmacokinetics of oral and sublingual cyproheptadine.
Journal of toxicology. Clinical toxicology, Volume: 42, Issue: 1		2004
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Cancer chemotherapy and pharmacology, Volume: 47, Issue: 6		2001
Pharmacokinetics of cyproheptadine and its metabolites in rats.
Biological & pharmaceutical bulletin, Volume: 16, Issue: 12		1993
Pharmacokinetics and dose proportionality of loratadine.
Journal of clinical pharmacology, Volume: 27, Issue: 9		1987
Loratadine: multiple-dose pharmacokinetics.
Journal of clinical pharmacology, Volume: 27, Issue: 7		1987
Pharmacokinetics of loratadine in patients with renal insufficiency.
Journal of clinical pharmacology, Volume: 30, Issue: 4		1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Onset of Action (1)

ArticleYear
Double-blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action.
Annals of allergy, Volume: 61, Issue: 6		1988
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (9)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
European journal of drug metabolism and pharmacokinetics, Volume: 41, Issue: 2		2016
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Clinical therapeutics, Volume: 30, Issue: 9		2008
Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Clinical therapeutics, Volume: 29, Issue: 5		2007
Disposition of cyproheptadine in cats after intravenous or oral administration of a single dose.
American journal of veterinary research, Volume: 59, Issue: 1		1998
Bioavailability of d-pseudoephedrine and azatadine from a repeat action tablet formulation.
The Journal of international medical research, Volume: 10, Issue: 2		1982
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (80)

ArticleYear
Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, Volume: 31, Issue: 10		2022
Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study.
Clinical therapeutics, Volume: 43, Issue: 10		2021
Cyproheptadine as an appetite stimulant in children with cystic fibrosis.
Clinical nutrition ESPEN, Volume: 42		2021
Resonance Rayleigh scattering and spectrofluorimetric approaches for the selective determination of rupatadine using erythrosin B as a probe: application to content uniformity test.
Luminescence : the journal of biological and chemical luminescence, Volume: 36, Issue: 3		2021
[USEFULNESS OF RUPATADINE FOR PRURITUS OF PATIENTS WITH ATOPIC DERMATITIS].
Arerugi = [Allergy], Volume: 69, Issue: 3		2020
Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.
Journal of dermatological science, Volume: 94, Issue: 3		2019
Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial.
International journal of psychiatry in clinical practice, Volume: 23, Issue: 1		2019
Determination of synthetic pharmaceutical adulterants in herbal weight gain supplements sold in herb shops, Tehran, Iran.
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, Volume: 26, Issue: 2		2018
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs.
Scientific reports, 05-09, Volume: 8, Issue: 1		2018
Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.
Acta dermato-venereologica, Volume: 96, Issue: 1		2016
Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents.
PloS one, Volume: 8, Issue: 7		2013
Rupatadine for the treatment of urticaria.
Expert opinion on pharmacotherapy, Volume: 14, Issue: 13		2013
Pre-treatment of BALB/c mice with a centrally acting serotonin antagonist (cyproheptadine) reduces mortality from Boophone disticha poisoning.
Clinical toxicology (Philadelphia, Pa.), Volume: 51, Issue: 1		2013
Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males.
The British journal of dermatology, Volume: 163, Issue: 6		2010
Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine.
Toxicological sciences : an official journal of the Society of Toxicology, Volume: 117, Issue: 2		2010
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Clinical therapeutics, Volume: 30, Issue: 9		2008
Determination of rupatadine in pharmaceutical formulations by a validated stability-indicating MEKC method.
Journal of separation science, Volume: 31, Issue: 16-17		2008
Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers.
Human psychopharmacology, Volume: 22, Issue: 5		2007
Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study.
Allergy, Volume: 59, Issue: 7		2004
A chart review of cyproheptadine for stimulant-induced weight loss.
Journal of child and adolescent psychopharmacology,Spring, Volume: 14, Issue: 1		2004
Prophylactic treatment of pediatric migraine.
Headache, Volume: 44, Issue: 3		2004
Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis.
Drugs of today (Barcelona, Spain : 1998), Volume: 39, Issue: 6		2003
Cyproheptadine for intrathecal baclofen withdrawal.
Archives of physical medicine and rehabilitation, Volume: 84, Issue: 5		2003
Paroxetine as a 5-HT neuroendocrine probe.
Psychopharmacology, Volume: 167, Issue: 1		2003
Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia.
Physical medicine and rehabilitation clinics of North America, Volume: 12, Issue: 4		2001
Second messengers in platelet aggregation evoked by serotonin and A23187, a calcium ionophore.
Life sciences, Oct-26, Volume: 69, Issue: 23		2001
Headshaking in horses: possible aetiopathogenesis suggested by the results of diagnostic tests and several treatment regimes used in 20 cases.
Equine veterinary journal, Volume: 32, Issue: 3		2000
Use of cyproheptadine to control urine spraying in a castrated male domestic cat.
Journal of the American Veterinary Medical Association, Aug-15, Volume: 215, Issue: 4		1999
Disposition of cyproheptadine in cats after intravenous or oral administration of a single dose.
American journal of veterinary research, Volume: 59, Issue: 1		1998
Effect of the appetite stimulant cyproheptadine on deoxynivalenol-induced reductions in feed consumption and weight gain in the mouse.
Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes, Volume: 32, Issue: 3		1997
Cyproheptadine treatment in Cushing's disease.
Journal of endocrinological investigation, Volume: 19, Issue: 4		1996
Studies on the acute lethality of diethylcarbamazine in the rat.
Veterinary and human toxicology, Volume: 35, Issue: 1		1993
Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs.
Journal of the American Veterinary Medical Association, Aug-01, Volume: 205, Issue: 3		1994
Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian).
Postgraduate medical journal, Volume: 71, Issue: 834		1995
Comparative studies of the effects of 5-hydroxytryptamine and noradrenaline on the rat anococcygeus muscle.
Agents and actions, Volume: 11, Issue: 6-7		1981
Azatadine maleate (Zadine): evaluation in the management of allergic rhinitis.
The New Zealand medical journal, Aug-12, Volume: 94, Issue: 689		1981
Azatadine maleate in perennial allergic rhinitis: effects on clinical symptoms and choice reaction time.
British journal of clinical pharmacology, Volume: 10, Issue: 6		1980
Effects of atypical antidepressants on LSD potentiated apomorphine hypermotility in rats.
Acta biologica et medica Germanica, Volume: 39, Issue: 8-9		1980
[Mechanism of action of cyproheptadine (peritol) on the hypothalamo-pituitary-adrenal axis].
Biulleten' eksperimental'noi biologii i meditsiny, Volume: 94, Issue: 9		1982
The calcium antagonistic effects of cyproheptadine on contraction, membrane electrical events and calcium influx in the guinea-pig taenia coli.
British journal of pharmacology, Volume: 74, Issue: 3		1981
Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.
The Journal of clinical investigation, Volume: 68, Issue: 4		1981
Effect of minor tranquilizers, tryptamine antagonists and amphetamine on behavior punished by brain stimulation.
Pharmacology, biochemistry, and behavior, Volume: 15, Issue: 3		1981
The use of antiserotonin-cyproheptadine HCL in pregnancy: an experimental and clinical study.
Advances in experimental medicine and biology, Volume: 27		1972
Serotonergic regulation of prolactin and growth hormone secretion in man.
Acta endocrinologica, Volume: 110, Issue: 2		1985
Central anticholinergic syndrome in a child: a case report.
The Journal of emergency medicine, Volume: 3, Issue: 6		1985
Cytoplasmic vacuolation of pancreatic beta cells of rats after oral administration of a derivative of isoquinoline.
Toxicology and applied pharmacology, Sep-15, Volume: 85, Issue: 2		1986
A model for quantitative evaluation of embolic stroke therapy.
Brain research, Dec-01, Volume: 435, Issue: 1-2		1987
Cyproheptadine-mediated inhibition of growth hormone and prolactin release from pituitary adenoma cells of acromegaly and gigantism in culture.
Acta endocrinologica, Volume: 109, Issue: 4		1985
Effects of loratadine (SCH 29851) in suppression of histamine-induced skin wheals.
Annals of allergy, Volume: 60, Issue: 6		1988
Excretion of loratadine in human breast milk.
Journal of clinical pharmacology, Volume: 28, Issue: 3		1988
Pharmacokinetics and dose proportionality of loratadine.
Journal of clinical pharmacology, Volume: 27, Issue: 9		1987
Loratadine: multiple-dose pharmacokinetics.
Journal of clinical pharmacology, Volume: 27, Issue: 7		1987
A role for dopamine as an endogenous protective factor in the rat stomach.
Gastroenterology, Volume: 96, Issue: 4		1989
Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland.
The Journal of clinical endocrinology and metabolism, Volume: 68, Issue: 2		1989
Loratadine: a nonsedating antihistamine with once-daily dosing.
DICP : the annals of pharmacotherapy, Volume: 23, Issue: 6		1989
Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
Drugs, Volume: 37, Issue: 1		1989
A comparative study of cyproheptadine and DL carnitine on psychomotor performance and memory in healthy volunteers.
Fundamental & clinical pharmacology, Volume: 4, Issue: 2		1990
Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma.
The Journal of allergy and clinical immunology, Volume: 86, Issue: 6 Pt 1		1990
[Loratadine and dexchlorpheniramine in the treatment of perennial allergic rhinitis in pediatric patients].
Minerva pediatrica, Volume: 42, Issue: 5		1990
[Analgesic and antipyretic effects of cyproheptadine].
Zhongguo yao li xue bao = Acta pharmacologica Sinica, Volume: 11, Issue: 3		1990
Pharmacology of antihistamines.
The Journal of allergy and clinical immunology, Volume: 86, Issue: 4 Pt 2		1990
Lack of subsensitivity to loratadine during long-term dosing during 12 weeks.
The Journal of allergy and clinical immunology, Volume: 86, Issue: 2		1990
Drug interaction between cyproheptadine and tipepidine. Effect of single and repeated administrations.
Journal of pharmacobio-dynamics, Volume: 14, Issue: 12		1991
Studies on facial temperature rise and involvement of serotonin in the respiratory stimulation by CRH.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, Volume: 23, Issue: 10		1991
[Non-sedative antihistaminics and binding to central and peripheral H1 histamine receptors].
Allergie et immunologie, Volume: 23, Issue: 2		1991
Evaluation of loratadine as an inducer of liver microsomal cytochrome P450 in rats and mice.
Biochemical pharmacology, May-28, Volume: 43, Issue: 10		1992
Effects of cetirizine, loratadine and terfenadine on histamine weal and flare reactions.
Skin pharmacology : the official journal of the Skin Pharmacology Society, Volume: 5, Issue: 1		1992
Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartate-induced intracellular Ca2+ levels in neuronal culture.
European journal of pharmacology, Aug-14, Volume: 219, Issue: 1		1992
Inhibitory effect of loratadine and clemastine on histamine release in human skin.
Skin pharmacology : the official journal of the Skin Pharmacology Society, Volume: 5, Issue: 2		1992
[Therapeutic possibilities in idiopathic headaches. Analysis of about 1000 cases].
Minerva medica, Jun-23, Volume: 67, Issue: 31		1976
[Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)].
Monatsschrift fur Kinderheilkunde, Volume: 126, Issue: 3		1978
Deanol acetamidobenzoate (Deaner) in tardive dyskinesia.
Diseases of the nervous system, Volume: 38, Issue: 12 Pt 2		1977
Naloxone reversal of drug-induced diarrhea in mice.
Archives internationales de pharmacodynamie et de therapie, Volume: 240, Issue: 2		1979
Suppression of histamine-induced pruritus by three antihistaminic drugs.
The Journal of allergy and clinical immunology, Volume: 55, Issue: 3		1975
Effects of azatadine maleate on subjective appraisal and psychomotor functions relevant to driving performance.
Current medical research and opinion, Volume: 6, Issue: 1		1979
Comparison of a new antihistamine HC 20-511 with cyproheptadine (Periactin) in chronic urticaria.
Acta allergologica, Volume: 32, Issue: 5		1977
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (9)

ArticleYear
Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes.
Computational intelligence and neuroscience, Volume: 2022		2022
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Clinical therapeutics, Volume: 30, Issue: 9		2008
Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Human psychopharmacology, Volume: 21, Issue: 1		2006
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Pharmacology & therapeutics, Volume: 106, Issue: 1		2005
Trypanocidal resistance in Trypanosoma evansi in vitro: effects of verapamil, cyproheptidine, desipramine and chlorpromazine alone and in combination with trypanocides.
Veterinary parasitology, Volume: 62, Issue: 1-2		1996
Effects of single and repeated application of clonazepam and diazepam independently and in combination with cyproheptadine on apomorphine stereotypy in rats.
Acta physiologica et pharmacologica Bulgarica, Volume: 10, Issue: 3		1984
Antimigraine drug interactions with 5-hydroxytryptamine1A receptors.
Annals of neurology, Volume: 19, Issue: 5		1986
Drug interaction between cyproheptadine and tipepidine. Effect of single and repeated administrations.
Journal of pharmacobio-dynamics, Volume: 14, Issue: 12		1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]